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ABSTRACT 
Over the past few years the healthcare setting has seen a vast increase in the use of 
medical devices and whilst this may have improved clinical outcomes for patients 
their increase in use has given rise to an increase in medical - device associated 
infections.  It has been reported that urinary tract infections (UTIs) account for up to 
40% of all healthcare associated infections and about 80% of those are associated 
with catheter use [1].  Urinary catheters are hollow, flexible, tubular devices 
designed to drain urine when inserted into a patient¶s bladder.  They are widely used 
both on patients requiring short - term urinary catheterisation e.g. during and after 
some types of surgical procedures or long - term urinary catheterisation e.g. due to 
urinary incontinence.  For patients undergoing long - term indwelling urinary 
catheterisation (LTC) it is almost inevitable that their catheter will become colonised 
with bacteria and a biofilm (an accumulation of microorganisms and their 
extracellular products that form a functional, structured community on a surface) [2] 
develop which can result in a symptomatic or asymptomatic catheter associated 
urinary tract infection (CAUTI).  Infections associated with biofilms are difficult to 
treat due to the bacteria within the biofilm being insusceptible to antibiotic treatment.  
Often to resolve the infection, removal and replacement of the catheter is required 
and antibiotic treatment if necessary.  Certain patients may require their catheter to 
be changed frequently, often causing considerable distress and morbidity and giving 
rise to increased medical costs.  Biomaterials used to produce long - term urinary 
catheters that are able to completely resist bacterial colonisation for significant 
periods, remain elusive.  The development of antimicrobial urinary catheters has, 
however, shown some success in clinical trials but only in the short - term. 
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This project proposes to modify a silicone urinary catheter used for LTC by 
impregnating it with a suitable combination and concentration of antimicrobial 
agents.  The aim of the study is to develop an antimicrobial catheter that will provide 
protection from bacterial colonisation and subsequent biofilm development by the 
principle organisms involved in CAUTIs over a prolonged period (12 weeks).  
 
Silicone material was processed using an impregnation method.  A variety of agents 
were assessed using drug screening tests to establish their potential duration of 
antimicrobial activity and ability to prevent bacterial colonisation.  The combination 
of agents showing the most potential were selected and impregnated into the catheter 
material.  They were: rifampicin, sparfloxacin and triclosan.  Further testing involved 
the development of an in - vitro model designed to test the ability of the 
antimicrobial catheter to resist colonisation following repeated bacterial challenges.  
The emergence of bacterial resistance was also monitored during this time.  In 
addition, the total antimicrobial content, drug release profiles and uniformity of drug 
distribution were elucidated using high performance liquid chromatography (HPLC) 
and time of flight secondary ion mass spectroscopy (ToF-SIMS) respectively.  The 
effect impregnating antimicrobial agents into the catheter had on its surface 
properties and the impact on mechanical performance of the catheter shaft and 
balloons were also examined. 
 
Drug screening tests revealed a combination of rifampicin, sparfloxacin and triclosan 
had the potential to deliver a long duration of protective activity against principal 
uropathogens.  In - vitro model results demonstrated the antimicrobial catheter was 
able to prevent colonisation by Escherichia coli and Meticillin Resistant 
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Staphylococcus aureus for >12 weeks, Klebsiella pneumoniae and Proteus mirabilis 
for 8 weeks but only 8 days against Enterococcus faecalis.  K.pneumoniae and 
P.mirabilis colonised catheters did, however, show an increase in the sparfloxacin 
and triclosan minimum inhibitory concentrations (MICs), highlighting that the 
development of bacterial resistance could be an issue.  The catheter was found to 
contain (w/w) 0.006% rifampicin, 0.16% sparfloxacin and 0.17% triclosan of which 
19.8% sparfloxacin and 29.9% triclosan were released by a diffusion process over 
the first 28 days.  Rifampicin release was not detected possibly due to low 
concentrations.  With the drug release trend suggesting a continued steady release of 
sparfloxacin and triclosan above the MIC and with 80.2% of sparfloxacin and 70.1% 
of triclosan remaining, this would suggest there should be sufficient drug to provide 
protection from bacterial colonisation over a 12 week duration.  However, why the 
MICs increased as catheters became colonised with K.pneumoniae and P.mirabilis 
could be due to a number of factors.   
 
ToF-SIMS revealed the drugs which could be traced (sparfloxacin and triclosan) 
were mostly uniformly distributed on the catheter surface, with some drug 
localization being seen which may have added to the initial burst effect and could be 
important in the prevention of bacterial colonisation during catheter insertion.   
Surface analysis techniques also showed the incorporation of antimicrobial agents 
lead to an increase in the surface hydrophilicity but following exposure to an aqueous 
environment no difference was seen compared to control catheters.  As drugs eluted 
from the catheter the surface topography marginally deteriorated but the impact of 
this in terms of bacterial colonisation is not thought to be of a clinical significance.  
No adverse affect to the mechanical performance of the antimicrobial catheter shaft 
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or balloon compared to the conventional silicone Foley urinary catheter was shown, 
indicating that it would be as mechanically stable as the catheter in clinical use and 
therefore suitable if applied to clinical practice. 
 
Further work on the drug release concentrations and ratios are needed to help 
overcome the potential of bacterial resistance.  The catheter could have a greater 
effect on reducing bacterial colonisation and potential for resistance development if 
drug concentrations were adjusted to release at higher concentrations and equal ratios 
and more data could be gathered if drug release studies were taken to the end point of 
12 weeks rather than 28 days.  In - vitro model challenges using urine as the 
perfusion medium and a larger array of microorganisms is required and 
investigations are also necessary to assess the antimicrobial catheters ability to 
prevent encrustation, a further complication of LTC.    
 
This preliminary study has shown with further work there is potential that the 
antimicrobial catheter could have a substantial effect on reducing/delaying 
colonisation by several of the main organisms involved in CAUTIs over a prolonged 
course.  This in turn would help reduce CAUTI rates, reduce the frequency at which 
catheters need to be replaced and improve the quality of life for patients on LTC. 
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1.0. INTRODUCTION AND AIMS 
1.1. Overview  
The use of medical devices has become an essential part of modern day medicine and 
over the past few years the healthcare setting has seen a vast increase in their use.  
The diversity of such devices is wide, varying from those of a complex nature like 
automatic implantable cardio defibrillators to more simple devices such as urinary 
catheters [3].  Whilst medical devices have improved clinical outcomes for patients 
their increase in use has given rise to an increase in medical - device associated 
infections [4].  A large array of biomaterials is used in the production of medical 
devices and one thing they have in common is their inability to prevent bacteria from 
colonising their surfaces.  This is especially true of urinary catheters.  Urinary 
catheters are hollow tubular devices which upon insertion into a patient¶s bladder 
allow for urine to drain.  Urinary tract infections (UTIs) are the most common type 
of hospital - acquired infection accounting for up to 40% of all cases and 80% of 
those are associated with catheter use [1].  Patients may require catheterisation for 
short or more prolonged periods of time and with patients undergoing long - term 
indwelling urinary catheterisation (LTC) it is almost certain that microbes will 
colonise the catheter surface leading to the formation of a biofilm and a catheter 
associated urinary tract infection (CAUTI) develop at some point [5].  Such 
infections are difficult to resolve and can cause considerable morbidity.  There is a 
great deal of interest in devising strategies to minimise biofilm formation to prevent 
CAUTIs but biomaterials used to produce urinary catheters that are completely 
resistant to bacterial colonisation for clinically significant periods currently remain 
elusive.  Clearly on the basis of prevalence and associated morbidity, ways of 
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reducing bacterial colonisation associated with long - term urinary catheters is an 
area that continues to warrant investigation if CAUTI rates are to decline. 
 
This chapter will provide an introduction to the issues surrounding CAUTIs amongst 
patients on LTC.  The urinary system, reasons for catheterisation and problems 
associated with catheterisation will be discussed along with the microorganisms 
involved in infection and their routes of entry.  The process of bacterial attachment to 
catheter surfaces and progression to biofilm state will be explained and issues 
regarding treatment of CAUTIs as well as ways and methods of trying to reduce 
CAUTIs will be discussed and the concept of antimicrobial catheters introduced. 
 
1.2.  The Urinary System 
 
1.2.1.  Components and Functions 
The urinary sysWHPLVRQHRIWKHERG\¶VPDMRUUHJXODWRU\V\VWHPVDQGFRQVLVWVRItwo 
kidneys, two ureters, the bladder and urethra (Figure 1.1).  It plays vital roles in the 
excretion of wastes from the body in the form of urine and in the regulation of the 
amount of water in the body and in turn salts within the blood [6].  It also functions 
in acid-base balance to maintain correct ionic composition, pH and osmotic 
concentrations and has a role in endocrine function releasing various amounts of 
hormones and altering others [6].   
 
The kidneys contain millions of nephrons that filter soluble components from blood 
and water.  Substances the body requires get selectively reabsorbed back into the 
blood to maintain proper balance whilst waste products that do not get filtered 
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become secreted into the urine [6].  The ureters are 25 - 30 cm muscular tubes that 
arise from the renal pelvis and transport the urine towards the bladder.  The bladder, 
a hollow, muscular, elastic sac is located on the floor of the pelvic cavity and every 
few seconds small amounts of urine are forced into it, typically at a rate of 0.5 - 1 
mL/min [7].  It usually accumulates 300 to 400 mL of urine before emptying but can 
expand to hold up to 1000 mL, although this varies from person to person [6].  As the 
bladder fills with urine it becomes distended and a layer of smooth muscle fibres 
within the bladder wall known as the detrusor muscle signals to the parasympathetic 
nervous system to contract the detrusor muscle which results in the urge to urinate 
[6].  For the urine to be expelled from the bladder the internal and external sphincters 
which are usually contracted to prohibit the urine from releasing prematurely, need to 
be open.  The urethra, a tube of smooth muscle lined with mucosa, is the passageway 
through which urine is discharged from the body during urination.  In a female the 
urethra is about 4 cm in length whereas in a male it is about 20 cm in length [6].   
 
 
Figure 1.1: Front view of the urinary system [8]. 
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1.2.2.  Urine and its Constituents 
Urine is a supersaturated solution which is normally transparent, has a slightly 
aromatic but not unpleasant odour and is yellow to amber in colour.  Urine of a 
turbid nature may indicate bacterial infection or be due to the crystallisation of salts.  
Depending upon the level of hydration of the body, diet, illness and drugs a person 
may be taking, the colour of the urine can also vary from near colourless to 
red/brown.  Odour can be affected by certain foods, bacterial contamination and if 
left to stand outside of the body can lead to a stale, unpleasant smell.  The pH of 
urine is typically near to neutral or slightly acidic but may fluctuate from 4.5 to 8 and 
is affected by fluid intake, diet, exercise and temperature [9].  Specific gravity, the 
ratio of the weight of a unit volume of urine to the same volume of distilled water is 
typically 1.001 to 1.035 (g·cmí) and deviations from this may be associated with 
urinary disorders [6].  In adults the average amount of urine produced in a day is 
approximately 1 - 2 L [6].  This obviously varies and depends upon factors such as 
hydration, health, size, environmental factors and emotional state.  Producing too 
much (>2.5 L/day) or too little (<100 mL/day) urine may require medical attention 
 
The physical properties of normal urine and its constituents (Table 1.1) varies often 
quite considerably between individuals and within the same individual over time 
[10].  The urinary system can encounter a variety of problems which may result in 
the urine being unable to drain from the body in the normal manner.  In such 
instances a hollow tubular device known as a urinary catheter may need to be 
inserted to allow for more effective drainage.    
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Table 1.1: Main constituents of normal urine [6]. 
 
Substance Origin Amount 
 
  
Water Diet, metabolism  1500 mL 
Organic Substances   
Urea Protein deamination  30 g 
Creatinine Metabolism of creatinine in 
muscle 
1.6 g 
Hippuric acid Liver detoxification of 
benzoic acid 
0.7 g 
Uric acid Catabolism of nucleic acid  0.7 g 
Ketone bodies Lipid metabolism 0.04 g 
Inorganic Substances   
Sodium Diet 1.5 g 
Chloride Diet 7 g 
Potassium Diet 4 g 
Phosphates Diet, metabolism of 
phosphate-containing 
compounds 
2.5 g 
Sulfates Diet, metabolism of 
sulfate-containing 
compounds 
2.5 g 
Ammonia Deamination of amino 
acids 
0.7 g 
Calcium Diet and bone 
demineralisation 
0.3 g 
Magnesium Diet 0.1 g 
   
Total Solids  About 50 g 
Total Volume  About 1500 mL 
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1.3.  Urinary Catheterisation 
 
 
1.3.1.  History of Urinary Catheterisation 
The word catheter in Greek means to let or to send down [11].  Catheterisation of the 
urinary tract has been performed from time immemorial and a variety of materials 
have been used to form the tubes.  Amongst the materials used to form the shaft of 
the catheter have been metals such as tin and bronze, silver and gold by the Greeks in 
the 3rd century, lead and papyrus by the Egyptians and dried reeds and palm leaves 
by the Chinese [11, 12].  Advancements in catheter design came in the 11th century 
when more malleable materials were developed and it was realised that by boring 
holes into the sides of the catheter shaft this helped to facilitate urinary drainage.  
Latex catheters became popular in the 18th century but initially were weak and friable 
at body temperature.  The process of vulcanization, however, saw the firmness, 
IOH[LELOLW\ DQG GXUDELOLW\ RI WKH UXEEHU LPSURYH  %\ WKH PLG ¶V WKH ILUVW VHOI
retaining urinary catheter consisting of a retention balloon made of rubber or woven 
fabric was formed [12].   
 
1.3.2.  Urinary Catheters Today 
Urinary catheters nowadays come in a variety of designs, sizes and materials.  The 
most common type of self retaining catheter in use today is the Foley catheter, 
developed by the American urologist, Frederick E.B. Foley [12].  It has been 
commercially available since the mid-¶V DQG UHPDLQV UHODWLYely unchanged in 
design today.  A typical Foley catheter is 220 - 380 mm in length and consists of a 
balloon at the proximal tip near to the drainage eyelet and a two - or three - way 
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outlet at the other end (Figure 1.2).  The outlets are for urine drainage, as a means of 
inflating the balloon with saline to secure the catheter in place within the bladder, 
and for bladder irrigation if necessary.  Catheter size is measured in French units, 
where 1 French unit = 0.33 mm diameter.  Adult catheters vary in diameter from 12 
Fr to 30 Fr (4 to 10 mm) with the standard being 14 Fr (4.6 mm) and in balloon size 
that have a capacity of 5 mL to 30 mL.  In the first few decades of use, DQ µRSHQ
FDWKHWHU V\VWHP¶H[LVWHGZKHUHE\ WKH )ROH\FDWKHWHUVZHUH DWWDFKHG WR WXEHVZKLFK
drained the urine into buckets [13].  Nowadays, a drainage bag is attached to the 
urine outlet forming a µclosed system¶ and is either hung beside WKHSDWLHQW¶VEHGor 
strapped to the patient¶s leg.  Urine can either drain freely by gravity into the 
drainage bag or a catheter valve can be fitted into the end of the catheter which may be 
switched on or off to allow for the urine to drain.   
 
The most widely used materials for Foley catheters are latex or silicone with the first 
being manufactured from latex.  Latex is inexpensive, has good elastic properties but 
tends to be more prone to bacterial adherence and have more allergic  potential than 
some other materials [14].  Silicone is soft, non - irritating and clinically stable 
making it ideal for long - term use in the urinary tract [15].  Silicone catheters are 
more expensive than latex catheters but are inert putting patients at less risk of 
allergic reaction.  Their surface properties make for easy insertion and lower rates of 
bacterial adherence and encrustation as reported by some studies possibly relating to 
their smoother surfaces exhibiting less niches for microbial aggregation than latex 
catheters [14, 16].  
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Figure 1.2: A polytetrafluoroethylene (PTFE) coated latex Foley catheter with the balloon inflated 
[12].  
 
1.3.3.  Forms of Urinary Catheterisation 
There are two main forms of urinary catheterisation: intermittent and indwelling.   
 
1.3.3.1.  Intermittent Catheterisation 
Intermittent catheterisation is a form of self - catheterisation that is used in 
individuals who are unable to empty their bladder properly.  It is often a method of 
choice for patients requiring long - term care but is not always suitable if a patient is 
mentally or physically unable to carry out catheterisation e.g. spinal cord injuries and 
dementia patients, although catheterisation can also be carried out by a carer.  
Intermittent catheters differ from Foley catheters described in section 1.3.2 as they 
do not have retention balloons to hold the catheter in the bladder.  Instead, once the 
flow of urine has stopped the catheter is immediately removed and disposed of or 
many can be re - used as required. 
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1.3.3.2.  Indwelling Catheterisation 
The most common form of catheterisation is indwelling where the catheter is held in 
the bladder.  This category can further be divided into short and long - term use, 
although this is somewhat arbitrary.  Short - term catheterisation (STC) is classed as 
a catheter being in place for <14 days [5] and long - term catheterisation (LTC)  as a 
catheter remaining in situ for 30 days or more [1].  Indwelling catheters can be 
inserted in two ways: - either directly into the bladder through a small incision in the 
wall of the abdomen known as suprapubic catheterisation, or most commonly 
through the urethra into the bladder, which is what this study concentrates on.  
 
1.3.4.  Reasons for Long - Term Urinary Catheterisation 
It has been reported that up to 25% of patients admitted to a hospital in the UK will 
require a urinary catheter at some point [13].  Prolonged catheterisation is common 
not only in patients in hospital but also amongst residents in nursing home settings as 
well as people within the community.  LTC is utilised in the management of a wide 
range of conditions both in acute and chronic care settings [1].  Frequently older 
adults with urinary retention or incontinence problems are catheterised.  Other 
indications for LTC are listed in Table 1.2.  Many of these patients can be 
catheterised for months or years.   
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Table 1.2: Some indications for long - term urinary catheterisation [1].   
 
Bladder outlet obstruction not correctable medically or surgically 
Intractable skin breakdown caused or exacerbated by incontinence 
Patients with neurogenic bladder and retention 
Patients who have not responded to specific incontinence treatments 
Palliative care for terminally ill or severely impaired incontinent patients for whom 
bed and clothing changes are uncomfortable  
 
 
1.4.  Problems Associated with Long - Term Urinary 
Catheterisation 
Below are some of the complications that are associated with LTC.  Due to these, 
catheterisation should only be undertaken when all other interventions have been 
assessed as being inappropriate [15].   
 
1.4.1.  Physiological and Social Aspects 
Urinary catheterisation can have significant effects upon a patient both socially and 
physiologically and these are important factors to acknowledge.  Catheterisation for 
the first time can bring about feelings of shame, stigma, and embarrassment which 
may lead to depression.  The loss of control over bodily function can often serve as a 
reminder to patients of illness, particularly amongst the elderly.  Catheter 
replacement and drainage bag changes can also cause discomfort and distress to a 
patient and interfere with their daily lives.  On a positive note however, following the 
initial period of adjustment, users do often accept them as part of their life and 
recognise how a catheter can be convenient and a positive way of freeing them from 
urine accidents [17]. 
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1.4.2.  Trauma   
Patients on LTC may present with lower abdominal pain which may amongst other 
things be related to trauma to the urethra, bladder or surrounding tissue due to 
incorrect catheter insertion.  This can result in urine bypassing the catheter and may 
cause urethral strictures [18].  Traction on the catheter either by the patient or 
inadvertently can also cause trauma to the bladder neck and the prostatic bed which 
can lead to haematuria [11].  Distension or incorrect positioning of the retention 
balloon on Foley catheters may lead to pressure necrosis and urethral rupture [19].  
Over - or under - inflation can cause the balloon to rupture or the catheter to slip out.  
Good catheterisation techniques, patient education and compliance can help to 
minimise complications such as trauma.   
 
1.4.3.  Bladder Spasms and Contraction 
Bladder spasms can cause urine to leak and reflux of any infected urine into the renal 
pelvis can increase the risk of pyelonephritis, renal scarring and renal failure [13].   
Indwelling catheters can also lead to contraction of the bladder, decreasing its 
capacity and tone [11].  This can make bladder retraining after catheter removal 
difficult, but can be helped by intermittent clamping of the catheter several days or 
weeks prior to catheter removal [11].  
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1.4.4.  Encrustation 
Encrustation of urinary catheters poses a significant complication to patients on LTC, 
with incidence rates reported to be as high as 58% [1].  Encrustation is a result of the 
ionic components in the urine crystallising out onto the surface of the catheter [20].  
Proteus mirabilis is the organism most commonly involved in encrustation.  It 
produces the enzyme urease, that catalyses the hydrolysis of urea in the urine to 
ammonia and carbon dioxide [21].  Ammonia dissolves to form ammonium 
hydroxide, a strong alkali which has a high dissociation constant whilst carbon 
dioxide dissolves to form carbonic acid, a weak acid which has a low dissociation 
constant.  This results in the generation of alkaline conditions in the urine.  This 
elevation in pH causes calcium and magnesium salts within the urine to precipitate in 
the form of struvite and hydroxyapatite.  The precipitation of calcium and 
magnesium salts is pH-dependent.  It begins at pH 6.7 - 6.8, peaks at approximately 
pH 7.5 and declines at higher pHs [1].  The analysis of encrusted urethral catheters 
has shown them to usually be composed of struvite (magnesium ammonium 
phosphate) and calcium apatite (a form of calcium phosphate) [20, 22].  If 
encrustation is left to continue, this crystalline material (Figure 1.3) can block the eye 
holes of the catheter and the lumen.  Failure to change the catheter can lead to 
incontinence due to leakage or painful distension of the bladder due to retention and 
reflux of infected urine to the kidneys which can trigger symptomatic pyelonephritis, 
septicaemia and endotoxic shock [21, 23, 24].  Encrustation is of major concern in 
clinical practice and is often associated with bacterial colonisation of catheters.   
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Figure 1.3: Scanning electron micrograph of a section of P.mirabilis formed on a urinary            
catheter that was removed after 24 hours incubation in a model supplied with urine [25]. 
 
 
1.4.5.  Infection 
One of the main complications of LTC is infection in the form of CAUTIs (for more 
detail refer to section 1.5).  Bacteria are highly adaptable organisms and biomaterials 
imitate the basic substrata for which bacteria have developed colonisation and 
survival strategies [14].  Bacteria that colonise catheter surfaces can develop into 
biofilms and cause infection.  Catheters produced from silicone - based materials are 
most commonly used in patients undergoing LTC and as with other materials they 
provide an abiotic surface upon which invading microorganisms can attach and form 
dense aggregates of biofilms.   
 
In a non - catheterised patient the urethra normally acts as a barrier in preventing 
microorganisms from entering the bladder.  Should binding of bacteria to the bladder 
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mucosa occur however, it triggers an inflammatory response that results in an influx 
of neutrophils and sloughing of epithelial cells with bound bacteria [26].  The high 
flow rates brought about by micturition, typically 10 - 20 mL/s are often successful at 
flushing out the bacteria as well [27].  This bacterial shearing effect is due to the 
release of pressure build - up from within the bladder as the sphincters open.  The 
placement RI D FDWKHWHU KRZHYHU GLVUXSWV WKH ERG\¶V QRUPDO LPPXQH PHFKDQLVPV
and prevents effective clearance of microorganisms.  It has also been reported [27] 
that the catheter and balloon orientation can lead to the formation of a urine sump at 
the bottom of the bladder and an accumulation of bacteria that can bring about 
infection.   
 
It has been estimated that more than 60% of healthcare - associated infections are 
biofilm - related [28, 29].  As stated in section 1.1, UTIs are the most common type 
of hospital - acquired infection (Table 1.3), accounting for 40% of all cases and of 
those 80% are catheter - associated [1].  The consequences of CAUTIs can be 
substantial, both medically in terms of morbidity and mortality and economically.  
Mortality rates associated with CAUTIs are low compared to that of infection in 
central venous lines but there are a higher absolute number of infections associated 
with urinary catheters compared to central venous lines and this results in significant 
morbidity (Table 1.3).  A CAUTI acquired in a hospital setting will lead to an 
increased stay and subsequently increased costs.  Patients who develop CAUTIs in 
primary care settings have greater contact with their GPs, more outpatient 
appointments and district nurse visits which represents a significant economic burden 
to the health care sector.  In the UK it is estimated that the management of CAUTIs 
and associated complications due to  urinary incontinence cost between £120 and 
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£2600 per patient for each quarter of a year [12].  Depending on the seriousness of 
complications that can arise from LTC, this represents an estimated total cost of £1.4 
billion per year [12].  With demographic studies suggesting an increasing population 
within the UK, with the greatest growth seen in the elderly population and 
catheterisation more frequent in this group, the use of LTC is likely to increase [12].   
 
 
Table 1.3: Estimated number of indwelling medical devices inserted in the United States per year 
with estimated infection rates and attributable mortality [15, 30]. 
 
Device Estimated No. of 
devices placed per 
year 
Infection rate  
(%) 
Attributable 
mortality 
Urinary catheters >30,000,000 10 ± 30 Low 
Central venous 
catheters 
5,000,000 3 ± 8 Moderate 
Fracture fixation 
devices 
2,000,000 5 ± 10 Low 
Dental implants 1,000,000 5 ± 10 Low 
Joint prosthesis 600,000 1 ± 3 Low 
Vascular grafts 450,000 1 ± 5 Moderate 
Cardiac 
pacemakers 
300,000 1 ± 7 Moderate 
Breast implants 130,000 1 ± 2 Low 
Mechanical heart 
valves 
85,000 1 ± 3 High 
Penile implants 15,000 1 ± 3 Low 
Heart assist devices 700 25 ± 50 High 
 
NB: It is almost inevitable that patients with long term indwelling urinary catheters will develop an 
infection. 
Scale for attributable mortality: low = <5%, moderate = 2 ± 25%, high = >25%. 
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The duration of catheterisation plays a vital role in the development of infection.  
The risk of infection increases by approximately 3 - 6% per day so approximately 
50% of those with a urinary catheter in place for 7 to 10 days will develop an 
infection whilst almost all of those on LTC will develop a CAUTI at some point [5].  
The definition of a CAUTI as defined by the Center for Disease Control and 
Prevention [31] includes symptomatic UTI and asymptomatic bacteremic UTI.  A 
symptomatic CAUTI refers to a patient who has had a urinary catheter in place 
within a 48 hour period before the onset of UTI and who presents with bacteriuria 
(bacteria in the urine) with counts of >103 cfu/mL of a predominant pathogen in a 
sample collected aseptically, who is suffering from associated UTI symptoms or has 
a high white blood cell (WBC) count in their urine indicative of infection [31-33].  
The patient has to demonstrate clinical symptoms aswell as having laboratory 
evidence of a UTI with no more than 2 uropthogens being present [31].  Progression 
to >105 cfu/mL can ensue within 24 to 72 hours [1].  Patients with asymptomatic 
bacteremic UTI show no signs or symptoms of infection but have a urine culture of 
>105 cfu/mL with no more than 2 species of uropathogens and a positive blood 
culture with at least 1 matching uropathogen to the urine culture [31].  A small study 
of patients who were chronically catheterised found that 98% of 605 consecutive 
weekly urine specimens contained >105 bacteria/mL and 77% of those contained 
multiple species [34]. 
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1.4.6.  Other Complications 
A recent article by Maughan et al (2010) [35] found that 79% of patients on LTC 
within the community experienced at least one complication over two years.  62% 
had a CAUTI, 55% reported moderate interference with their daily lives, 33% visited 
an emergency department, 32% found catheter changes to be uncomfortable and 32% 
had urinary leakage.  Most patients with an indwelling catheter experience some kind 
of complication.  Further potential complications are given in Table 1.4.  
 
 
Table 1.4: Potential complications of urinary catheterisation [11]. 
 
Urethral/Penile/Scrotal/Prostatic 
 
Urethritis 
Urethral stricture 
Urethral diverticulum/false passage 
Paraphimosis 
Funiculitis, epididymitis, epididymoorchitis 
Prostatitis 
 
Renal/Urethral 
 
Vesicoureteric reflux 
Pyelonephritis 
Renal/ureteric calculus 
Obstructive hydronephrosis 
Chronic renal failure 
Bladder 
 
Asymptomatic bacteriuria 
Cystitis 
Vesical, catheter calculi 
Bladder spasms 
Decrease in bladder capacity, atony 
Bladder cancer (transitional cell carcinoma, 
squamous cell carcinoma) - rare 
Extraperitoneal perforation of the bladder - 
rare 
 
General 
 
Haematuria 
Pain 
Urine leakage around the catheter 
Systemic sepsis 
Retained, knotted, fractured catheter 
- rare 
Hypersensitivity, anaphylaxis (latex 
catheters) 
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1.5.  Catheter Associated Urinary Tract Infections 
 
1.5.1.  Causative Organisms  
There are a multitude of organisms associated with CAUTIs, both of the Gram 
positive and Gram negative varieties as well as fungi such as the Candida species.  
Of the bacterial species the major ones involved are Escherichia coli, Proteus 
mirabilis, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus spp 
(mostly E.faecalis and E.faecium), and Staphylococcus spp. (mostly S.aureus and 
Coagulase Negative Staphylococci (CoNS)) [1, 27].  In addition, depending on the 
SDWLHQW¶VKHDOWKDQGLPPXQHVWDWXVmany opportunistic pathogens may be involved, 
for example Providencia stuartii and Morganella morganii [27].  Strains producing 
extended-spectrum-ȕ-lactamases (ESBL < ampC) and Meticillin Resistant 
Staphylococcus aureus (MRSA) can also be troublesome [36].  In the early stages of 
infection, a single bacterial species may colonise the catheter.  The longer a catheter 
remains in place, the more likely infection with complex mixed communities of 
microorganisms will develop [37].  Table 1.5 summarises the bacterial species 
isolated from a set of 106 urinary catheter biofilms:- 14 species were commonly 
found of which most biofilms contained mixed bacterial communities of more than 2 
species [23].   
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Table 1.5: The number (%) of bacterial species isolated from 106 catheter biofilms [23]. 
Species All catheter 
biofilms 
Mixed-species 
biofilms  
(76 catheters) 
Single-species 
biofilms  
(30 catheters) 
    
Pseudomonas 
aeruginosa 
38 (35.9) 31 (40.8) 7 (23.3) 
Enterococcus faecalis 36 (34.0) 34 (44.7) 2 (6.7)  
Escherichia coli 33 (33.1) 31 (40.8) 2 (6.7) 
Proteus mirabilis 32 (30.2) 26 (34.2) 6 (20.0) 
Klebsiella pneumoniae 19 (17.9) 18 (23.7) 1 (3.3) 
Morganella morganii 14 (13.2) 11 (14.5) 3 (10.0) 
Providencia stuartii 11 (10.4) 9 (11.8) 2 (6.7) 
Staphylococcus aureus 11 (10.4) 10 (13.2) 1 (3.3) 
Enterobacter cloacae 9 (8.5) 7 (9.2) 2 (6.7) 
Klebsiella oxytoca 9 (8.5) 8 (10.5)  1 (3.3) 
Providencia rettgeri 5 (4.7) 4 (5.3) 1 (3.3) 
Coagulase-negative 
staphylococci 
5 (4.7) 4 (5.3) 1 (3.3) 
Citrobacter species 4 (3.8) 4 (5.3) 0 (0.0) 
Proteus vulgaris 3 (2.8) 2 (2.6) 1 (3.3) 
 
 
1.5.2.  Microbial Entry 
Microbes can gain access to a urinary catheter via the intraluminal or extraluminal 
routes.  Entry to the catheter lumen is primarily through failure of the closed drainage 
system.  To drain the urine from the collection bag the drainage tube must be 
routinely opened.  Should the drainage tube become contaminated with bacteria, they 
may gain entry to the drainage bag and either by capillary action or if the bag is 
raised during movement bacteria can ascend the catheter lumen and travel to the 
bladder to establish infection [13, 38, 39].  The source of organisms that access via 
the intraluminal route may originate from the skin of the patient or may be transitory, 
from a healthcare worker.   
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Organisms that gain entry to the urinary tract via the extraluminal route are primarily 
endogenous in nature and originate IURPWKHSDWLHQW¶Vown gastrointestinal tract [38].  
Organisms can be introduced at the time of catheter insertion if inadequate asepsis is 
used and track along the outside of the catheter.  Contaminating organisms from the 
periuretheral area may also ascend along the external surface of the catheter and 
establish infection [33, 39].  Despite meticulous attention to good hygiene practices, 
the space between the external surface of the catheter and the urethra gives bacteria 
the direct chance to enter the bladder via the outside of the catheter [13, 40, 41].   
 
Tambyah et al (1999), [42] examined the possible routes of entry infecting organisms 
take to access the catheterised urinary tract.  They found that 66% of infections were 
acquired extraluminally and 34% intraluminally.  They also reported that Gram 
positive cocci (enterococci and staphylococci) and yeasts were isolated more from 
the extraluminal pathway whereas Gram negative bacilli were equally cultured from 
extraluminal and intraluminal routes.  Both the external and internal routes of entry 
are thought to be of importance.   
 
Sabbuba et al (2003) [24] investigated the epidemiology of catheter - associated 
P.mirabilis infection using Pulse Field Gel Electrophoresis (PFGE) and found that 
strains isolated from crystalline biofilms were identical to those in samples taken 
from the patients urine.  Further to this Mathur et al (2005) [43] examined urine and 
faeces from eighteen patients on LTC whom had P.mirabilis infections and 
suggested that faecal strains may contaminate the perineum and urethral meatus and 
ascend the external surface of the catheter to cause bacteriuria, encrustation and 
biofilm development.    
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1.5.3.  Biofilm Formation 
The catheterised urinary tract provides the ideal conditions for microbial adhesion 
and the development of biofilm populations both on the inner and outer surfaces of 
the device [16].  The definition of a biofilm is ³an accumulation of microorganisms 
and their extracellular products that form a functional, structured community on a 
surface´ [2].  The development of a biofilm is a series of complex but discrete and 
well - regulated steps whereby highly complex structures designed to maximise 
survival and spread are formed [27, 44].  The molecular mechanisms of biofilm 
formation differ between organisms but the stages of biofilm development are similar 
[44].  Figure 1.4 depicts the stages of biofilm development and sections 1.5.3.1 - 
1.5.3.4 describes the stages involved in more detail. 
 
 
 
Figure 1.4: Biofilm formation and development [27]. 
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1.5.3.1.  Conditioning Film 
Once a catheter or any medical device has been inserted into the body, surfaces 
become exposed to bodily fluids, such as blood, saliva, mucus, or in the case of 
urinary catheters, urine.  As a result, urinary components adsorb onto the surface of 
the catheter to form a conditioning film layer [10].  Surface conditioning films are 
rapidly adsorbed whenever materials are exposed to natural and in - vitro solutions 
containing organic molecules.  The movement of organics from bulk phase to the 
surface is primarily the result of molecular diffusion.  Theoretical and experimental 
studies have indicated that molecular diffusion occurs rapidly, resulting in significant 
organic deposits after just 15 minutes [45].  The conditioning film does not cover the 
whole of the material surface but forms a mesh - like covering [46].  A conditioning 
film formed on a urinary device is largely composed of proteins e.g. albumin, Tamm-
Horsfall Protein and ɲl-microglobulin, electrolyte components and other unidentified 
molecules [10].  The creation of it is crucial as many organisms do not have 
mechanisms that allow them to adhere directly onto bare implant surfaces [47].  
Conditioning films can mask the original chemical surface composition and 
properties of the biomaterial as the matrix of adsorbed products provides receptor 
sites for bacterial adhesion which can lead to altered microbial adhesion profiles 
[48].  The consequence of conditioning films for the surface properties of a 
biomaterial is therefore of considerable significance in the infective process [49].  As 
stated in section 1.2.2, the composition of urine varies between individuals and 
within the same individual over time and it has been reported that such differences in 
the characteristics/composition of urine can alter the receptivity of surfaces to 
bacteria [10].   
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1.5.3.2.  Bacterial Attachment 
After the deposition of a conditioning film, the next step involves the approach and 
attachment of planktonic organisms to the catheter surface.  Planktonic bacteria 
move to a surface by physical forces such as Brownian motion, van der Waals forces, 
gravitational forces, hydrophobic interactions and electrostatic charge effects [50].  
These physical forces can further be divided into long - range interactions and short -
range interactions [50].  Bacteria are first transported to a surface by long - range 
interactions (>50 nm).  As the cells and surface become closer, the short - range 
interactions (<5 nm) dominate.  To understand the forces that determine microbial 
adhesion, researchers have investigated whether the same physicochemical 
interactions that determine the deposition of nonliving colloidal particles are the 
same as those for bacterial attachment to surfaces.   
 
Three theoretical approaches have been used: the Derjaguin, Landau, Verwey, 
Overbeek (DLVO) theory, the thermodynamic approach and the extended DLVO 
theory.  The DLVO theory describes the net interaction between a bacterial cell and a 
flat surface as a balance between two additive factors, resulting from van der Waals 
interactions (attractive) and repulsive interactions from the overlap between the 
electrical double layer of the cell and surface [51].  The thermodynamic approach 
takes into account the attractive and repulsive forces but expresses them collectively 
in terms of free energy [51].  It requires the estimation of a value for thermodynamic 
parameters i.e. surface free energy of bacterial and substratum surfaces and of the 
suspending solution [52].  The extended DLVO theory builds on the DLVO theory to 
include hydrophobic and hydrophilic interactions and osmotic interactions [51].    
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Only a small number of attached organisms are needed to initiate biofilm formation.  
The success of this depends on many factors, of bacterial origin and environmental 
or host derived [27].  Bacterial attachment is regulated through specific interactions 
between bacterial surface components (adhesins) and host cell or catheter surface 
receptors.  The bacterial adhesins initiate attachment by recognising host cell surface 
and extracellular matrix components such as proteins, glycoproteins, glycolipids and 
carbohydrates on the surface of the host cell or on the catheter [53].  Gram negative 
bacteria produce a variety of adhesins, such as flagellum, fimbriae, pili and 
nonfilamentous adhesins [53].  Uropathogenic E.coli strains (UPEC) for example, 
use specific adhesins including Type 1 and P fimbriae [53].  P.mirabilis produces 
various fimbriae such as MR/K and haemagglutinins which are involved in the 
colonisation of the urinary tract [53].  S.aureus adheres to the host surfaces mediated 
by surface adhesins (06&5$00¶V: microbial surface components recognising 
adhesive matrix molecules) [54].  Many of the Gram negative uropathogens use 
flagella and type IV pili motility to facilitate the spread of infection.    
 
Environmental properties of a materials surface such as hydrophobicity, charge and 
energy as well as properties of the surrounding medium such as flow rate, 
temperature and osmolarity also play important roles in the ability of bacteria to 
attach to a biomaterial [27].  In response to bacterial invasion is the hosts innate 
immune system and natural constituents within urine e.g. urea, salts, antimicrobial 
peptides, which act to eliminate bacteria.  The initial attachment is reversible and to 
progress to irreversible adhesion, permanent bonds need to form between 
complementary molecules on a cell/catheter surface.  Attached cells upregulate genes 
that direct the production of an accumulation of proteins and exopolysaccharides 
  Chapter 1 - Introduction and Aims 
26 
 
(EPS).  EPS are high molecular weight polymers composed of monosaccharides and 
some non - carbohydrate VXEVWLWXHQW¶V that are secreted by microorganisms into the 
surrounding area.  It acts to entrap and protect the bacteria by irreversibly fixing cells 
to one another and to the catheter surface [44, 55].   
 
1.5.3.3.  Proliferation/Maturation 
The arrival and irreversible attachment of the first bacterial cells facilitates the arrival 
of other cells as more diverse adhesion sites are provided.  As the matrix builds and 
cells undergo exponential binary division, daughter cells spread to form cell clusters.  
Progression of bacterial colonisation results in further proliferation and production of 
EPS which embeds aggregated cells and microcolonies are formed.  As the biofilm 
matures, a 3D structure is formed along the catheter appearing as patchy networks or 
as a continuous layer [44].  A coherent structure consisting of pillars separated by 
fluid filled spaces where organisms receive nutrients and wastes diffuse away is 
formed [27].  Bacteria such as P.aeruginosa and K.pneumoniae produce copious 
amounts of EPS and form mucoid biofilms that can occlude catheter lumens [16].   
 
Biofilms evolve according to the biochemical and hydrodynamic conditions and 
availability of nutrients in the surrounding area [27].  The success of microorganism 
survival is mostly due to their ability to sense small environmental changes and make 
rapid adjustments.  Cells within a biofilm constantly assess their own population 
dynamics and adjust their phenotypes accordingly [27].  Once a certain density of 
bacteria has been reached, a network of signals are produced by the biofilm cells 
allowing for communication between each other.  This type of cell - cell 
communication is known as quorum sensing (QS) [27].  A variety of molecules can 
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be used as signals, e.g. oligopeptides in Gram positive organisms, N-Acyl 
Homoserine Lactone (AHL) in Gram negative organisms and a host of autoinducers.  
Quorum sensing is capable of altering a number of biological responses including the 
development of biofilms.  For example, furanones found in the marine alga Delisea 
pulchra have antimicrobial and QS inhibitory effects in several Gram negative 
bacteria.  The development of synthetic analogs has been shown to effectively block 
P.aeruginosa biofilm formation and further development of furanone - based drugs 
may block QS systems in many other Gram negative bacteria [56].  Cirioni  et al 
(2007) [57] found that urethral stents coated in the QS inhibitor RNAIII-inhibiting 
peptide (RIP) that were implanted in rat bladders suppressed S.aureus biofilm 
formation on the stent and in the urine and was particularly effective when combined 
with teicoplanin.  However, Otto (2004) [58]  reported that the effects of RIP is due 
to its physico - chemical properties (detergent like action) rather than by a regulatory 
process that involves QS, so is actually a coating process opposed to a QS 
mechanism.  Vuong et al (2004) [59] reported that inhibition of the QS system in 
staphylococci  has been shown to enhance biofilm development in rabbit models and 
by disabling the QS system is likely to enhance the success of S.epidermidis 
infection of indwelling medical devices.  The use of molecules that interfere with QS 
shows some promise in counteracting microbial adaptation to host environments [60] 
but further investigations into specific pathogens and types of infections are required.    
 
1.5.3.4.  Detachment and Dispersal 
The formation of a biofilm is a universal strategy for microbial survival and to 
prevent density - mediated starvation within a mature biofilm, cells must detach and 
disseminate.  The detachment and dispersal process acts to spread and prolong 
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infections making them persistent and greatly increased in severity [27].  Biofilm 
cells may be dispersed by the shedding of daughter cells from actively growing cells, 
by detachment due to lack of nutrients and migration to more supportive growth 
areas or by QS whereby an increase in cell density induces cell - cell signalling to 
direct the chemical degradation of EPS sending clumps of biofilm into the circulation 
[61].  Shearing (erosion/shearing, sloughing or abrasion) due to the flow effects 
urinary catheters are under is also a mechanism whereby cells become dispersed.  It 
has been suggested that detachment is probably species specific and the mode of 
dispersal may affect the phenotypic characteristic of the organism [61].  Detached 
biofilm cells can reattach to other parts of the catheter surface and seed the urine and 
bladder with pathogens which may get into the systemic circulation and cause 
bloodstream infections [61].  This shedding effect is of most clinical importance as it 
can result in organisms remaining in the urinary tract even following device removal 
and replacement. 
 
1.6.  Microbial Resistance  
The microbiological aspects of biofilms associated with symptomatic CAUTIs in 
terms of the species identified and their susceptibility can be misleading as they may 
reflect the organisms that were free floating when the urine specimen was collected 
as opposed to being isolated from a biofilm on a section of catheter [26].  Antibiotic 
treatment of planktonic bacteria may suppress symptoms of infection but 
concentrations fail to act on bacteria embedded in the biofilm [62].  That being said, 
their ability to at least slow biofilm formation and clear planktonic bacteria is of 
critical importance and their use continues until better therapeutic options become 
available [14].  In addition, the use of antibiotics prior to device placement or 
  Chapter 1 - Introduction and Aims 
29 
 
between device changes is crucial in helping control infection.  It is normal for 
symptomatic patients to have their catheter replaced and by doing this removes the 
biofilm but detached bacteria may re - seed the urine so it is usual to prescribe a 
course of antibiotics that are based on the microbiology results of the urine culture 
[14].  However, when antibiotic treatment is stopped, recurrent infection is common.  
Of major concern in the formation of biofilms is that the cells embedded in the 
depths of the biofilm are insusceptible to antibiotics and are inherently protected 
from host defences.  Studies have shown that some organisms within biofilms require 
>1000 fold higher concentration of antibiotics compared to their planktonic forms in 
order to kill them [62].   
 
As the understanding of biofilm resistance developed, three main mechanisms were 
hypothesised:   
 
x Hypothesis 1:  the slow penetration of antimicrobial agents into the depths of 
a biofilm is probably a major factor in conferring resistance [62].  The EPS 
may retard the antibiotic from reaching buried cells within the biofilm and the 
matrix may also inhibit the transfer of the antibiotic by destruction, chelation 
or direct blockage [27].  This may result in sub - lethal concentrations of 
antibiotic and allow for the build - up of resistance mechanisms [27]. 
x Hypothesis 2:  the development of altered microenvironments within a 
biofilm may lead to resistance.  The decrease in oxygen within the deeper 
layers of the biofilm can lead to anaerobic niches and some antibiotics lose 
activity under these conditions [62].  An accumulation of waste products can 
lead to an alteration in pH which can antagonise the action of antibiotics and 
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waste product levels or depletion of substrates can also cause the bacteria to 
enter a non - growing state [62].  Several groups of antibiotics are effective 
only on rapidly growing bacteria.  A change in the osmotic environment 
within a biofilm may also lead to resistance by changing the proportion of 
porins in a way that reduces cell envelope permeability to antibiotics [62]. 
x Hypothesis 3:  the production of a sub - population of microorganisms forms 
a highly protected dormant state of cells that are similar to bacterial spores.  
This is supported by studies that found resistance in newly formed biofilms 
where the bacteria possess no particular resistance mechanisms to survive.  
These bacteria remain resistant upon repeat antimicrobial treatment and 
resume growth once the concentration of antibiotic drops to a sub - inhibitory 
concentration.  This may be a further mechanism that may explain why these 
persister type cells have reduced susceptibility to antibiotics [27].        
 
Proctor et al (1995) [63] report on small-colony variants (SCVs) of Staphylococcus 
aureus being cultured from patients with persistent and relapsing infections.  SCVs 
have been associated with some foreign body - associated infections, in particular 
with chronic catheter - related infections.  SCVs are a slow growing sub - population 
of bacteria which are better able to persist in mammalian cells and are less 
susceptible to antibiotics than their wild type counterparts [64].  They reflect 
impaired respiratory metabolism due to disruptions in the synthesis of constituents 
associated with the electron transport system and have unusual biochemical profiles 
[63, 64].  Clinically SCVs can be difficult to detect due to their atypical morphology 
and slow growing nature, but if detected, this may also be a reason for resistance to 
antibiotic treatment in clinical practice.   
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1.6.1.  Host Immune System Evasion 
In addition to cells within a biofilm being resistant to antimicrobial agents they are 
also inherently protected from host defence systems.  To maintain infection in the 
urinary tract organisms must evade the host immune response [53].  The urinary 
tract, however, contains receptors that recognize intruding pathogens by their 
invariant pathogen associated molecular patterns (PAMPs) and of the immune 
surveillance molecules, toll-like receptors are able to detect PAMPs [65].  These act 
to mobilize appropriate immune defence systems which help to eliminate bacteria 
from the urinary system.  Uropathogenic bacteria, however, excrete a variety of 
virulence factors that enable them to inhibit certain host functions and promote 
colonisation.  In Gram negative bacteria, the production of capsules plays a role in 
immune evasion as they resist phagocytosis.  During the course of a UTI, 
immunoglobulin (Ig) antibodies secreted by the host in response to infection 
recognise antigenic components of uropathogens.  However, some bacteria break 
down host Ig using Ig proteases and other host defence systems like complement 
(Clq and C3) [53].  Other virulence factors associated with Gram negative bacteria 
include toxins such as haemolysin and lipopolysaccharide (LPS).  LPS acts as an 
endotoxin and elicits a strong immune response and is in part responsible for the 
clinical manifestations during infection brought about through cytokine release.  
Figure 1.5 [53] depicts the virulence factors of the Gram negative uropathogens 
E.coli and P.mirabilis.  This evasion of the host immune system in response to 
infection by the biofilm cells along with their insusceptibility to antimicrobials 
makes treatment difficult and costly.     
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Figure 1.5: Virulence factors of the Gram negative uropathogens E.coli and P.mirabilis [53].                 
(IM = inner membrane, OM = outer membrane)     
 
 
1.6.2.  Symptoms 
 
Although long - term urinary catheterisation is synonymous with bacteriuria, 
bacteriuria is not synonymous with symptomatic UTI [26].  Over 90% of cases are 
asymptomatic [32].  Current evidence suggests that asymptomatic patients should not 
be treated unless the patient is immunosuppressed, at risk of bacterial endocarditis, 
pregnant or due to undergo urinary tract instrumentation, as these infections clear up 
once the catheter is removed [53, 66]   
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The symptoms a patient with symptomatic CAUTI may experience can vary from 
mild to severe.  They may feel pressure in their lower pelvis, have urine that has an 
odour to it or is cloudy which sometimes may contain blood (haematuria), and a 
patient may also experience leakage of urine [67].  Additional symptoms may 
include:- fatigue, fever, vomiting, mental changes or confusion [67].  Often in the 
elderly, mental changes or confusion are the only symptoms of a possible CAUTI 
[26].  Symptoms however may be subtle and may also be due to the presence of the 
catheter itself as opposed to infection [26].  If suspected, analysis of the urine may 
show the presence of white blood cells (WBCs).  A high WBC count of >10 per µl is 
indicative of infection.  A urine culture with counts of >103 cfu/mL of a predominant 
pathogen will determine the type of bacteria present and susceptibility tests will 
determine the appropriate antibiotic for treatment.  If left untreated, pylenephritis, 
calculus formation, bacteraemia, urosepsis and even death can result [53].   
 
1.6.3.  Treatment 
For all patients on LTC, it is recommended that their catheters be changed according 
to their clinical needs or as recommended by the manufacturer of the catheter which 
is usually at 10 - 12 week intervals [21].  If symptomatic CAUTI is confirmed, 
evidence indicates that it is better to change the catheter before antibiotic treatment is 
initiated [16].  Infection with one type of organism can be treated with either 
trimethoprim, which acts upon most uropathogens except for Pseudomonas and 
Enterococcus species, fluoroquinolones which are effective against many Gram 
negative organisms including most Pseudomonas and Proteus species or with 
nitrofurantoin, a UTI - specific antibiotic that is effective against most uropathogens 
except Pseudomonas and Proteus species [53].  Patients with infections that are 
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polymicrobial may be treated with trimethoprim or a cephalosporin such as 
cefuroxime [53].  Seriously ill patients may require a two - drug treatment regimen to 
control infection, especially if they have repeated polymicrobial infections.  For 
certain symptomatic patients, due to the high relapse rate, catheter replacement may 
have to be performed as often as every 2 - 3 weeks.   
 
Infections associated with biofilms are rarely resolved using antibiotics alone even 
when the patient¶s immune system is fully functioning [27].  Even if a symptomatic 
patient¶s catheter is replaced and antibiotics given, there is a high incidence of 
recurrent infection causing severe distress and long - term morbidity to the patient 
[38].  It has been known for P.mirabilis infections of a single genotype to persist in 
the urinary tract despite many catheter changes, antibiotic treatment and periods of 
non - catheterisation [24].  Universally the only recommended guidelines to reduce 
the risk of bacterial infection are to maintain a closed drainage system and to 
minimise the duration of catheter usage as much as possible [53].  Despite the 
treatment measures, for some patients there is no satisfactory resolution to the 
problem and there remains a need to develop a strategy/measure to reduce the 
occurrence of CAUTIs. 
 
1.7.  Reducing CAUTIs 
Little has changed in the way Foley catheters are designed other than the change 
from an open drainage system to a closed one which dramatically reduced CAUTIs.  
The correct size of catheter, proper aseptic technique upon catheter insertion and post 
- catheterisation care are important measures to limit the chance of acquiring an 
infection.  The isolation of catheterised patients in some hospital settings is also 
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recommended to help prevent cross infection along with continued good hand 
washing practice.  The overuse of catheters in particular needs to be carefully 
monitored and alternatives such as suprapubic and intermittent catheterisation should 
be considered as a means to reducing CAUTIs. 
 
In the past irrigating the bladder with antimicrobial agents, instilling antimicrobial 
solutions into the drainage bag and soaking the catheter in an antiseptic prior to 
insertion have been studied as ways of reducing CAUTIs [68], [69].  These methods 
have proved unsuccessful and in cases with continuous exposure to anti - infective 
irrigating fluid an increase in resistant microorganisms has been shown [69].  A 
newer approach has involved examining the effect instilling aganocides into the 
bladder has on reducing urinary catheter blockage, encrustation and infection.  
$JDQRFLGHVPLPLFWKHERG\¶VRZQQDWXUDOGHIHQFHVDJDLQVWLQIHFWLRQ7KHDJDQRFLGH
NVC-422 LVDGHULYDWLYHRIWKHERG\¶s natural biocide N-chlorotaurine which mimics 
the activity of pathogen - killing neutrophils [70].  Studies involving the instillation 
of NVC-422 into the bladder for 1 hour before being drained away showed it to 
possess broad spectrum antimicrobial activity against uropathogens, bacteria 
resistant to antibiotics, and bacteria encased in a biofilm [70].  As NVC-422 mimics 
the ERG\¶V own natural defences, bacterial resistance to it is thought to be low.  
NovaBay Pharmaceuticals are currently in the process of undergoing Phase 2 clinical 
trials on the use of NVC-422 solutions to control bacteria that develop on urinary 
catheters and in the bladder and if a positive reduction in CAUTIs and blockage is 
shown it is possible that installation of aganocide into the bladder could become a 
routine part of catheter care.            
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Jones et al (2006) [21] investigated loading the antimicrobial agent triclosan into 
catheter retention balloons to determine whether the membrane of the balloon could 
act as a barrier to control the release of the agent into the urine over a prolonged 
period.  Catheterised bladder models infected with P.mirabilis revealed that triclosan 
diffused through the balloon and into the urine which allowed the catheters to drain 
freely for the experimental period of 7 days with little sign of encrustation.  It was 
estimated that the retention balloon could give protective activity at a rate that was 
estimated to cover at least 12 weeks.  The group did, however, highlight the 
importance of monitoring urinary flora for signs of the emergence of resistance to 
triclosan and this should always be considered when introducing antimicrobial agents 
to deal with infections. 
 
The potential of bacteriophage (viruses that selectively infect bacteria) therapy in 
reducing/treating CAUTIs is also a strategy that has been studied.  Carson et al 
(2010) [71] found that Foley catheters coated in a hydrogel treated with a cocktail of 
bacteriophage cultures were capable of not only preventing biofilm formation by 
bacteria commonly found in CAUTIs but was also able to kill off >99.9% of an 
established E.coli biofilm.  Similarly Curtin et al (2006) [72], report on a hydrogel 
catheter coated in Staphylococcus epidermidis phage which significantly reduced 
biofilm counts of S.epidermidis by >4 logs over 24 hours.  There are, however, 
important factors which should considered when evaluating the potential of phage to 
control biofilms.  The high specificity of phage, bacterial mutants which exhibit 
phage resistance, how a SDWLHQW¶V immune system will respond to phage, the purity of 
phage and potential for transfer of genes encoding bacterial toxins or other virulence 
factors are areas of concern over their use [73].  A mixture of phage or engineered 
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phage may however help overcome these potential drawbacks.  However, for urinary 
catheter biofilms, careful selection of phage would be required as a variety of 
bacterial strains may potentially colonise the catheter.  The capacity of the catheter 
coating to adsorb phage, ensure their stability and infectivity and the impact of the 
presence of a conditioning film on the ability of phage to kill bacteria, require 
investigations but with further validation the approach may show some potential in 
reducing biofilms on medical devices. 
 
Perni et al (2009) [74] reported on silicone elastomers containing a light - activating 
antimicrobial agent (LAAA) - methylene blue (MB) with and without gold 
nanoparticles (AU).  Light of certain wavelengths transforms MB to an active state 
and in the process produces reactive oxygen species (ROS) [74].  ROS cause damage 
to a range of microbial components and thereby reduces the opportunity for the 
organism to develop resistance [75].  Polymers containing MB with AU showed a 
significant reduction in E.coli and MRSA within five minutes of irradiation [74].  It 
is envisaged that short pulses of laser irradiation at the catheter entry site and along 
the catheter length would be sufficient to prevent the accumulation of bacteria and 
would hence reduce the incidence of catheter - related infections.  The scale - up of 
this to a commercial catheter system is critical but could prove to be beneficial in 
reducing CAUTIs.  Similarly the incorporation of the photosensitiser toluidine blue 
(TBO) into polymers such as polyurethane and silicone have exhibited exceptional 
kill against MRSA and E.coli  [75].   
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A more common approach to prevent bacterial colonisation on urinary catheters and 
subsequent biofilm formation has involved loading catheters with broad spectrum 
antimicrobial agents.   
 
1.7.1.  Means of Making Catheters Antimicrobial 
There are a variety of ways in which catheter materials can be made antimicrobial 
and are detailed below.  
 
1.7.1.1.  Immersion/Dipping 
Simply immersing or dipping the material into an aqueous antibiotic/antiseptic 
solution forms a protective anti - infective layer over the material.  A recent example 
of this by Hernandez et al (2009) [76] involved dipping a polymer into a 
combination of N-acetylcysteine, gentamicin and amphotericin B for the prevention 
of microbial colonisation of ventricular assist devices.  The antimicrobials adsorb to 
the surface but are not dispersed throughout the polymer matrix, making the drugs 
wash off easily.  This may be sufficient to reduce early onset bacterial colonisation 
but is not suitable for preventing colonisation upon devices that are used long - term 
[77].  It has been reported that immersion of hydrophobic materials into an 
antimicrobial solution results in more weak and limited surface attachment compared 
to hydrophilic materials [77].  Applying hydrogels to catheters makes them more 
hydrophilic and also helps in the insertion process by reducing trauma caused the 
urethral mucosa.  As a consequence of their high water content, antimicrobial agents 
are easily taken up and released but their effectiveness with regards to CAUTIs has 
primarily been studied over a short duration (<7 days) [78].   
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1.7.1.2.  Coating 
Coating polymers with antimicrobial agents is and continues to be a much researched 
area both for use in urinary catheters and other catheter - related devices.  Coatings 
are usually formed on the external surfaces of catheters.  The nitrofurazone - coated 
urinary catheter, however, is an example where both the external and internal 
surfaces of the catheter are coated [58].  Nitrofurazone is applied in a silicone coating 
onto the catheter surfaces which releases into the surroundings.  Coatings can be 
added to polymers post - manufacture which has its benefits but like materials that 
are immersed/dipped into antimicrobial solutions, coatings of antimicrobial agents 
are easily washed off once inserted into the body making their duration of protective 
activity suitable only for short - term use.  The formation of a conditioning film on 
the surface can also result in the coating being masked affecting the release of 
antimicrobial agents. 
 
1.7.1.3.  Matrix Loading 
Matrix loading is a further technology used whereby antimicrobials become directly 
incorporated into the polymer matrix either by an admixture or impregnation process.  
This can be performed at the polymer synthesis stage or post - manufacture.  The 
admixture process involves mixing the antimicrobial powders into the raw material 
during the pre - manufacture stage.  A polymer in which the drugs are distributed 
throughout the whole of the device in the form of small drug particles is created.  An 
example of this technology is the External Ventricular Drain (EVD) (VentriClear II) 
[79] used in neurosurgery and the Central Venous Catheter (CVC) [80] which both 
contain an admixture of minocycline and rifampicin.  Similarly antimicrobial agents 
can be distributed through the whole polymer protecting the internal and external 
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parts of the catheter, by using an impregnation process [81].  Impregnation is a 
solvent - based procedure that introduces the antimicrobial agents into the polymer 
matrix as molecules [81].  A successful application of this is the Bactiseal Shunt used 
in neurosurgery that contains rifampicin and clindamycin [82-84].  Neither the 
admixture nor the impregnation process result in the rapid wash off of the 
antimicrobials, instead the agents are continually and gradually released over time.  
The impregnation process also has the added benefit of the drugs being in a 
molecular form giving a more even distribution and release from the polymer 
compared to the crystalline admixture polymers.  Although the Ventriclear EVD and 
Bactiseal Shunts are designed to release antibiotics short - term there may be scope 
for matrix loaded devices to be effective over a longer duration.   
 
1.7.2.  ReleaseNF® Urinary Catheter  
Currently there are two main antimicrobial urinary catheters on the market.  The 
ReleaseNF® catheter (Rochester Medical Corporation, Minnesota, USA) (Figure 
1.6) and the Bardex® I.C. catheter (Bard Medical, Georgia, USA) (Figure 1.7).  The 
ReleaseNF® catheter contains the urinary antibiotic nitrofurazone which is matrixed 
LQWR WKHVLOLFRQHRI WKH FDWKHWHU¶V LQQHU DQGRXWHU VXUIDFHDOORZLQJ WKHDQWLELRWLF WR
elute both intraluminally and extraluminally [85].  Nitrofurazone is a broad spectrum 
agent that is claimed to be effective against many organisms associated with CAUTIs 
and the catheter works by eluting the nitrofurazone into the urethral tract and killing 
any planktonic bacteria before they get chance to colonise the catheter and develop 
into a biofilm [85].  
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Figure 1.6: ReleaseNF® urinary catheter [85]. 
 
 
1.7.2.1.  Review of the ReleaseNF® Urinary Catheter Clinical Trials 
There have been several clinical trials evaluating the effectiveness of the 
ReleaseNF® catheter on reducing CAUTIs.  Maki et al (1997) [86] conducted a 
prospective double blind trial involving 344 patients and found a three - fold 
reduction in the rate of CAUTI using the nitrofurazone catheters compared to 
conventional silicone catheters (2.4% vs 6.9%) which was significant for the first 5 
days of use.  Leclair et al (2000) [87] reported on the effect of the nitrofurazone 
catheters in a non - randomized surveillance study involving 30 patients on burns 
intensive care units.  A baseline incidence of CAUTI in the burns unit was reported 
as being 24.4 infections per 1000 catheter days.  The introduction of the 
nitrofurazone catheter to the unit showed a significant reduction to 7.3 infections per 
1000 catheter days.  Lee et al (2004) [88], reviewed 177 patients from five university 
hospital settings and also found a significantly lower number of infections using the 
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nitrofurazone catheter between days 5 - 7.  Stensballe et al (2008) [89], reported on a 
double blind randomized controlled trial involving 212 trauma patients.  They found 
the incidence of catheter - associated bacteriuria/funguria to be significantly less in 
the nitrofurazone group (13.8/1000 catheter days compared to 38.6/1000 catheter 
days in the control group).  From the examples of the clinical trials given and the 
many more, overall the clinical data imply that the nitrofurazone - coated urinary 
catheters are effective in reducing the rate of CAUTIs in patients on short - term 
catheterisation. 
 
1.7.3.  Bardex I.C.® Urinary Catheter 
The second of the main antimicrobial urinary catheters on the market is the Bardex 
I.C.® catheter which is coated on its inner and outer surface with a proprietary silver 
alloy.  It has a layer of hydrogel on the outside, a gold and palladium layer that 
claims to mediate the slow sustained release of the silver ions and keeps the silver 
surface stable, and the silver itself which is chemically anchored to the catheter 
surface and is released to minimise microbial adherence and biofilm formation [90].  
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Figure 1.7: Bardex I.C.® urinary catheter [90]. 
 
 
1.7.3.1.  Silver as an Antimicrobial Agent 
As silver conveys strong antimicrobial activity to a broad spectrum of organisms 
even at low concentrations, silver - based compounds are used in many medical 
applications.  Various forms of silver e.g. metallic silver, ionic silver, and silver 
nanoparticles have been employed to decrease infections associated with burns as 
well as in the prevention of bacterial colonisation upon numerous medical devices 
including catheters [91].  It has even been used within textiles and deodorants to 
eliminate bacteria.  The vast majority of silver antimicrobial activity is attributable to 
the action of the silver ion (Ag+) [92].  Due to the increase in multidrug - resistant 
bacteria against conventional antibiotic treatment, there has seen a resurgence in the 
use of silver [93].   
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Until recently little has been known about the mechanisms silver uses to kill 
microbes and these are still only partially understood [94].  It is known that silver has 
an ability to attack multiple sites within a cell which has benefits in the protection 
against resistance [92].  Silver ions bind strongly to electron donor groups containing 
sulphur, oxygen and nitrogen and interact with thiol groups of bacterial proteins and 
enzymes [93, 95, 96].  It inhibits bacterial growth, cell wall division and causes 
structural changes to cell membranes and contents within the cell [94, 95, 97].  Once 
inside the cell the silver ions interfere with DNA functions and cause suppression of 
processes such as respiration and electron transport components ultimately leading to 
cell death [93, 95].  There is still some scepticism as to whether bacteria can become 
resistant to silver.  The lack of standardised methods to determine bacterial 
susceptibility to silver and absence of recognised breakpoints complicates the 
interpretation of silver susceptibilities and resistance.  A few papers have however 
reported on silver - resistant bacteria found in environments where silver usage is 
greatest [98, 99].  Plasmid mediated silver resistance has been identified in some 
bacteria and in one case the silver resistant plasmid isolated from a Salmonella strain 
resulted in the deaths of several patients on a burns unit [96, 99].  The probability of 
transfer of silver resistance genes is considered to be low and the contribution to the 
emergence of antibiotic resistant bacteria is unclear [96].  Whether silver will cause 
resistance problems in the clinical setting or remain a rare occurrence is uncertain but 
it is important to monitor because modern day technology has developed a wide 
range of products that depend on silver as a key microbicidal component [98].     
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1.7.3.2.  Review of the Bardex I.C.® Urinary Catheter Clinical Trials 
Numerous clinical trials have taken place to determine how effective the silver alloy 
- coated urinary catheters are in reducing CAUTIs.  To highlight a few, Verleyen et 
al (1999) [100], performed a prospective randomized trial involving 180 patients on 
general and medical surgical wards and reported that by day 5 there was a 
significantly lower (p = <0.003) percentage of patients (6.3%) with the silver alloy 
catheter whom developed a CAUTI compared to (11.9%) the control latex catheter 
group.  Newton et al (2002) [101] reported on a retrospective trial where they took a 
baseline rate of CAUTI in burns patients who where catheterised between the years 
of 1998 and 1999.  Upon the introduction of the silver alloy catheter from the year 
2000 over the same length of time they found there to be a significantly lower (p = 
0.029) incidence of CAUTI.  A meta-analysis conducted by Schumm and Lam 
(2010) [5], also suggests that the use of silver alloy indwelling catheters for 
catheterising hospitalised adults short - term reduces the risk of catheter associated 
bacteriuria.  Overall the clinical data implies that the silver alloy - coated catheter is 
effective in reducing the rate of CAUTIs in patients on short - term catheterisation. 
 
1.7.4.  Limitations 
There are however limitations to the studies involving the nitrofurazone and silver 
alloy - coated urinary catheters.  Poor quality of available evidence, small study sizes 
and heterogeneity, unclear randomization and blinding, wide variation in antibiotic 
usage, absence of data on clinically meaningful endpoints and extensive post - 
randomization exclusions are amongst the limitations.  Patients having asymptomatic 
bacteriuria were commonly used as an outcome but the definition between studies 
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varied and no reference was made to distinguishing between symptomatic and 
asymptomatic bacteriuria (both were called UTI) [5].  Traunter et al (2004) [26] 
argued that the presence of bacteria in the urine in otherwise asymptomatic 
catheterised patients does not necessarily indicate that invasive infection of the 
urinary tract has taken place.  Further well - designed trials with clear aims, 
definitions and outcomes are needed to clarify the comparative utility and economic 
value of these types of antimicrobial urinary catheters [102].   
 
1.7.5.  Other Antimicrobial Urinary Catheters 
Besides the two marketed antimicrobial urinary catheters, several other antimicrobial 
agents have been incorporated into catheters and investigated for their ability to 
reduce CAUTIs.  A large randomized clinical trial by Riley et al (1995) [103] 
involving 1309 patients on indwelling catheterisation found that 11.4% of patients 
who had a silver oxide catheter in place developed bacteriuria compared to 12.9% of 
patients in the control group, this was not statistically significant (p = 0.45).  
Similarly a meta - analysis conducted by Saint et al (1998) [104] reported on clinical 
studies, four of which involved the silver alloy - coated urinary catheter [105-108] 
which had a significant effect on reducing CAUTIs as previously stated and four 
involving the silver oxide urinary catheter [103, 109-111] which did not significantly 
reduce CAUTIs and has since been taken off the market.   
 
Further to this Gaonkar et al (2003) [112], impregnated urinary catheters on the 
outside with chlorhexidine/triclosan and/or chlorhexidine/silver sulfadiazine/triclosan 
(latex and silicone) and monitored the ability of bacteria to adhere to the extraluminal 
surface of the catheter in an in - vitro model.  The chlorhexidine/silver 
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sulfadiazine/triclosan silicone catheters were found to resist colonisation by S.aureus 
and S.epidermidis for 23 and 24 days respectively.  Cho et al (2003) [113] showed 
that urethral catheters prepared by dipping with poly ethylene-co-vinyl acetate 
(EVA) and EVA/poly ethylene oxide (PEO) blends containing gentamicin exhibited 
antibacterial activity for 7 days against P.vulgaris, S.aureus and S.epidermidis.  
Similarly norfloxacin - releasing urethral catheters prepared by dipping with EVA 
and PEO and poly(dimethyl siloxane) (PDMS) as above were found to release 
norfloxacin for 30 days with the growth of E.coli, K.pneumoniae and P.vulgaris 
being inhibited for 10 days [114].  In addition to antimicrobial catheters, urinary 
catheters which are designed to be non - stick such as those with coatings consisting 
of polyethylene glycol (PEG) sidechains have also been investigated and have 
displayed a good ability to resist microbial attachment [115].   
 
Despite the countless studies that have looked into developing biofilm - resistant 
materials, with some good in - vitro, in - vivo and clinical evidence of biofilm 
inhibition, nothing has led to a urinary catheter or treatment that has been considered 
a true success in reducing CAUTI in patient on LTC.    
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1.8.  Release Mechanisms of Antimicrobials from Polymers  
The mode in which antimicrobial agents are incorporated into devices can affect the 
mechanism in which the agents release.  For example, drug release may involve 
diffusion, dissolution, erosion or swelling.  Matrix type devices, in which the 
antimicrobial agent is dispersed in a carrier e.g. a polymer, usually have some degree 
of mobility and may release by a diffusion process.  Once the polymer containing the 
agent comes into contact with an aqueous environment, drug molecules diffuse to the 
interfacial region of the polymer and migrate from it to the external environment.  
This is usually a result from differences in the concentration gradient.  Agents may 
also be triggered to release due to the ingress of an environmental agent e.g. water 
into a matrix, which can effectively act to swell the system and increase the polymer 
mesh size.  The aqueous content within the formulation enables the drug to diffuse 
through the swollen network to the external environment.  Alternatively, the event 
could lead to a chemical reaction which unbinds the agent e.g. hydrolysis or 
plasticise the matrix which allows physically bound molecules to diffuse out of the 
system [116].  A further drug release mechanism more common in tablet matrix 
systems is the process of dissolution where the drug is embedded in a slowly 
dissolving substance i.e. the drug particles are coated or encapsulated with slowly 
dissolving materials like cellulose [116, 117].  In the early stages of dissolution when 
the polymer comes into contact with a fluid environment, the polymer and drug may 
swell before dissolution starts and drugs start to exert their effects.  With erodible 
devices the agents are incorporated into a carrier which becomes eroded away by the 
environment through physical processes such as dissolution or chemical processes 
such as hydrolysis of the polymer backbone or crosslink [116, 117]. 
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Thus far, the mainstay of anti - infective urinary catheters has focussed the delivery 
of drugs over a short duration and clinical trials on long - term use are limited.  
Extrapolation of short - term studies to those catheterised long - term is unwise.  A 
study by Kohnen et al (2003) [118] produced a ventricular catheter by impregnating 
it with rifampicin and sparfloxacin using the solvent - based impregnation process.  
They report the catheter in in - vitro experiments showed a 99.8% reduction in the 
colonisation of S.epidermidis compared to control material which was effective for at 
least one year.  The successful clinical trial results achieved through the use of the 
Bactiseal Shunt [82-84] and the potential of this impregnation technology as reported 
by Kohnen et al (2003) [118] for extending the duration of activity has lead to the 
possibility of using this processing technology to see if it could be implemented to 
prevent bacterial colonisation on urinary catheters in patients on LTC. 
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1.9.  AIMS 
Biomaterials used to produce urinary catheters for long - term use that are completely 
resistant to bacterial colonisation for clinically significant periods remain elusive.  
This project proposes to modify a silicone urinary catheter by impregnating it with a 
suitable combination and concentration of antimicrobial agents intended to provide 
protection against bacterial colonisation and subsequent biofilm development in 
patients that are on LTC.  Patients on LTC will require a catheter to deliver a long 
duration of protective activity covering a broad array of uropathogens without the 
development of bacterial resistance if the rates of CAUTIs are to be reduced.     
 
The thesis takes a multidisciplinary approach and reports on the manufacture, 
development and rigorous in - vitro testing of the antimicrobial urinary catheter.  In 
addition to the ability of the antimicrobial agents to inhibit bacterial colonisation 
(Chapters 2 and 3), antimicrobial content and release profiles (Chapter 4), the effect 
of processing on the catheter surface (Chapter 5), and mechanical properties (Chapter 
6) will be elucidated in order to achieve the desired properties of the product.   
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2.0.  SCREENING TESTS 
 
2.1.  INTRODUCTION 
2.1.1.  Requirements of an Antimicrobial Urinary Catheter 
The main requirements which must be considered in the development of an 
antimicrobial biomaterial for use as a long - term indwelling urinary catheter are that 
it should be effective against principal pathogens involved in CAUTIs over a long 
duration typically the whole period of catheter implantation (10 - 12 weeks).  To 
inhibit bacterial colonisation, protection must cover both the inner and outer surfaces 
of the catheter and the antimicrobial agents used to achieve this must have a clean 
clinical history with no known significant risk of toxicity.  The drugs should remain 
stable upon sterilisation and storage and the incorporation of them into the silicone 
must not adversely affect the mechanical performance of the catheter or balloon.  
The selection of antimicrobial agents and their concentrations are most important to 
prevent the emergence of bacterial resistance.  The catheter is not intended to be 
capable of preventing bacterial attachment but rather to prevent colonisation and 
subsequent biofilm formation which make treatment more difficult.  
 
2.1.2.  Method of Antimicrobial Delivery 
A controlled release of a continuous delivery of sufficient doses of antimicrobial 
agents over a prolonged period is required if the antimicrobial catheter is to show any 
potential in reducing CAUTIs.  Ideally the drugs must be evenly dispersed 
throughout the polymer matrix but produce an initial burst effect to reduce the risk of 
infection upon catheter insertion followed by a long period of slow sustained release 
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to inhibit later infection.  The matrix loaded impregnation process is a suitable 
method for incorporating agents in this way.  A long duration of activity without the 
drugs being immediately released and incorporation throughout the whole of the 
material providing inner and outer surface protection can be provided using this 
process.  The impregnation process [81] requires the antimicrobial agents to be 
dissolved in a solvent e.g. chloroform.  Upon immersion of the silicone material, the 
chloroform acts to swell the matrix and the antimicrobial agents become incorporated 
through the whole of the material at a molecular level.  Once the chloroform is 
removed the silicone returns to its original shape and size leaving the antimicrobial 
agents within the matrix.  The main limitations of the impregnation process are that 
not all antimicrobial agents readily dissolve in chloroform and not all agents combine 
well.   
 
2.1.3.  Antimicrobial Agent Selection 
Several criteria need to be taken into account when selecting antibiotics for 
incorporation into silicone materials.  The agents need to be capable of molecular 
migration through the cross linked silicone polymer [81] and due to the possibility of 
bacteria becoming resistant if the catheter contains only one drug, a combination of 
antimicrobial agents is required to reduce this risk, the objective being that at least 
two if not three drugs with different mechanisms could act on Gram positive and 
Gram negative invading organisms at any one time.   
 
The antimicrobial agents investigated in this project are listed in Table 2.1 and those 
selected for further testing are highlighted.   
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Table 2.1: Antimicrobial agents and their properties [119-121]. (agents highlighted in red were 
selected for further testing) 
 
 
Class/drug Molecular 
weight 
(g/mol) 
Solubility 
in water 
Solubility in 
organic 
solvents 
Antibacterial 
spectrum 
Reason for 
rejection or 
acceptance of 
agents 
Aminoglycosides      
Gentamicin 
sulphate 
477.6 Highly 
soluble 
 
Low: alcohol, 
acetone, CHCl3, 
ether, benzene 
  
Broad spectrum, 
many Gram positive 
and Gram negative 
bacteria 
Not dissolvable 
in CHCl3 
Lincosamides      
Clindamycin 
hydrochloride 
424.9 Highly 
soluble 
High: DMF, 
EtOH, MeOH, 
CHCl3, ether, 
benzene 
Low: acetone 
Mostly active on 
Gram positive 
bacteria 
Good Gram 
positive activity 
but not 
compatible with 
some other 
agents and 
expensive 
Quinolones      
Norfloxacin 319.3 Slightly 
soluble 
High: acetic 
acid, CHCl3  
Slight: alcohol, 
acetone, ethyl 
acetate  
More effective 
against Gram 
negative than Gram 
positive bacteria but 
covers several 
important pathogens 
in both groups 
Good Gram  
negative activity 
but sparfloxacin 
gave longer 
duration of 
activity 
Sparfloxacin 392.4 Practically 
insoluble 
High: acetic 
acid, CHCl3, 
NaOH 
Slight: EtOH 
Low: ether 
More effective 
against Gram 
negative than Gram 
positive bacteria but 
covers several 
important pathogens 
in both groups 
Long duration 
of activity 
particularly 
towards Gram 
negatives  
Rifamycins      
Rifampicin 823.0 Slightly 
soluble 
 
High: DMSO, 
THF, CHCl3, 
MeOH, ethyl 
acetate 
Low: acetone 
Mostly Gram 
positive bacteria 
and some fastidious 
Gram negatives. 
Mycobacteria 
Long lasting 
Gram positive 
(staphylococcal) 
activity 
Tetracyclines      
Minocycline 457.5 Soluble 
 
High: alkali 
hydroxides and 
carbonates 
Low: EtOH, 
CHCl3, ether 
Broad spectrum, 
many Gram positive 
and Gram negative 
bacteria 
Not dissolvable 
in CHCl3 
Trimethoprim      
Trimethoprim 290.3 Slightly 
soluble 
High: benzyl 
alcohol  
Slight: alcohol, 
acetone, CHCl3 
Low: ether 
Mostly Gram 
negative bacteria 
but with some Gram 
positive activity 
Good Gram 
negative activity 
but commonly 
used to treat 
UTIs and 
showed signs of 
resistance  
 
 
 
 
 
 
 
  Chapter 2 - Screening Tests 
55 
 
Antiseptics      
Triclosan 289.5 Practically 
insoluble 
High: EtOH, 
MeOH, acetone 
CHCl3 
Low: water 
Broad spectrum, 
many Gram 
positive and Gram 
negative bacteria 
(except 
Pseudomonads), 
some antifungal 
activity 
Long duration 
of activity 
against a broad 
spectrum of 
bacteria 
Hexetidine 339.6 Slightly 
soluble 
High: acetone, 
alcohol, CHCl3, 
dichloromethane 
Broad spectrum, 
many Gram 
positive and Gram 
negative bacteria 
Short duration 
of activity even 
at higher 
concentrations 
Octenidine 
dihydrochloride 
623.8 Slightly 
soluble 
High: EtOH, 
MeOH, CHCl3 
Broad spectrum, 
many Gram 
positive and Gram 
negative bacteria 
Short duration 
of activity even 
at higher 
concentrations 
 
2.1.4.  Resistance Theory and Approach  
The increasing problem of bacterial resistance in healthcare settings is a worldwide 
issue, hence the potential for the development of resistance to antimicrobial agents 
introduced into polymers for clinical use is of concern [77].  Antibiotics can be 
classified according to their minimum inhibitory concentration (MIC).  This refers to 
their ability to inhibit the growth of susceptible bacteria.  Antibiotics released at sub - 
cidal concentrations may evoke selection of resistant strains and intensify infectious 
complications [119].  This can depend on the concentration of antibiotic, duration of 
action, size of the inoculum and frequency of resistant variants.  
 
An antibiotic concentration window as shown in Figure 2.1 exists in which resistant 
mutants are selectively amplified [122].  The lower boundary is the drug 
concentration at which growth inhibition of the majority of the susceptible cells 
begins, and is approximated by the MIC [122].  At a concentration just above the 
MIC, only one mutation is required for a bacterial cell to grow in the presence of the 
antibiotic and an infection can contain sufficient cells for first step resistant mutants 
to be present.  It has been proposed that the upper boundary of the window acts an 
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antibiotic concentration that blocks the growth of first step resistant mutants and  
requires cells to attain two resistance mutations in order to grow [122].  Events of 
this type are rare and it is expected that mutants will not be recovered above this 
concentration.  This is termed the mutant prevention concentration (MPC) [122].    
Resistant mutants are therefore selectively enriched in the concentration range 
between the MIC and the MPC.  This is designated the mutant selection window 
(MSW) [122].     
 
 
 
Figure 2.1: A pharmacodynamic depiction of the mutant selection window [123]. 
 MPC = Mutant prevention concentration.  MIC = Minimum inhibitory concentration   
 Cmax = Maximum concentration 
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Each type of bacterial - antimicrobial combination has its own characteristic MSW.  
Resistant mutants can also be enriched by repeated passage of cells at concentrations 
just below the MIC [123].  Low drug concentrations do not enrich resistant mutants 
per se but allow for bacterial populations to increase which consequently indirectly 
fosters the generation of new mutants that will be enriched by subsequent 
antimicrobial challenge.  If antibiotic treatment were continued, resistant mutants 
would be selectively enriched and treatment may fail.  Passage of a pathogen through 
many treated patients is expected to gradually increase the mutant fraction of the 
bacterial population [123].  Antimicrobials may cure the vast majority of infections 
but when millions of cells are considered the development of resistance is an 
inevitable consequence of dosing strategies that place drug concentrations inside the 
MSW, especially if treatment is prolonged [123]. 
 
If the MSW can be made narrower or closed, no mutant will be selected.  One of the 
ways to achieve this is to avoid prolonged therapy within the MSW concentration 
range as mutant fractions will be enriched [122], but this is difficult to achieve for 
patients undergoing urinary catheterisation as certain groups require long - term 
therapy.  Dual drug therapy involving a combination with two or more different 
classes of drugs released at concentrations above their MICs should require two 
resistance mutations for growth.  This can close the mutant selection window if their 
normalised pharmacokinetic profiles superimpose at concentrations that inhibit 
growth [123].  When antibiotic concentrations drop below the MIC both mutants and 
wild type cells increase in numbers and more spontaneous mutants are generated.  If 
treatment is stopped before mutants reach a high number they may not be detected.  
For mutants to be selected, the concentration of one compound must occasionally fall 
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below its MIC while that of the other remains above its MIC but below its MPC.  
The MSW is open for the drug that remains above its MIC for resistance to that 
compound to be enriched.  After a population resistant to one compound has grown 
out, selection of resistance to the second compound soon follows when its 
concentration approximates the MIC [122]. 
 
It has been demonstrated that rifampicin at concentrations higher than its MIC can 
select for resistant staphylococci if applied to a large inoculum but at sub - inhibitory 
concentrations and if applied to a smaller inoculum, rifampicin resistance may not be 
enhanced [124].  The risk for selection of resistant microorganisms is therefore the 
period at which the concentration of antibiotics approximates to the MIC or when it 
is lower than its value [124].  The longer the concentration of antibiotic is below the 
MIC the greater the risk that resistant organisms will be selected.  An example of 
where the use of a combination of antimicrobials has been successful in acting to 
decrease the selection for resistant organisms is in the drugs prescribed for the 
treatment of tuberculosis.  It is therefore important to try to create a combination of 
antimicrobial agents that release equally from the biomaterial at concentrations over 
prolonged periods that are above their MIC towards the uropathogens if resistance is 
to be avoided.  It is anticipated that the antimicrobial agents selected for further 
investigation, combined would have the potential to prevent the emergence of 
bacterial resistance.  As rifampicin is active on Gram positive organisms, 
sparfloxacin predominantly on Gram negative organisms and triclosan on both, if 
bacteria are sensitive to two or more of the agents then this could provide a dual drug 
type therapy that could help in the protection from resistance.     
  Chapter 2 - Screening Tests 
59 
 
2.1.5.  Selected Antimicrobial Agents 
 
Below is a description of the antimicrobial agents selected from Table 2.1 to 
impregnate into the urinary catheter.  Further reasoning for the selection of these 
agents is given in Section 2.4. 
 
2.1.5.1.  Rifampicin 
Rifampicin is a bactericidal antibiotic belonging to the rifamycin group (Figure 2.2).  
It acts by inhibiting RNA polymerasHE\ELQGLQJWRLWVȕ-subunit thereby preventing 
the transcription to mRNA and subsequent translation to polypeptides and proteins 
[125].  It is used to treat a variety of bacterial infections especially those due to 
organisms that are Gram positive.  Rifampicin is well tolerated and a typical oral 
dose consists of 150 - 300 mg.  Excretion via faeces i.e. bile accounts for 60 - 65% 
with the remaining being excreted via the urine.  Rifampicin is a solid red coloured 
antibiotic and can impart a harmless red/orange colour to urine and to a lesser extent, 
tears and sweat.  Bacterial resistance to rifampicin is common since it only requires a 
single mutation step to render them resistant hence it is normal to use rifampicin in 
combination with other drugs that act synergistically to improve outcomes of 
infection [15].  
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Figure 2.2: Structural representation of rifampicin [126]. 
 
 
2.1.5.2.  Sparfloxacin 
Sparfloxacin is a member of the quinolone family.  Quinolones are chemotherapeutic 
bactericidal drugs which can be further divided into the subset fluoroquinolones, to 
which sparfloxacin belongs.  It has a fluorine atom attached to its central ring system 
at the C6-C8 position (Figure 2.3) and possesses a broad range of anti - Gram 
positive and anti - Gram negative activity [127].  It acts by interfering with DNA 
gyrase or topoisomerase enzyme types II and IV thereby inhibiting DNA replication 
and transcription [127].  DNA gyrase is the target in many Gram negative organisms 
and topoisomerase IV enzyme the target in many Gram positive organisms [127].  
Sparfloxacin has been used in the past to treat respiratory disorders.  A typical oral 
dose is 400 mg once daily on the first day, reducing to 200 mg per day thereafter 
[127].  Elimination of sparfloxacin is through the renal, biliary and transintestinal 
secretion routes [128].  Fluoroquinolones are quite well tolerated with most side 
effects involving the gasterointestinal and central nervous system being mild to 
moderate.  Photosensitivity has been shown to be prevalent amongst all quinolone 
antibiotics and this is especially true of sparfloxacin [129] with reactions such as 
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erythema and rashes being reported [127].  Adverse events are unusual, but 
quinolones have been associated with problems of the cardiovascular system such as 
prolongation of the QT interval and of the muscoskeletal system such as tendinitis 
and tendon rupture in particular being more common amongst the elderly and 
athletes in training who are receiving corticosteroids [130].  Quinolones may 
adversely interact with anticoagulants e.g. warfarin and medications for seizures e.g. 
epilepsy medications and should be used judiciously to minimise complications as 
Clostridium difficile associated diarrhoea [130].  Resistance to quinolones can occur 
via three mechanisms: efflux pumps, plasmid mediated or mutations at sites within 
DNA gyrase and topisomerase IV enzyme which can decrease the binding affinity to 
quinolones and their effectiveness [131].      
 
 
 
 
Figure 2.3: Structural representation of sparfloxacin [132]. 
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2.1.5.3.  Triclosan 
7ULFORVDQ ¶-trichloro-¶-hydroxydiphenylether) belongs to a class of 
compounds known as the bisphenols (Figure 2.4).  It has a broad spectrum of activity 
acting mostly as an antibacterial but possesses some antifungal and antiviral activity.  
Triclosan acts on the fatty acid biosynthetic pathway.  It binds to the enoyl-acyl 
carrier protein reductase enzyme (ENR) which is coded by the Fab1 gene [133].  
Binding to this increases the enzyme¶s affinity for nicotinamide adenine dinucleotide 
(NAD+) and by interacting with amino acid residues of the enzyme¶s active site, a 
stable ternary complex of ENR-NAD+ is formed which cannot participate in fatty 
acid synthesis [133, 134].  Fatty acids are components of phospholipids and 
sphingolipids that make up cell membranes which are essential for microbial systems 
[135].   
 
 
 
Figure 2.4: Structural representation of triclosan [136]. 
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Triclosan has been in use for more than 40 years and can be found in many products 
including surgical scrubs, deodorants, hand soaps, toothpastes as well as in the 
fabric/plastics industries, for example having been incorporated into chopping boards 
[137].  It is not used as a systemic antimicrobial agent but is found in clinical use, for 
example in antibacterial sutures (coated polyglactin 910 suture containing triclosan) 
[138].  Triclosan has a favourable safety profile.  Toxicology studies show that it is 
not a carcinogen, mutagen or teratogen and has been found to be safe in reproductive 
studies [135, 139, 140].  Recently however the U.S. Food and Drug Administration 
(FDA) has raised concerns on the overuse of triclosan, its efficacy in household 
products and conflicting studies regarding links between triclosan and adverse health 
effects in animals and its uncertainty over potential harmful effects in humans [141, 
142].  Questions have been raised as WR ZKHWKHU WULFORVDQ GLVUXSWV WKH ERG\¶V
endocrine system which regulates growth and development and if the overuse of 
triclosan causes bacteria to become more resistant to antibiotics.  Bacteria develop 
resistance to triclosan using a variety of mechanisms.  These include target 
mutations, increased target expression, active efflux and enzymatic inactivation or 
degradation [134, 143].  Certain bacteria like P.aeruginosa have innate resistance to 
triclosan as they possess efflux pumps that pump triclosan out of the cell.  Due to the 
similar mechanisms of resistance to those seen with antibiotics, there is concern that 
biocides may share target sites with antibiotics used in clinical practice and bring 
about cross - resistance.  This has in fact been shown in laboratory studies where a 
Fab1 mutation in triclosan caused cross - resistance with other antibiotics in E.coli 
[144].  Whether its widespread use and potential overuse will cause a major increase 
in antibiotic resistance in a clinical setting is a subject of much debate.  A regulatory 
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report reviewing data indicating triclosan to be safe and the more recent conflicting 
data from the U.S FDA is due to be published in 2011 [145]. 
 
2.1.6.  Laboratory Testing Methods 
 
Before clinical trials commence, laboratory tests need to be undertaken to gain 
insight into the likely outcome of reducing infections in clinical situations.  A 
number of techniques and models have been used to study the effectiveness of 
antimicrobial materials in reducing bacterial numbers, although there is no standard 
method. 
 
A conventional screening system used is the agar diffusion assay which is based on 
the inhibition of microbial growth on an agar plate by the diffusible activity of the 
antimicrobial agent [146].  The size of the zone of inhibition (ZI) surrounding the test 
material is indicative of its antimicrobial activity.  The method is, however, only 
applicable to those antimicrobial systems that give rise to diffusible activity and 
cannot be used when silver is the antimicrobial agent.  The agar diffusion method can 
be adapted and by transferring the material onto freshly inoculated agar plates, the 
duration of antimicrobial activity can be examined [81].  This test is termed the serial 
plate transfer test (SPTT).  It is a useful screening test for investigating the 
diffusibility of agents from polymers and to study their spectrum of antimicrobial 
activity as well as an indirect way of gauging the DJHQW¶V ability to provide a long 
duration of activity.  A short SPTT duration can indicate activity is refined to the 
surface of the material whereas a more persistent duration indicates the antimicrobial 
agents diffuse from the matrix.  Antimicrobial agents can be assessed on an 
individual basis or in combination.  The SPTT can also help to detect for the 
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possibility of bacteria becoming resistant to the agents.  As the drugs leach out from 
the material its repeated passage through lawns of bacteria can result in visible 
bacterial growth attached to the material or colonies within the ZI indicating possible 
resistance which can be examined further.  
 
Historically, to assess the bactericidal activities of antimicrobial agents, time - kill 
studies have been used [147].  There are several ways of performing these studies but 
all basically involve exposing the material to a suspension of cells for a determined 
period of time to allow for the cells to attach.  Non - adherent cells are removed by 
rinsing and the remaining adhered cells quantified [52].  It is important to assess the 
antimicrobial agents activity against attached bacteria as they can show a decrease in 
antimicrobial susceptibility compared to planktonic forms [148].  There are a number 
of ways of quantifying adhered bacteria, each with their own advantage for specific 
purposes.  Examples include: microscopy techniques (light, image analysed 
epifluorescence, scanning electron microscopy) for counting and morphological 
observations of adherent bacteria, and viable bacterial counting techniques which can 
involve removal of the bacteria from the surface by sonication and quantifying them 
by colony counting on agar plates, radiolabelling or 5-cyano-2,3,-ditolyl tretazolium 
chloride (CTC) staining methods [52, 149].  Roll plate methods where bacteria 
attached to the material are rolled back and forth over an agar plate and bacterial 
growth observed have also been used [150].  A major disadvantage of this is that 
only the external surface can be cultured [151].  Ideally it is hoped that the 
antimicrobial agent release will be sufficient to kill 100% of attached bacteria.  The 
test is termed the tK100 test and refers to the time taken to kill 100% of attached 
bacteria [152]. 
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2.1.7.  Objectives 
It is a requirement of the antimicrobial urinary catheter to give a long duration of 
activity against pathogens commonly isolated from patients on LTC and to provide 
protection from bacterial colonisation and the development of resistance.  This 
chapter describes the screening tests used to select the effectiveness of the chosen 
antimicrobial agent¶s ability to provide a long duration of protective activity.  It is 
expected that as rifampicin acts on Gram positive organisms, sparfloxacin 
predominantly on Gram negative organisms and triclosan on both, the combination 
of agents could also help reduce the opportunity of bacteria becoming resistant.  The 
SPTT and tK100 tests were used to establish this.   
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2.2.  METHODS 
 
2.2.1.  Biomaterial 
Medical grade all silicone sheets (Goodfellow, Huntingdon, UK) of 1 mm thickness 
were cut to form 6 mm discs and used in the SPTT (see section 2.2.5) and tK100 (see 
section 2.2.6) tests.  For Chapters 3 to 6, Simpla all - silicone (14 Fr, Male) Foley 
catheters supplied by Coloplast, Peterborough, UK were used for testing purposes. 
 
2.2.2.  Antimicrobial Agents  
Rifampicin R3501 (Sigma-Aldrich, Poole, UK), Sparfloxacin 56968 (Sigma-Aldrich 
Poole, UK) and Triclosan USP (Ciba Speciality Chemicals, Macclesfield, UK) were 
the antimicrobial agents used predominantly through the course of the project.  
 
2.2.3.  Bacterial Characterisation 
Clinical strains of bacteria isolated from the urine of patients with CAUTIs were 
obtained from the Microbiology Department at the Queen¶s Medical Centre, 
Nottingham, UK.  Organisms were received plated on Chromogenic UTI Medium 
(Oxoid, Basingstoke, UK).  Chromogenic UTI Medium is a differential agar which 
provides presumptive identification of the main pathogens associated with CAUTIs 
as indicated by the colony colour (Table 2.2).  Individual colonies were sub - 
cultured onto Blood Agar Base No.2 with sheep blood (SBA, Oxoid) or Cystine-
Lactose-Electrolyte-Deficient Agar (CLED, Oxoid) as appropriate to obtain pure 
cultures.  Organisms were fully characterised by the following standard 
microbiological techniques: Gram Stain (Pro-Lab Diagnostics, Cheshire, UK), 
catalase test (hydrogen peroxide - Thornton and Ross Ltd, Huddersfield, UK), 
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DNAse test (Oxoid) and oxidase test (Oxoid) as appropriate.  API Staph or API 20E 
were carried out according to the manufacturer¶s instructions (bioMérieux® SA, 
0DUF\O¶(WRLOH)UDQFHDQGDQWLELRJUDPV2[RLGDVVKRZQLQ7DEOHMeticillin 
susceptibility was determined by growth on Iso-Sensitest Agar (ISA, Oxoid) by 
incorporating 4% Polyvinyl Pyrrolidone (Sigma-Aldrich, Dorset, UK) with or 
without meticillin at 12 µg/mL [153].  Precise MICs were obtained of rifampicin 
using E-Test strips (AB Biodisk, Solna, Sweden) and of sparfloxacin and triclosan 
using an agar incorporation method with a concentration ranging from 0.008 - 3 
µg/mL  as shown in Appendix 1.  All organisms were stored in Cryobank vials (Mast 
Diagnostics, Merseyside, UK) and kept in a -80°C freezer for future use.  Bacteria 
selected for this study were those most commonly isolated from the urine of patients 
with CAUTIs and which had an antimicrobial susceptibility profile that was 
representative of the individual organisms on the whole.  
 
 
Table 2.2: Chromogenic UTI Medium Colony Identification. 
Organism Colony Colour 
Enterococci Light Blue 
E.coli Pink 
Coliforms Purple 
Proteus/Morganella/Providencia spp Brown 
Pseudomonads Fluoresce 
Staphylococci Normal pigmentation 
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Table 2.3: Antibiogram Interpretation. 
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Discs containing different antibiotics were placed on ISA plates seeded with bacteria.  The antibiotics diffuse to create a ZI.  If the ZI was greater than the specified 
diameter (mm) for that antibiotic, the bacteria were classed as being sensitive (S) to that agent.  If the ZI was less than the specified diameter for that antibiotic, the 
bacteria were classed as being resistant (R) to that agent and were given a score.  All scores were added up to give an antibiogram number. 
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2.2.4.  The Impregnation Process: Production of Antimicrobial 
Catheter Material 
Rifampicin, sparfloxacin and triclosan were accurately weighed out and added to 
chloroform to give concentrations (w/v) of 0.2%, 1% and 1% respectively.  Once 
fully solubilised, the silicone material, either the 6 mm silicone discs or the silicone 
Foley catheters were immersed in the appropriate volume of the antimicrobial 
solution (50 mL or 250 mL) and left for 1 hour at room temperature.  The 
antimicrobial solution was then removed and the silicone rinsed with ethanol to 
remove residual chloroform.  Samples were left overnight to air dry at room 
temperature for solvents to evaporate and for the silicone to return to its original size 
entrapping the antimicrobial agents throughout [154].  Control material was 
processed in the same manner but without the addition of the antimicrobial agents.  
All samples were sterilised by autoclaving at 121°C for 15 minutes. 
 
2.2.5.  Serial Plate Transfer Test 
Uropathogens were sub - cultured onto SBA or CLED to obtain pure cultures.  1 - 3 
colonies were added to 5 mL of sterile distilled water to make a 0.5 McFarland 
suspension.  20 mL ISA plates were prepared and inoculated using a cotton bud stick 
with bacterial suspension.  Antimicrobial impregnated silicone discs were applied to 
the centre of the plates and incubated overnight at 37°C.  Silicone discs without 
antimicrobial agents served as controls.  ZI (minus the disc diameter) were measured 
using digital callipers and recorded.  Those discs showing ZI were removed and 
transferred to further freshly seeded agar plates, ensuring that the same side of the 
disc surface was in contact with the agar.  All tests were carried out in triplicate.  The 
process was continued until no more ZI were seen, or until the test was terminated at 
100 days.  If there was still a ZI around the antimicrobial disc but evidence of 
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bacteria attaching to it, it may be an indication of resistance development.  If 
suspected, the attached bacteria were isolated, their identity compared to the original 
inoculum to exclude contamination and MIC to the agent/s in the disc determined as 
shown in Section 2.2.3. 
   
For the SPTT, discs were impregnated with 0.2% rifampicin only, 1% sparfloxacin 
only, and 1% triclosan only, and in combination (0.2% rifampicin, 1% sparfloxacin, 
1% triclosan).  The spectrum and duration of activity were established for the single 
agents and all three agents combined.  The other agents listed in Table 2.1 were also 
screened using the SPTT against several of the uropathogens for their potential 
duration of activity and resistance development.  If the bacteria showed signs of 
becoming resistant, the MIC of the agent was determined.  
 
2.2.6.  Determination of Time Taken to Kill Attached Bacteria 
Uropathogens were sub - cultured onto SBA or CLED to obtain pure cultures.  A 
loopful of each was placed into 20mL universal containers containing Tryptone Soya 
Broth (TSB, Oxoid) and grown to early log phase in a 37°C shaker incubator set at 
200 rpm for 4 hours.  Universals were centrifuged for 20 minutes at 3000 rpm and re 
- suspended in a predetermined percentage (%) TSB (refer to section 2.2.6.1).  
Bacterial suspensions were adjusted to A490 0.6 - 0.7 using a Jenway 6705 UV/Vis 
Spectrophotometer (Fisher Scientific, Leicestershire, UK), which equates to 
approximately 108 cfu/mL.  Suspensions were used at either 108 cfu/mL or diluted in 
the correct % TSB to approximately 105 cfu/mL.   
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As highlighted in Section 1.5.3.1 once a urinary catheter has been inserted into the 
body it rapidly becomes coated in urinary components and a conditioning film forms.  
A conditioning film was formed on control discs (containing no antimicrobial agents) 
and antimicrobial silicone discs by exposing them to human urine.  The urine (pH 
6.8) was sterilised by filtration through a 0.2 µm cellulose nitrate membrane 
(Whatman, Dassel, Germany) and discs soaked in the urine for 1 hour at 37°C with 
rocking.  Following this discs were removed and placed into 1.5 mL eppendorfs.  1 
mL of bacterial suspension was added and incubated for 1 hour at 37°C with rocking 
to allow for bacterial attachment.  The discs were then rinsed in 1 mL of the correct 
% TSB corresponding to each strain to remove non - adherent bacteria and placed 
into fresh TSB.  Bacteria were detached from the discs by placing the eppendorfs 
into a sonicator for 20 minutes set at 50 Hz (Ultra Wave Ltd, Cardiff, UK).  200 µL 
of the detached bacteria were spread onto SBA or CLED plates.  Plates were 
incubated for up to 72 hours and surviving bacteria counted as cfu/mL.   
 
All tests were performed in triplicate and sampled/counted at 0, 24, 48 and 72 hours 
time points.  Each day the discs were rinsed in TSB to prevent antimicrobial build - 
up and if not tested at that time point were re - incubated.  The time taken for the 
antimicrobial material to kill attached bacteria was determined and compared to 
control material where attached bacterial counts should remain high.   
 
tK100 tests were also performed on control and antimicrobial silicone discs that had 
been soaked in phosphate buffered saline (PBS, Oxoid) for 5 days at 37°C.  This was 
to examine the effect that drug elution had on the antimicrobial material¶s ability to 
kill attached bacteria.  The PBS was changed daily to prevent the build - up of 
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antimicrobial agents and to broadly simulate drug elimination within the urinary 
tract.  
 
2.2.6.1.  Percentage TSB Determination 
It is important to keep the silicone discs in the correct % TSB, in order to try to 
supply the attached bacteria with sufficient nutrients to allow them to survive but not 
for them to vastly increase in numbers [93].  To determine the % TSB to achieve 
this, control silicone discs were exposed to 108 or 105 cfu/mL of bacteria in varying 
% TSB concentrations.  A tK100 test was performed as in 2.2.6 and the correct % 
TSB selected according to the concentration at which the attached bacterial counts on 
the control material remained high and were constant over the 72 hour time period, 
i.e. counts should remain high and equal to or close to the cfu/mL at 0 hours as at the 
72 hour point [93].    
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2.3.  RESULTS 
 
2.3.1.  Bacterial Characterisation 
Bacteria used throughout the report and their sensitivities to the antimicrobial agents 
are shown in Table 2.4.  They include S.aureus (MRSA), E.coli, P.mirabilis, 
K.pneumoniae, E.faecalis and CoNS (S.saprophyticus) which represent the 
organisms most commonly isolated from the urine of patients with CAUTIs and 
which have a typical antimicrobial sensitivity profile and individual MIC values.  
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Table 2.4: Identification of bacteria isolated from the urine of patients with a CAUTI. 
 
                                                                                                MIC (µg/mL) 
F. No Organism API 
Profile 
Antibiogram 
Profile 
Rifampicin  Triclosan Sparfloxacin 
       
1232 S.aureus 
MRSA 
6736153 
97.8% ID 
47604 0.008 0.032 
 
>3 
1693 E. Coli 5145552 
99.9% ID 
46370 R 0.19 0.023 
1691 P. mirabilis 0437000 
95.7% ID 
66370 R 0.094 0.19 
2630 K.pneumoniae 5215773 
97.6% ID 
46370  R 0.19 0.032 
2633 E.faecalis 5143711 
99.7% ID 
62700 1 
 
2 0.38 
2636 CoNS 
S.saprophyticus 
6634152 
88.7% ID 
46000 0.012 0.125 0.19 
 
F. No = Freezer bank identity number.  R = Resisitant
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2.3.2.  Serial Plate Transfer Test  
Figures 2.5 to 2.8 show the SPTT results of silicone impregnated with rifampicin, 
sparfloxacin, and triclosan as single agents and in combination (rifampicin, triclosan, 
sparfloxacin) exposed to MRSA, CoNS, E.faecalis, E.coli, K.pneumoniae and 
P.mirabilis.  Control discs showed no intrinsic activity towards the organisms.  
 
 
2.3.2.1.  0.2% Rifampicin 
 
 
 
 
Figure 2.5: The antibacterial activity of silicone impregnated with 0.2% rifampicin against MRSA, 
CoNS, E.faecalis, E.coli, K.pneumoniae and P.mirabilis assayed by the SPTT.  The assay was 
performed in triplicate and each point represents the mean with standard error (SE).  SE may not be 
visible at every point as they were very small.  K.pneumoniae and E.coli are superimposed with 
P.mirabilis (displaying no activity towards rifampicin). 
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MRSA and CoNS were sensitive to rifampicin and E.faecalis moderately sensitive, 
and they displayed a ZI that lasted for 66 days, 24 days and 2 days respectively.  On 
day 24, all three discs exposed to CoNS showed signs of bacteria adhering to the 
material, indicating resistance.  Upon further testing, it was revealed that this was 
actually cross contamination with E coli, probably due to a failure in aseptic 
technique whilst transferring the discs of the SPTTs.  The test was stopped, but it is 
likely that unless true resistance developed, the activity would have otherwise 
continued judging by the ZI diameter compared with MRSA.  Figure 2.5 shows large 
zone diameters, particularly against CoNS and MRSA on Day 1 followed by a rapid 
decline until a steadier state of release is reached.  E.faecalis only showed activity 
lasting for 2 days, possibly relating to the higher MIC of rifampicin.  As expected, no 
zones were displayed against the Gram negative organisms, corresponding to their 
innate resistance to rifampicin.     
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2.3.2.2.  1% Sparfloxacin 
 
 
Figure 2.6: The antibacterial activity of silicone impregnated with 1% sparfloxacin against MRSA, 
CoNS, E.faecalis, E.coli, K.pneumoniae and P.mirabilis assayed by the SPTT.  The assay was 
performed in triplicate and each point represents the mean with standard error (SE).  SE may not be 
visible at every point as they were very small. 
 
 
 
All bacteria apart from MRSA showed varying degrees of sensitivity to sparfloxacin.  
E.coli was most sensitive and E.faecalis the least.  By days 6 and 7, sparfloxacin no 
longer displayed any activity towards E.faecalis and P.mirabilis respectively.  
Activity towards CoNS also stopped at day 38, whereas >100 day duration of activity 
towards E.coli and K.pneumoniae was shown.  For the latter organisms, an initial 
high release of sparfloxacin is shown followed by a decline until it reached a steady 
state.  Impregnation with sparfloxacin alone showed no signs of resistance.  
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2.3.2.3.  1% Triclosan 
 
 
 
Figure 2.7: The antibacterial activity of silicone impregnated with 1% triclosan against MRSA, 
CoNS, E.faecalis, E.coli, K.pneumoniae and P.mirabilis assayed by the SPTT.  The assay was 
performed in triplicate and each point represents the mean with standard error (SE).  SE may not be 
visible at every point as they were very small. 
  
   
 
The concentration of triclosan required to inhibit the growth of E.faecalis was the 
highest at 2 µg/mL compared to the other five bacteria and the shortened duration of 
activity, <22 days, reflects this.  Triclosan showed continued activity towards the 
remaining bacteria, displaying large zone sizes that continued for 100 days and 
beyond.  Unlike rifampicin and sparfloxacin there appears to be less in terms of an 
initial burst of the drug but more of a steady persistent release.  No sign of resistance 
was seen over the duration.      
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2.3.2.4.  Combination of Antimicrobial Agents 
 
 
 
 
Figure 2.8: The antibacterial activity of silicone impregnated with a combination of 0.2% rifampicin, 
1% triclosan and 1% sparfloxacin against MRSA, CoNS, E.faecalis, E.coli, K.pneumoniae and 
P.mirabilis assayed by the SPTT.  The assay was performed in triplicate and each point represents the 
mean with standard error (SE).  SE may not be visible at every point as they were very small. 
  
 
 
All three antimicrobial agents combined showed a 100 day activity towards all of the 
uropathogens with the exception of E.faecalis.  Images of the E.coli SPTT at day 1 
and 100 are shown in Figure 2.9 (A and B).  The results in Figure 2.8 are similar to 
those with material impregnated with triclosan alone.  Results generated from the 
SPTT performed with silicone discs impregnated with single antimicrobial agents 
provided information on the duration of activity to which bacteria are sensitive to one 
or more of the drugs.  E.coli and K.pneumoniae were affected by triclosan and 
sparfloxacin over the 100 day duration and CoNS probably by rifampicin and 
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triclosan over a prolonged period with sparfloxacin giving short - term activity.  
P.mirabilis was affected mostly by triclosan alone with sparfloxacin activity in the 
short - term and MRSA by rifampicin and triclosan.  E.faecalis showed only a short - 
term duration of <22 days using this combination with activity coming from 
triclosan.  No signs of resistance were seen.   
  
2.3.2.5.  Serial Plate Transfer Test and Depiction of Resistance 
 
In selecting suitable antimicrobial agents from Table 2.1, all were screened against 
several of the microorganisms using the SPTT (not all data shown).  Impregnation of 
the silicone discs with trimethoprim alone repeatedly exposed to K.pneumoniae 
showed signs of resistance on day 38 of transfer as shown in Figure 2.9 (C).  Upon 
identification and MIC testing, the bacteria from day 38 were found to be resistant to 
trimethoprim (>32 µg/mL compared to the original MIC of 0.38 µg/mL).  No 
bacterial resistance developed when bacteria were exposed to the other agents listed 
in Table 2.1, either as single agents or when combined. 
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(A)                                                                               (B)             
 
 
(C)  
Figure 2.9: SPTT of rifampicin, sparfloxacin, triclosan (combination) impregnated silicone discs 
exposed to E.coli on (A) Day 1 and (B) Day 100 and (C) K.pneumoniae exposed to material 
containing 1% trimethoprim, showing signs of resistance.  Though there is a ZI, the bacteria that are 
attached to the disc are surviving and growing on it. 
Signs of Resistance 
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 2.3.3.  Time Taken to Kill 100% of Attached Bacteria 
 
Figures 2.10 and 2.11 show the results of the time taken for the rifampicin, triclosan 
and sparfloxacin containing silicone to kill ideally 100% of attached bacteria.  The 
correct % TSB to perform the assay with was established and is shown in Table 2.5.  
A urinary conditioning film was formed on control and antimicrobial silicone discs, 
pre and post soaking/drug elution, and prior to being exposed to 108 cfu/mL or 105 
cfu/mL of E.faecalis, CoNS, MRSA, E.coli, K.pneumoniae or P.mirabilis.  
 
 
Table 2.5: Determination of percentage TSB required to maintain bacterial viability. 
Organism TSB (%) upon exposure 
to 108 cfu/mL bacteria 
TSB (%) upon exposure 
to 105 cfu/mL bacteria 
MRSA 1 1 
CoNS 1 1 
E.faecalis 0.1 1 
E.coli 0.1 0.1 
K.pneumoniae 0.1 0.1 
P.mirabilis 0.5 1 
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(A) 
 
 
(B) 
Figure 2.10: tK100 results for material impregnated with 0.2% rifampicin, 1% triclosan, 1% 
sparfloxacin and controls.   Material was exposed to urine for 1 hour to form a conditioning film prior 
to exposure to (A) 108 cfu/mL E.faecalis, CoNS,  MRSA, and (B) E.coli, K.pneumoniae at 108 cfu/mL 
and P.mirabilis at 105 cfu/mL  respectively.  After, material was sonicated at time intervals and the 
viable bacteria in the sonicate counted.  Each point represents the mean of three tests with standard 
errors.  Figure A shows lines for CoNS and MRSA which are superimposed.   
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The tK100 results for discs impregnated with rifampicin, triclosan and sparfloxacin 
with a conditioning film show that no viable CoNS, MRSA or K.pneumoniae cells 
remained attached by the end of 24 hours, or E.coli by 48 hours and E.faecalis by 72 
hours.  Material exposed to 108 cfu/mL P.mirabilis (data not shown) was not able to 
kill all of the attached bacteria.  Upon exposure to 105 cfu/mL, <25 cfu/mL remained 
attached at 72 hours.  Bacterial numbers attached to control discs remained steady 
throughout at approximately 105 cfu/mL.   
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(A) 
 
 
 
(B) 
Figure 2.11: tK100 results for material impregnated with 0.2% rifampicin, 1% triclosan, 1% 
sparfloxacin and controls.  The material was soaked in PBS for 5 days to simulate drug release 
followed by exposure to urine for 1 hour to form a conditioning film prior to exposure to (A) 105 
cfu/mL E.faecalis, CoNS, and MRSA, and (B) 105 cfu/mL E.coli, K.pneumoniae and P.mirabilis 
respectively.   After, material was sonicated at time intervals and the viable bacteria in the sonicate 
counted.  Each point represents the mean of three tests with standard errors.   
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Following soaking to simulate drug release, the rifampicin, triclosan, sparfloxacin 
combination reduced the number of bacteria attached to the materials surface but did 
not eradicate all of them when exposed to a 108 cfu/mL inoculum (data not shown).  
A lower inoculum of 105 cfu/mL was therefore used.  Although small numbers of 
bacteria adhered to the antimicrobial discs when exposed to 105 cfu/mL bacteria, the 
trend for bacteria adhering to control discs was to increase over time where the 
opposite effect was shown for the antimicrobial discs.  E.coli and K.pneumoniae 
were eliminated within 24 hours, E.faecalis within 48 hours and CoNS and MRSA 
within 72 hours.  >50 cfu/mL P.mirabilis remained attached to the antimicrobial 
discs.   
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2.4. DISCUSSION 
 
The SPTT is based on the ability of the antimicrobial agents to diffuse out of the 
polymer to create a ZI against susceptible organisms.  It is a static test that can be 
used to screen the antimicrobial agents potential duration of activity against target 
organisms due to its serial nature.  A variety of antimicrobial agents shown in Table 
2.1 were investigated for impregnating into silicone discs and the spectrum and 
duration of activity against a range of CAUTI organisms assessed using the SPTT as 
an initial screening test.   
 
Having successfully been incorporated into bone cements as a means of applying 
localised antibiotic delivery [155], gentamicin sulphate was investigated but is 
insoluble in chloroform so was ruled out.  Similarly minocycline having been used as 
coatings on various catheters to prevent microbial colonisation was not suited to the 
solvent - based impregnation process as it is also poorly soluble in chloroform.  On 
screening clindamycin and rifampicin it appeared that long lasting activity in 
particular against staphylococci was possible from using a 0.2% concentration in the 
chloroform [81].   
 
Yassien et al (1995) [156] studied the effects of four types of quinolones on reducing 
biofilms formed on vascular catheters in an in - vitro model.  They found that a 
concentration of agents 4 - 25 times the MIC of planktonic P.aeruginosa showed 
<5% growth of adherent cells compared to the controls.  The effect of quinolones on 
actual catheter biofilms and reports of incorporation into material to prevent 
progression to the biofilm state [118] led to viewing quinolones for potential activity 
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and duration against uropathogens.  Sparfloxacin and norfloxacin were readily 
soluble in chloroform based on a 1% concentration [157], and gave a broad spectrum 
of activity and the potential of a long duration upon screening.  They were also 
investigated as some microorganisms that are resistant to fluoroquinolones may be 
sensitive to the lesser - used agents.  Sparfloxacin was found to give longer lasting 
activity against Gram negative bacteria compared to norfloxacin (data not shown).   
 
Incorporating trimethoprim into polymers along with rifampicin in an in - vitro 
model showed that S.aureus colonisation was reduced by >99.97% [158].  Similarly 
trimethoprim, rifampicin and triclosan incorporated into peritoneal dialysis catheters 
has shown to inhibit bacterial colonisation by E.coli and MRSA in an in - vitro 
model following repeated bacterial challenges for 90 days [157].  Upon screening, 
trimethoprim (1%) showed a prolonged duration of activity particularly against Gram 
negative organisms (data not shown) but resistance was generated to K.pneumoniae 
(Figure 2.9).  This agrees with research [159] which has highlighted that as a drug 
commonly used to treat UTIs, resistance to trimethoprim is increasing and this could 
be an issue if many of the organisms isolated from patients with CAUTIs have been 
treated with trimethoprim in the past.    
 
The potential of antiseptics were also investigated.  Hexetidine and octenidine 
dihydrochloride are said to have a broad spectrum of activity but when incorporated 
into silicone even at concentrations of 5%, they displayed only a small ZI against 
common uropathogens which was short lived (data not shown).  There is much 
scientific research as highlighted in section 1.6.5 which indicates that triclosan is 
highly effective in reducing bacterial colonisation.  The SPTT of triclosan 
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impregnated silicone discs using a 1% concentration in the solvent [157] displayed a 
broad spectrum of activity with zone diameters that looked likely to continue for a 
long duration.  Silver was not assessed in this project. 
 
Of the antimicrobial agents screened, clindamycin or rifampicin could act to affect 
predominantly Gram positive organisms especially the staphylococci.  Sparfloxacin 
or trimethoprim could act to affect mostly Gram negative bacteria but give some 
Gram positive protection whilst triclosan could cover both.  Clindamycin and 
sparfloxacin however upon combination did not combine well and analytical grade 
clindamycin powder is an expensive drug to use for testing purposes.  Due to the 
increasing reports of resistance to trimethoprim, a combination of 0.2% rifampicin, 
1% triclosan and 1% sparfloxacin was therefore selected to become impregnated into 
the urinary catheter. 
 
Several studies [160, 161] have compared the efficacies of antimicrobial catheters 
using the ZI test but zone diameters were only measured after overnight incubation 
and no further tests performed.  By transferring the material to freshly seeded agar 
plates we can see that often there is a sudden drop in antimicrobial activity after the 
first day.  For example, Figure 2.5 shows that E.faecalis when exposed to silicone 
containing rifampicin, the initial zone diameter was ~18 mm but by the third day no 
zone of inhibition remained.  This indicates that in some instances activity may be 
limited to a few days and is an effect of surface activity and it is important to see if 
the activity is likely to continue thereafter rather than draw conclusions from a one - 
day zone of inhibition test [157].   
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The SPTT showed that rifampicin incorporated as a single agent into the silicone 
discs gave a duration of activity that persisted for 65 days against MRSA and despite 
the contamination of all three discs exposed to CoNS, it appeared from the zone sizes 
that the duration of activity against CoNS would have otherwise continued.  To 
verify this, the experiment should have been repeated.  Sparfloxacin was active 
against E.coli and K.pneumoniae over the whole 100 day SPTT duration and 
displayed some shorter term Gram positive (CoNS) activity.  Triclosan showed a 
broad spectrum of prolonged activity with the exception of E.faecalis (22 days).  
E.faecalis is an organism commonly isolated from the urine of patients on LTC and 
the short duration of antimicrobial activity against it may be of concern and could be 
related to the higher MIC values.  However, the impact that E.facealis has on 
symptomatic CAUTI requires further investigation.  Combining all three agents 
displayed persisting activity against the uropathogens which gradually declined over 
the 100 days, with the exception of E.faecalis.  It is anticipated that if the bacteria are 
sensitive to the individual antimicrobial agents and display a persisting ZI, the agents 
combined should act in a manner similar to the agents by themselves but 
synergistically to provide protection from the emergence of resistance.  Protection 
provided by two antimicrobial agents (sparfloxacin and triclosan) looked possible for 
E.coli and K.pneumoniae over the whole SPTT duration and for a long duration 
towards CoNS and MRSA (rifampicin and triclosan).  P.mirabilis was mostly acted 
upon by triclosan alone over the 100 day duration and E.faecalis by triclosan but 
only short - term. 
   
The SPTT can also be used to detect the development of resistance which can be 
visualised by microbial growth around or under the impregnated silicone material.  It 
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emerged that K.pneumoniae became resistant at day 38 following repeat exposure to 
material impregnated with trimethoprim alone, with the MIC increasing to >32 
µg/mL.  It is proposed that as only one side of the material is exposed to the bacteria, 
if the level of trimethoprim reaching the surface was approximating the MIC of the 
organism or was sub - inhibitory over a prolonged period then it is possible that the 
bacteria would mutate to a more resistant phenotype which will allow survivors to 
remain attached to the disc and a rise in MIC occur [157].  The Dual Drug Principle 
[122] works on the basis that if bacteria are to survive they must undergo 
simultaneous resistance mutations in two different genes distant in the genome and 
the chances of this are extremely low if more than one antimicrobial agent is used at 
correct concentrations.  By applying this principle thus far, the SPTT has not shown 
bacteria to develop resistance towards the rifampicin, sparfloxacin, triclosan 
combination.   
 
Studies by Sherertz et al (1993) [161, 162] suggested that there was a relationship 
between in - vitro anti-infective catheter zones of inhibition and in - vivo efficacy.  
They report that a >15 mm ZI against S.aureus was necessary to prevent bacterial 
colonisation in a rabbit model and that the concept may be generalizable to other 
organisms.  A study by Tambe et al (2001) [163], however, found that catheters 
containing chlorhexidine, chlorhexidine acetate and silver sulphadiazine formed 
small sized zones after soaking (<7.2 mm) upon exposure to S.epidermidis but were 
able to kill the adhered bacteria.  On the other hand the minocycline and rifampicin 
catheters showing larger zone sizes (14 mm) were unable to prevent colonisation by 
S.epidermidis.  They suggest that zone size may be related to the solubility and 
diffusion characteristics of the drugs, while the ability to resist bacterial colonisation 
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may depend on the type of antimicrobial action (static or cidal) and slow and rapid 
kill [163].   
 
The SPTT is a useful screening tool but in this study was not used to assess the 
ability of the antimicrobial combination to provide protective activity against 
bacterial colonisation.  The antimicrobial catheter works by preventing bacterial 
colonisation rather than by the inhibition of adherence [152] and the tK100 assay 
addresses this by attaching the bacteria to the antimicrobial material and monitoring 
the time it takes for the agents to kill the attached bacteria.  Due to the length of time 
the tK100 assay is run (72 hours) it is important to establish the appropriate TSB 
concentration which is used to support the bacteria.  The correct TSB concentration 
should ensure bacterial viability but not allow for too much multiplication and this 
was determined for each bacterium as shown in Table 2.5.  Too high a % TSB can 
cause exponential growth whereas too low a % TSB can result in insufficient 
nutrients being available causing the bacteria to die off.  
  
Initially to ensure that bacteria became attached to the material, it was exposed to a 
108 cfu/mL suspension of bacteria.  Some bacterial species (P.mirabilis) remained 
attached to the material after the 72 hour test period and all species remained 
attached (data not shown) following soaking of the material when exposed to 108 
cfu/mL.  Following this, it was thought that 108 cfu/mL was too high a number to be 
exposing the material to, so for some assays challenge with 105 cfu/mL bacteria was 
adopted.  This was deemed to be a reasonable level of bacteria to expose the silicone 
to as in clinical practice a CAUTI is diagnosed if  >103 cfu/mL of a predominant 
bacteria is isolated [32, 33].  The numbers of bacteria attached to the control discs 
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when exposed to 108 cfu/mL remained relatively constant over the 72 hour test 
period whereas the numbers attached to the control discs following exposure to 105 
cfu/mL were low at 0 hours and increased with time.  Bacterial numbers attached to 
the antimicrobial material showed the opposite effect and decreased over time, 
revealing the ability of the agents to release from the matrix and kill the number of 
attached bacteria.  
 
It is also important during the tK100 assay to take into account the effect 
conditioning films have on bacterial colonisation.  Conditioning films were formed 
on the silicone discs by exposing them to human urine for 1 hour.  X-Ray 
Photoelectron Spectroscopy (XPS) was used to confirm that 1 hour exposure to urine 
was sufficient time for a conditioning film layer to be formed on the catheter surface 
and this is discussed further in Chapter 5 (Surface Analysis).  The antimicrobial 
catheter was found to be capable of killing attached bacteria in the presence of a 
urinary conditioning film.  There has, however, been conflicting reports concerning 
the effect that conditioning films have on bacterial attachment.  A study by Gorman 
et al (1997) [49] examined the adherence of S.epidermidis to silicone peritoneal 
catheters in the presence and absence of a conditioning film formed by exposing the 
material to artificial spent peritoneal dialysate (ASD) for 1 hour.  They found that 
treatment with ASD decreased the adherence of S.epidermidis.  Murga et al (2001) 
[164] investigated the effect that a conditioning film formed by exposing central 
venous catheter connections to blood had on biofilm formation caused by Gram 
negative bacteria.  They reported that the conditioning film formed of blood 
components promoted biofilm formation.  In urine, 67 protein forms from which 47 
unique proteins have been isolated and identified [165].  Santin et al (1999) [166] in 
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an in - vitro model demonstrated that a conditioning film formed by exposure to 
urine enhanced crystal precipitation on the catheter surface but they did not study 
bacterial colonisation per se.  The studies highlight the differences in results and the 
importance of taking into account the effect conditioning films may have on bacterial 
colonisation. 
 
Kohnen et al (2003) [118] report on silicone ventricular catheters impregnated with 
rifampicin and sparfloxacin challenged with 107 cfu/mL of S.epidermidis in a time 
kill assay.  They found a 99.8% reduction in attached bacteria compared to catheter 
segments with no antimicrobial agents.  Following soaking of the material for up to 1 
year there was still a 99.8% reduction in bacterial colonisation compared to control 
ventricular catheters.  Tambe et al (2001) [163], however, showed that the mean 
adherence of S.epidermidis isolates to minocycline and rifampicin catheters 
increased following up to 24 days soaking.  The rifampicin, sparfloxacin, triclosan 
containing silicone discs showed a reduction in ability to kill attached bacteria 
following 5 days soaking.  As the agents eluted, the material was unable to kill all 
attached bacteria that were applied as a 108 cfu/mL initial load (data not shown).  It 
was, however, more capable of killing attached bacteria that were applied as a 105 
cfu/mL initial load and eliminated all attached bacteria within a 72 hour time period 
with the exception of 50 cfu/mL P.mirabilis remaining. 
  
P.mirabilis was not completely eradicated by the action of the antimicrobial agents 
before or after the 5 day drug elution.  The effect of a few colonies remaining 
attached to the material in its ability to prevent bacterial colonisation will need to be 
examined further in a flow model system.  Even though P.mirabilis remained after 
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72 hours, compared to the control material a >99.9% reduction of attached bacteria 
was shown.  A tK100 was, however, achieved for both soaked and un - soaked 
material following challenge with CoNS, MRSA, E.faecalis, E.coli, and 
K.pneumoniae within 24 to 72 hours.  Despite a short duration of activity displayed 
by the SPTT towards E.faecalis, the tK100 showed the agents to be effective in 
killing attached E.faecalis.  This is likely to be due to the action of triclosan over the 
72 hours but is not to say that the antimicrobial material would be effective if 
challenged further with E.faecalis. 
 
It can be seen from the tK100 test that the antimicrobial material did prevent the 
colonisation of the majority of the uropathogens tested.  Although this is a static test 
and applies only one bacterial challenge to the material, the duration of activity 
shown by the SPTT reveals that there is potential that the material may be successful 
in preventing colonisation if challenged further with certain organisms.  The burst 
effect from sparfloxacin and rifampicin and the sustained release of triclosan shown 
from the SPTT along with the tK100 results have demonstrated that the antimicrobial 
combination may be effective in preventing bacterial colonisation at the time of 
catheter insertion, in particular against CoNS, MRSA, E.coli and K.pneumoniae.  
Urinary catheters are, however, exposed to potential bacterial entry at any point 
during their use, so a long - lasting effect is required if infection is to be reduced.  An 
in - vitro model simulating flow conditions within the bladder that subjects the 
material to repeated bacterial challenges will help to determine the effectiveness of 
the antimicrobial catheter in preventing bacterial colonisation over a longer term. 
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3.0.  IN - VITRO MODEL 
 
3.1.  INTRODUCTION 
Despite the problems caused by bacterial colonisation on urinary catheters there is no 
standard in - vitro test to quantify this.  There are, however, several types of models 
reported in the literature that examine ways of studying the effectiveness of drug 
releasing catheters at inhibiting bacterial colonisation and encrustation and are 
discussed in section 3.1.2.  Ideally controlled human clinical trials are the best way of 
assessing the effectiveness of medical devices but these can be slow to set up, 
expensive and often evaluate small numbers of patients [167].  The variability of 
human models in terms of diet, fluid intake, urinary constituents and infection by a 
wide range of organisms has made comparing biomaterials difficult because any real 
differences in the biomaterials are confounded by other uncontrollable variables 
[168], however, in order for a medical device to gain CE marking and MHRA 
(Medicines and Healthcare Products Regulatory Agency) clearance, human studies 
are essential.  To assess safety, tolerability, pharmacokinetics and 
pharmacodynamics of a product, Phase I clinical trials involving a small number of 
humans is required.  Progression to Phase II trials involving larger numbers of people 
to assess how well the product works and Phase III involving a randomised 
controlled multicentre trial to assess how effective the product is compared to the 
cuUUHQW µJROG VWDQGDUG¶ DUH WKHQ UHTXLUHG WR HVWDEOLVK VXLWDELOLW\ IRUPDUNHWLQJ 7R
progress to human studies, pre - clinical (in - vivo and in - vitro) studies are required 
in the first instance to demonstrate safety of the device and to confirm proof of 
principle.  Animal models can be more easily controlled than humans in terms of 
  Chapter 3 - In - Vitro Model 
99 
 
fluid and diet but their urinary constituents can still vary and differences in their 
pharmacodynamic ability compared to humans can make efficacy evaluation 
problematic.  To gain knowledge into how a medical device may perform in the 
body, it is common for in - vivo studies to be supplemented by in - vitro studies.   
 
3.1.1.  The Ideal In - Vitro Model 
In an ideal in - vitro model of medical device efficacy, all variables should be 
controlled except the biomaterial under review, thus allowing in this instance to 
determine the direct effect the material has in preventing bacterial colonisation.  
Choong et al (2000) [168] stated that the ideal model should include: control of pH 
and temperature, uniform exposure of bacteria to the material, have a  flow of urine 
mimicking human urinary flow rates which should flow evenly over the material and 
not be recycled.  Separate chambers for test and control material to prevent cross - 
contamination should be provided, results must be reproducible and the model 
should be simple, of low cost and be able to be adapted to accommodate a variety of 
catheter sizes.  There are of course many differences between in - vitro and in - vivo 
models that cannot be accounted for in laboratory models.  The lack of host defences 
such as white blood cells, immunoglobulins, complement and cytokines,  fever in 
patients, the diversity of bacteria, microbial load and the virulence of organisms are a 
few examples [167].  The complexities of infection are difficult to simulate in an in - 
vitro model but they can give pointers to the extent an antimicrobial catheter may 
affect bacterial colonisation in order to satisfy regulatory requirements for 
subsequent testing in humans.   
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3.1.2.  In - Vitro Models Used to Study the Effectiveness of Drug -                      
Containing Materials 
 
Of the few catheterised urinary models cited [7, 168, 169], many report on 
encrustation of urethral catheters.  The better - designed models take the form of two 
- compartmental type models.  They generally consist of a vessel connected to input 
and output ports through which medium can flow.  This is known as the central 
compartment and represents the blood and equilibrating tissue sites [167].  Inserted 
into the central compartment is a peripheral compartment which corresponds to the 
tissue site containing the infection [167].  Two - compartment models can be 
modified and made more specific to what is being investigated.  An example of a 
glass bladder model used by Stickler et al (1999) [7] and Barford et al (2008) [169] 
to investigate the impact that different urinary catheters have on encrustation by 
P.mirabilis is depicted in Figure 3.1.    
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Figure 3.1: Model of the catheterised urinary tract detailing one of the bladders with a catheter in situ 
[7, 169]. 
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The glass vessel represents the bladder through which a urinary catheter tip is 
inserted that extends through a glass tube representing the urethra.  Urine is pumped 
into the glass bladder which flows through the catheter to a drainage bag.  Bacteria 
are inoculated directly into the urine within the glass bladder and as the bacterially 
infected urine flows through the catheter lumen, encrustation and biofilm formation 
can be studied.  Human urine, artificial urine or laboratory culture medium can be 
used.  Human urine is very variable and if large volumes are required over a 
prolonged period, ensuring a constant supply may be problematic.  Artificial urine 
has the advantage that its composition can be controlled but there are many 
constituents in human urine that can inhibit or promote bacterial 
colonisation/encrustation which are not present in artificial urine.  Filtration of the 
quantities of artificial urine required may also be difficult to keep supplied over a 
long course.  As urinary fluid is a complex milieu whose contents can influence 
bacterial adhesion to substrata [170], models often use laboratory nutrient broths to 
give an indication of the likely effect of the test material under review. 
     
In a study by Choong et al (2000) [168], a model of encrustation similar to that 
shown in Figure 3.1 was devised for the purpose of validating in - vitro performance 
with in - vivo results.  Catheter material was subject to pooled human urine at a flow 
rate of 0.5 mL/min over a course of 5 days.  To ensure that bacteria did not grow in 
the urine, gentamicin and vancomycin were added.  They reported that in - vitro 
results of the effectiveness of biomaterials in preventing encrustation correlated well 
with in - vivo implantation into the bladder of rats.     
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Tunney et al (1999) [171] designed a continuous flow model to study biofilm 
development and encrustation by P.mirabilis on urethral catheters.  It was based on a 
modified Robbins device where artificial urine containing the bacteria was re - 
circulated at 0.5 mL/min through tubing feeding to pieces of test catheter.  
Intraluminal encrustation was formed and studied.  In investigating the prevention of 
bacterial colonisation of urinary catheters, urine should ideally not be re - circulated 
and to add antimicrobial agents to urine to prevent bacterial growth as in the Choong 
et al (2000) [168] study may hide away the effect the drug - releasing catheter has on 
preventing bacterial colonisation.   
 
An example of a further model is the catheter bridge model reviewed by Kazmierska 
et al (2010) [172] which studies the migration of P.mirabilis over catheter sections as 
shown in Figure 3.2.  It uses an agar plate through which a horizontal channel is cut 
where the catheter segment lies.  Bacteria are inoculated one side of the channel and 
migrate over catheter segments.  In this instance material coated in a hydrogel with 
and without iodine was studied to see how effective the material was at preventing 
the bacteria from reaching the other side of the catheter.   
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Figure 3.2: Catheter bridge model depicting the migration of P.mirabilis over catheter segments 
coated with hydrogel and hydrogel plus antibacterial agent. 
 
 
P.mirabilis was found to move quicker through the hydrogel - coated catheter and 
slower when it was combined with iodine.  The model however is a static test and is 
not useful for studying the potential duration of activity that a drug - releasing 
material has and is suitable only for organisms that are motile.  An improved version 
of this could involve the migration of Proteus inside the test catheter from one end to 
the other under flow conditions using a pump system.  In general, the study of 
catheter colonisation in the absence of confounding biological factors could be 
modelled as a catheter with fluid flow and bacteria attached to the inner surface.  To 
examine the potential duration of protective activity an antimicrobial catheter gives, 
the catheter could be repeatedly challenged with bacterial loads.   
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3.1.3.  Objectives 
The aim of this chapter is to develop a novel in - vitro model that represents the 
catheterised urinary tract and to evaluate the ability of the antimicrobial catheter to 
resist bacterial colonisation.  It is anticipated that the antimicrobial catheter under 
flow conditions would be able to prevent bacterial colonisation and the development 
of resistance over a prolonged period following repeat weekly challenges with high 
doses of bacteria.  The in - vitro model along with drug content and release analysis, 
could be used to determine if the dosing regimen is sufficient to maximise the 
eradication of the pathogens and if it is effective at limiting the development of 
resistance [167].   
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3.2.  METHODS 
 
3.2.1.  Growth Curve to Assess Bacterial Growth Rates in TSB and   
Artificial Urine 
Ideally in - vitro models designed to test bacterial colonisation on urinary catheters 
require real or artificial urine as the perfusion medium.  A flow rate of 0.5 mL/min 
would require each catheter to be perfused with 720 mL/day.  With each 
antimicrobial catheter being tested in triplicate plus controls and 2 or 3 bacterial 
species being tested in any 12 week testing period this amounts to between 8 to 12 L 
of urine required each day.  Artificial urine described by Griffith et al (1976) [173] 
and as shown in Section 3.2.1.1 was examined for use in the in - vitro model.  
Difficulties in the ability to sterilise the quantity of artificial urine via membrane 
filtration and the time it took led to the search for an alternative medium that would 
support bacterial growth characteristics similar to those in urine.  Artificial urine 
could also not be sterilised by autoclaving.  Bacterial growth rates in pure TSB were 
therefore compared to those in artificial urine over a period of 8 hours. 
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1.  One isolated bacterial colony from a SBA or CLED plate was removed using a  
     sterile loop, inoculated into 10 mL sterile TSB and incubated overnight at 37°C. 
2.  0.5 mL was inoculated into 50 mL TSB and 50 mL artificial urine (Table 3.1). 
3.  The cultures were placed into a 37°C orbital incubator set at 200 rpm. 
4.  Every hour for 8 hours, 100 µL of the bacterial suspensions were removed for   
     bacterial quantification.  Ten - fold dilutions were made as necessary and 200 µL  
     of the appropriate dilution plated out and spread evenly onto SBA or CLED. 
5.  Plates were incubated overnight at 37°C and cfu/mL recorded. 
6.  Graphs of time against log bacterial counts/mL were plotted. 
 
3.2.1.1.  Artificial Urine 
 
Table 3.1: Recipe for artificial urine [173]. 
  
 Amount: g/L 
Ammonium Chloride 1.0 
Calcium Chloride 0.49 
Potassium Chloride 1.6 
Sodium Chloride 4.6 
Magnesium Chloride Hexahydrate 0.65 
Sodium Sulphate 2.3 
Trisodium Citrate Dihydrate 0.65 
Disodium Oxalate 0.02 
Potassium Dihydrogen Phosphate 2.8 
Gelatin 5 
Urea 25 
 
The above chemicals (Sigma-Aldrich) were accurately weighed out and dissolved in 
1 L sterile distilled water.  The pH was adjusted to 6.1 and sterilisation by membrane 
filtration through a 0.2 µm pore using a vacuum system was employed.  TSB was 
sterilised separately by autoclaving and added to the above to give a final 
concentration of 10 g/L. 
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3.2.2.  Principle of the In - Vitro Model 
All silicone Foley catheters were used in either their ³DV UHFHLved´ state for control 
purposes or impregnated with rifampicin, triclosan and sparfloxacin as described in 
Section 2.2.4.  Section 3.2.2.1 to 3.2.2.3 detail the in - vitro model set, assembly, 
testing and sampling procedure and Figure 3.3 depicts this.  TSB was used as the 
perfusion medium at a flow rate of 0.5 mL/min.  The lumens of the urinary catheters 
were inoculated with 105 cfu/mL of bacteria suspended in TSB (E.coli, E.faecalis, 
K.pneumoniae, MRSA, P.mirabilis) and catheter ends clamped for 1 hour to allow 
the bacteria in the suspension to attach to the luminal surface.  The tK100 screening 
tests and previous studies have indicated that 1 hour exposure time is sufficient for 
bacteria to become attached to material [81, 174].  The flow was restarted and 
samples of perfused TSB taken from the distal end of the catheters were collected on 
a daily/near to daily basis.  200 µL was plated out onto SBA or CLED and incubated 
for up to 72 hours.  Surviving colonies were counted.  If no bacterial counts were 
detected, catheters were re - challenged on a weekly basis and new control catheters 
set up.  Water surrounding the catheter in the glass tube was replaced on a weekly 
basis to prevent the build - up of antimicrobial agents.  Tests were carried out at 
37°C in triplicate.  Challenges were made for up to 12 weeks or until the 
antimicrobial catheters failed to stop bacterial colonisation.  Bacteria isolated from 
colonised antimicrobial catheters were identified and the MIC of rifampicin, 
sparfloxacin and triclosan determined as detailed in Section 2.2.3 and Appendix 1.  
All test catheters and a colonised control catheter from each of the bacterial species 
were subject to evaluation by Scanning Electron Microscopy (SEM). 
   
  Chapter 3 - In - Vitro Model 
109 
 
   
 
  
 Inoculation point 
               Water jacket 
 Catheter 
1 x 3mm tubing Parafilm 
 
 
 
 
 
  
 
 
 
 
 
 Pump tubing 
 Silicone Bung 
 
Flask containing       Sample Point                2 x 4mm tubing 
perfusion medium (TSB)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: In - vitro model. 
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3.2.2.1.  Description of In - Vitro Model Set - Up 
 
 
 Part 1: Perfusion Fluid Reservoir 
 
 
Step Action 
1 2 L flasks of TSB were made up as per PDQXIDFWXUHU¶V instructions 
2 A 3 mm hole was made through the bung/lid of the flask and 1 x 3 
mm tubing (SLS, Nottingham, UK) thread through until it reached the 
bottom of the fluid   
3 A glass connector (1 mm diameter) was inserted into the other end of 
the 1 x 3 mm tubing 
4 A clamp was placed onto the tubing to ensure the fluid does not 
escape 
5 The top of the flask and the end of the tubing was covered with 
aluminium foil and secured with tape 
6             All was sterilised by autoclaving. TSB was renewed as necessary 
   
 
 
Part 2:  Inlet Tubing 
 
Step Action 
1 A glass connector was pushed into one end of the pump tubing  
2 Attached to the above glass connector was 1 x 3 mm tubing  
3 A short piece of 2 x 4 mm tubing (SLS, Nottingham, UK) was 
attached to the other end of the 1 x 3 mm tubing 
4 A straight connector 3 - 5 mm (SLS, Nottingham, UK) was connected 
to the 2 x 4 mm tubing 
5 The end of the connectors were covered with aluminium foil and 
sterilised by autoclaving  
 
 
  
Part 3:  Catheter Section 
 
Step Action 
1 A suitable sized hole was made through the 14 x 20 mm silicone 
stoppers (SLS, Nottingham, UK) that fit into the glass tubes within 
the water jacket    
2 The control and antimicrobial catheters were cut to size (minus both 
ends of the catheter) and pushed through the hole in the silicone 
stopper until approx 2.5 cm poked through each end 
3 Ends were covered with aluminium foil and sterilised by autoclaving 
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Part 4 :  Outlet Tubing 
 
Step Action 
1 To one end of a straight connector a small section of 2 x 4 mm tubing 
was attached   
2 1 x 3 mm tubing was inserted into the end of the 2 x 4 mm tubing  
3 Ends of the tubing and connector were covered with aluminium foil 
and sterilised by autoclaving 
 
 
 
 
Part 5:  Waste Collection Vessel 
 
Step Action 
1 A 30 L Sharps Container was used for the collection of waste 
perfusion medium (TSB)  
2 Disinfectant (Trigene) was added to kill bacteria within waste 
perfusion fluid 
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3.2.2.2.  Assembly of In - Vitro Model  
 
 
Step Action 
1 The water jacket was filled with distilled water and maintained at 
37°C by the heating circuit 
2 From Part 2 of the inlet section, the pump tubing was clipped into 
place on the pump 
3 The 1 x 3 mm tubing from Part 1 of the perfusion reservoir was 
connected to the glass connector of the pump tubing 
4 The catheter from Part 3 was inserted up the centre of the tubes in the 
water jacket and the silicone stopper pushed securely into the bottom 
of the glass tubes  
5 The glass tubes of the water jacket were filled with distilled water to 2 
cm from the top and Parafilm wrapped around the top where the 
catheter protruded 
6 The straight connector from Part 2 of the inlet tubing was fitted into 
the top of the catheter 
7 To the bottom of the catheter, the straight connector from Part 4 of the 
outlet tubing was pushed through 
8 The end of the 1 x 3 mm tubing from Part 4 of the outlet tubing was 
inserted into the waste collection vessel.  The tubing was held in place 
with tape to ensure that it did not touch the sides of the container.  For 
each bacterial strain separate waste containers for both the 
antimicrobial and control catheters were used 
9 The clamp from the tubing attached the perfusion reservoir in Part 1 
was removed and the pump started at a flow rate of 0.5 mL/min.  
Checks were made to ensure that no leaks occurred and that the TSB 
flowed through unimpeded   
10 The system was allowed 1 hour to stabilize and reach 37°C before the 
catheters were challenged with bacteria  
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3.2.2.3.  Testing and Sampling Procedure  
 
Several colonies of MRSA, E.coli, E.faecalis, K.pneumoniae, or P.mirabilis 
from overnight SBA or CLED plates were placed into separate universal 
containers of 20 mL of TSB.  These were incubated in a 37°C orbital shaker set 
at 200 rpm for 4 hours and grown to early log phase.  Cultures were standardised 
to achieve an optical density (490 nm) of between 0.6 - 0.7 using a Jenway 6705 
UV/VIS spectrophotometer.  This gives approximately 108 cfu/mL which was 
diluted in TSB to 105 cfu/mL and inoculated down the lumens of the catheters.   
 
Inoculation Procedure 
Step Action 
1 A clamp was placed onto the inlet tubing and the pump turned off 
2 The straight connector on the top of the catheter was removed and the 
tip of the catheter swabbed using a steret   
3 A 2 mL syringe was filled with the bacterial suspension and injected 
down the catheter lumen trying to avoid any air bubbles 
4 Once the bacterial suspension reached the distal end of the catheter, the 
outlet tubing was clamped 
5 The area around the inoculation site was swabbed with a steret and the 
connector replaced 
6 The system was left for 1 hour to allow the bacteria to attach to the 
catheter surface 
7 After 1 hour, the clamp attached to the outlet tubing was removed 
followed by the clamp attached to the inlet tubing 
8 The pump was restarted and the perfusion medium flowed through for 
approximately 1 hour 
9 The inlet tubing with connector section and the outlet tubing with 
connector section were then renewed to prevent the migration of bacteria 
that may have attached to the silicone tubing from travelling to the test 
catheter 
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Sampling Procedure 
 
 
Step Action 
1 The outlet tubing (Part 4) connected from the distal end of the urinary 
catheter was disconnected for sampling 
2 A 7 mL bijou bottle was placed under the end of the catheter and 
approximately 1 mL of the perfusion medium running through the 
catheter collected 
3  The end of the catheter and outlet tubing connector were swabbed with 
a steret before rejoining and the system monitored to ensure no leaks 
occurred 
4  The collected effluent was vortexed and 200 µL plated onto SBA or 
CLED.  If the sample showed turbidity, 1:10 dilutions were made as 
appropriate 
5 Plates were incubated at 37°C for up to 72 hours 
6 If growth was detected, bacterial counts were recorded as cfu/mL 
7 If there was no growth, plates were re - incubated for a further 24 - 48 
hours 
8 Samples were collected on or as near to a daily basis as possible 
9 If no bacterial growth was shown following day 6 of sampling, the 
inoculation procedure was repeated each week (every 7 days) until 
bacterial colonisation persisted or until the 12 week point was reached.   
10 Following successful colonisation of control catheters, new ones were 
set up each week  
11 If bacterial growth persisted in the antimicrobial catheter, the test was 
stopped and the catheter taken down  
12 The identity of the bacteria isolated from the colonised antimicrobial 
catheters was checked and MICs of rifampicin, triclosan and 
sparfloxacin determined    
13 At the end of the test, approximately 5 x 1 cm segments were cut from 
all catheters and stored in cold acetone for Scanning Electron 
Microscopy (SEM) analysis 
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3.2.3.  Scanning Electron Microscopy 
1 cm segments were taken from the top section of the antimicrobial and control 
catheters tested by the in - vitro challenge and cut in half.  They were stored in cold 
acetone to fix the bacteria to the catheter lumens.  Catheter segments were removed 
from the acetone and dried using tetramethylsaline (Sigma-Aldrich).  Samples were 
mounted onto 12.5 mm diameter pin - type aluminium stubs using carbon double 
sided adhesive mounts.  They were coated with a thin layer (20 nm) of conductive 
platinum in an Emitech 1050 magnetron sputter coater and examined in a Philips 
(FEI) XL30 Scanning Electron Microscope using an accelerating beam voltage of 10 
kV utilizing the secondary electron imaging mode.  Images were captured at low 
(X500), medium (X5000) and high (X10000 - 20000) magnifications. 
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3.3. RESULTS 
3.3.1. Growth Curves 
 
Figure 3.4 shows the growth curve for E.coli in neat TSB and in artificial urine.  
Growth curves for MRSA, E.faecalis, K.pneumoniae and P.mirabilis are given in 
Appendix 2.  Results show that the bacteria grow at similar rates and equally well in 
TSB and artificial urine.  TSB was therefore selected as the perfusion medium to be 
used in the in - vitro model.  
 
 
 
 
 
Figure 3.4: E.coli growth curve in TSB and artificial urine.
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3.3.2.  In - Vitro Model 
 
3.3.2.1.  Meticillin Resistant Staphylococcus aureus 
 
 
 
Figure 3.5: In - vitro model results showing antimicrobial (test) and plain (control) catheters 
challenged with MRSA.  105 cfu/mL bacteria were inoculated down the lumen of the catheters and 
allowed 1 hour to adhere.  TSB was perfused through the catheter lumens at a flow rate of 0.5 
mL/hour and samples of perfusion fluid collected periodically for culture.  If no surviving bacteria 
was detected, repeat bacterial doses were given on a weekly basis with a new control catheter being 
set up.  The killing effect was studied over a period of 12 weeks or until bacterial colonisation 
occurred.  All test catheters were carried out in triplicate.  The graph shows control catheters became 
colonised with MRSA upon each challenge.  MRSA attached to the antimicrobial catheter by day 22 
(the 4th challenge) but colonisation did not ensue and a 12 week duration of protective activity was 
achieved.      
 
 
MRSA readily attached to the control catheters from day 1 of each of the weekly 
challenges and subsequently by sample day 6 numbers of bacteria had increased to 
an extent that caused the catheter to become occluded.  By the 4th challenge (day 22), 
MRSA became attached to the antimicrobial catheter the day following inoculation 
but were eradicated before the next challenge commenced.  At the end of the 12 
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week challenge, culture results from all three test catheters were negative, making 
the antimicrobial catheter effective at preventing bacterial colonisation by MRSA 
over the 12 week course. 
 
3.3.2.2.  Escherichia coli 
 
 
Figure 3.6: In - vitro model results showing antimicrobial (test) and plain (control) catheters 
challenged with E.coli.  105 cfu/mL bacteria were inoculated down the lumen of the catheters and 
allowed 1 hour to adhere.  TSB was perfused through the catheter lumens at a flow rate of 0.5 
mL/hour and samples of perfusion fluid collected periodically for culture.  If no surviving bacteria 
was detected, repeat bacterial doses were given on a weekly basis with a new control catheter being 
set up.  The killing effect was studied over a period of 12 weeks or until bacterial colonisation 
occurred.  All test catheters were carried out in triplicate.  The graph shows control catheters became 
colonised with E.coli upon each challenge.  The antimicrobial catheter prevented colonisation by 
E.coli for 12 weeks.       
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Culture results obtained from the antimicrobial catheters challenged with E.coli 
showed no evidence of bacterial colonisation throughout the 12 week course.  The 
antimicrobial agents were therefore effective at preventing E.coli colonisation over 
the test period.  Control catheters became readily colonised with E.coli upon each 
challenge. 
 
3.3.2.3.  Klebsiella pneumoniae 
 
 
 
Figure 3.7: In - vitro model results showing antimicrobial (test) and plain (control) catheters 
challenged with K.pneumoniae.  105 cfu/mL bacteria was inoculated down the lumen of the catheters 
and allowed 1 hour to adhere.  TSB was perfused through the catheter lumens at a flow rate of 0.5 
mL/hour and samples of perfusion fluid collected periodically for culture.  If no surviving bacteria 
was detected, repeat bacterial doses were given on a weekly basis with a new control catheter being 
set up.  The killing effect was studied over a period of 12 weeks or until bacterial colonisation 
occurred.  All test catheters were carried out in triplicate.  The graph shows control catheters became 
colonised with K.pneumoniae upon each challenge.  K.pneumoniae colonised the antimicrobial 
catheters following the 7th (day 43), 8th (day 50) and 9th (day 57) challenge respectively.       
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Test catheter 1 became colonised with K.pneumoniae upon the 8th challenge (day 
50), catheter 2 upon the 7th challenge (day 43) and catheter 3 on the 9th challenge 
(day 57).  All control catheters became colonised with K.pneumoniae with each 
bacterial challenge.  Samples collected from the colonised antimicrobial catheters 
were plated onto SBA and bacterial colonies that showed differing morphologies 
were subcultured, identified and MICs to rifampicin, triclosan and sparfloxacin 
determined as shown in Table 3.2.  
   
Table 3.2: Sparfloxacin, triclosan and rifampicin MICs and the susceptibility of the K.pneumoniae 
isolates retrieved from the colonised in - vitro model antimicrobial catheters.  
 
MIC (µg/mL) 
Test 
Catheter  
Isolate 
No: 
Organism Sparfloxacin Triclosan Rifampicin 
1 1 K.pneumoniae 1 2 R 
 2 K.pneumoniae 0.38 1 R 
2 1 Contaminant N/A N/A N/A 
3 1 K.pneumoniae  2 2 R 
Original  
Organism 
F2630 K.pneumoniae  0.032 0.19 R 
 
 
 
 
Catheter 2 became contaminated possibly due to failure in aseptic technique and was 
therefore discounted.  The MIC of sparfloxacin and triclosan for the organisms 
isolated from test catheters 1 and 3 were found to have increased.  An MIC of 2 
µg/mL shows signs of low level resistance.  The subsequent testing of these strains in 
a 7 day SPTT (data not shown) with silicone discs impregnated with sparfloxacin and 
triclosan and the three agents combined showed a decrease in the ZI diameter,  
indicating the strains showed reduced susceptibility to the antimicrobial agents 
compared to the original strain.   
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3.3.2.4.  Proteus mirabilis 
 
 
Figure 3.8: In - vitro model results showing antimicrobial (test) and plain (control) catheters 
challenged with P.mirabilis.  105 cfu/mL bacteria was inoculated down the lumen of the catheters and 
allowed 1 hour to adhere.  TSB was perfused through the catheter lumens at a flow rate of 0.5 
mL/hour and samples of perfusion fluid collected periodically for culture.  If no surviving bacteria 
was detected, repeat bacterial doses were given on a weekly basis with a new control catheter being 
set up.  The killing effect was studied over a period of 12 weeks or until bacterial colonisation 
occurred.  All test catheters were carried out in triplicate.  The graph shows control catheters became 
colonised with P.mirabilis upon each challenge.  P.mirabilis colonised the antimicrobial catheters 
following the 8th (day 50), 11th (day 71) and 12th (day 83) challenge respectively. 
 
 
 
 
Test catheter 1 became colonised with P.mirabilis on day 50 (8th challenge), catheter 
2 became colonised on day 71 (11th challenge) and catheter 3 following the 12th 
challenge on day 83.  Control catheters became colonised with each challenge. 
Samples collected from colonised test catheters were plated onto CLED agar, 
subcultured, identified and MIC to rifampicin, triclosan and sparfloxacin determined 
as shown in Table 3.3.   
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Table 3.3: Sparfloxacin triclosan and rifampicin MICs and the susceptibility of the P.mirabilis 
isolates retrieved from the colonised in - vitro model antimicrobial catheters.  
 
MIC (µg/mL) 
Catheter  Isolate Organism Sparfloxacin  Triclosan Rifampicin 
1 1 P.mirabilis 0.38 0.38 R 
2 1 P.mirabilis 0.19 0.19 R 
3 1 P.mirabilis 0.38 0.25 R 
Original 
Organism 
F1691 P.mirabilis 0.19 0.094 R 
 
 
 
The MIC of sparfloxacin for the P.mirabilis isolated from catheter 1 and 3 increased 
by 2 - fold and that of the organism isolated from catheter 2 remained the same as the 
original P.mirabilis.  The MIC of triclosan was found to have increased by between 2 
and 4 fold.  Although the MICs increased, this was not to a resistant level.  This 
elevation in MIC and the subsequent testing of these strains in a 7 day SPTT (data 
not shown) with silicone discs impregnated with the antimicrobial agents did not 
show any alteration in the ZI diameter relative to the parent strain.   
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3.3.2.5.  Enterococcus faecalis 
 
 
Figure 3.9: In - vitro model results showing antimicrobial (test) and plain (control) catheters 
challenged with E.faecalis.  105 cfu/mL bacteria were inoculated down the lumen of the catheters and 
allowed 1 hour to adhere.  TSB was perfused through the catheter lumens at a flow rate of 0.5 
mL/hour and samples of perfusion fluid collected periodically for culture.  If no surviving bacteria 
was detected, repeat bacterial doses were given on a weekly basis with a new control catheter being 
set up.  The killing effect was studied over a period of 12 weeks or until bacterial colonisation 
occurred.  All test catheters were carried out in triplicate.  The graph shows control catheters became 
colonised with E.facecalis upon each challenge.  All three antimicrobial catheters became colonised 
with E.faecalis by the 2nd challenge (day 8).      
 
 
All three antimicrobial catheters failed to prevent colonisation of E.faecalis by day 8 
(upon the 2nd challenge) and catheters became occluded.  Control catheters became 
colonised with each E.faecalis challenge.  Samples collected from colonised test 
catheters were plated onto SBA, subcultured, identified and MIC to rifampicin, 
triclosan and sparfloxacin determined as shown in Table 3.4.   
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Table 3.4: Sparfloxacin triclosan and rifampicin MICs and the susceptibility of the E.faecalis isolates 
retrieved from the colonised in - vitro model antimicrobial catheters.  
 
MIC (µg/mL) 
Catheter  Isolate Organism Sparfloxacin Triclosan Rifampicin 
1 1 E.faecalis 0.38 2 1 
2 1 E.faecalis 0.38 2 1 
3 1 E.faecalis 0.38 2 1 
Original 
Organism 
F2633 E.faecalis 0.38 2 1 
    
 
   
No difference in the MIC of sparfloxacin, triclosan or rifampicin to the isolates 
obtained from the failed antimicrobial catheters was seen compared to the original 
E.faecalis. 
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3.3.3.  Scanning Electron Microscopy 
 
 
Antimicrobial catheter SEMs at failure Control catheter SEMs at the end of the 
weekly challenge 
 
     
(A)                                                                  (B) 
 
 
     
(C)                                                                 (D) 
 
 
     
(E)                                                                  (F) 
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(G)                                                                 (H) 
 
 
      
(I)                                                                   (J) 
 
  (K) 
Figure 3.10: SEM images of the lumens of the antimicrobial (test) and plain silicone (control) Foley 
catheters following repeated bacterial challenges in in - vitro experiments.  (A) MRSA test catheter 
(B) MRSA control catheter (C) E.coli test catheter (D) E.coli control catheter (E) K.pneumoniae test 
catheter (F) K.pneumoniae control catheter (G) P.mirabilis test catheter (H) P.mirabilis control 
catheter (I) E.faecalis test catheter (J) E.faecalis control catheter (K) Control catheter not exposed to 
bacteria.  Images were taken at 10000 X magnification.  Image A and C show what could be remnants 
of dead bacteria, Image B and D to J reveal extensive 3D biofilms structures on the catheter lumens 
and Image K shows the surface of a control catheter in its as received state. 
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SEM images of the control catheters challenged with all bacteria in the in - vitro 
model revealed extensive colonisation and biofilm development on the catheter 
lumens.  Antimicrobial catheters showed colonisation on the luminal surface by 
K.pneumoniae, P.mirabilis and E.faecalis with evidence of EPS production.  At 
lower magnifications (data not shown) all colonised catheters revealed dense patchy 
networks of biofilm deposits along the catheter lumen.  Image A and C of 
antimicrobial catheters faced with repeated challenge by MRSA and E.coli 
respectively showed no evidence of viable bacteria upon culture at the end of the 12 
week challenge but SEM images revealed what is probably debris from dead biofilm 
and chemical residue from the perfusion of TSB over the catheter surface.     
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3.4. DISCUSSION 
The in - vitro model is designed to challenge the lumens of the antimicrobial 
catheters on a weekly basis with a high dose of bacteria and monitor its ability to 
prevent microbial colonisation.  It is based on a variation of the two - compartmental 
models used in encrustation studies and has separate chambers for test and control 
catheters which represent the catheterised urinary tract.  TSB is pumped through the 
catheter at a rate representative of that in the humans (0.5 mL/min) and this also 
allows for drug clearance.  Bacteria display a characteristic four - phase pattern of 
growth in liquid culture.  This includes the lag, log, stationary and decline phases.  
The lag phase is a slow period of growth in response to the bacteria adapting to their 
environmental conditions.  This is followed by the log phase where exponential 
growth occurs with bacteria doubling every few minutes.  As more bacteria compete, 
the nutrient supplies decrease and the exponential growth stops.  Bacterial numbers 
remain stable in what is the stationary phase.  The decline phase occurs when the 
build - up of toxic waste is such that some bacteria die whilst others adapt to a long - 
term survival mode.  It can be seen from Figure 3.4 and Appendix 2 that bacterial 
growth in TSB shows a similar pattern and counts to that in artificial urine, indicating 
that bacteria grow as well in TSB as in the artificial urine.  Because of this, the ease 
in preparation of the quantities required and lack of variation shown by the medium, 
TSB was selected for use in the in - vitro model.  It is acknowledged, however, that 
TSB lacks the constituents that artificial or real urine have and that antimicrobial 
agents could differ in activity in urine than laboratory media.   It was also noted that 
E.faecalis in particular favoured growth in TSB over artificial urine.  TSB was, 
however, deemed suitable for use in this preliminary study to give an indication to 
how effective the antimicrobial catheter may be in preventing bacterial colonisation. 
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The model is flexible and can accommodate a variety of different sized catheters and 
specifically looks at bacterial colonisation acquired by the intraluminal route.  The 
route of intraluminal infection is through contaminated drainage bags and connectors 
therefore colonisation occurs from the drainage end of the catheter and travels 
towards the tip.  For speed of bacterial colonisation, the in - vitro model challenges 
the catheters from the opposite direction, but it is not thought that the direction of 
inoculation would impact on the ability of the antimicrobial catheter to resist 
colonisation.  In - vivo, CAUTIs can consist of more than one bacterial species, 
however, this study examined the colonisation of individual species but mixed 
cultures could also be used and is a point for future research.  The whole system is 
held in a water jacket and maintained at 37°C, representative of body temperature.  
The catheters were challenged with bacteria weekly and surviving bacteria monitored 
before re - challenge up to the point of 12 weeks or until the antimicrobial catheters 
failed to prevent bacterial colonisation.  This testing period correlates with the 
duration catheters remain in place for asymptomatic patients before requiring 
replacement.   
 
Antimicrobial catheters challenged with E.coli and MRSA passed the 12 week 
challenge and colonisation was successfully avoided.  No bacterial counts were seen 
upon challenging catheters with E.coli.  Upon challenge with MRSA following the 
4th (day 22) challenge bacteria became attached to the material but were eradicated 
by day 2 or 3 prior to the next challenge.  For K.pneumoniae following the 8th 
challenge (day 50) a permanent re - growth of bacteria exceeding the initial bacterial 
load occurred and all 3 catheters failed to prevent colonisation by the 9th challenge 
(day 57).  Sparfloxacin and triclosan MICs for the bacteria isolated at the end of the 
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experiment were higher than for the original K.pneumoniae. Likewise, catheters 
challenged with P.mirabilis became colonised following the 8th challenge (day 50) 
and all 3 catheters became colonised by the final challenge.  MICs of sparfloxacin 
and triclosan also increased but only marginally.  All 3 catheters challenged with 
E.faecalis failed to prevent colonisation on the 2nd challenge (day 8) but MICs 
remained the same as for the original organism.   
 
SEM images of the control and colonised antimicrobial catheters revealed extensive 
3D biofilm structures on the luminal surface.  SEM images of antimicrobial catheters 
challenged with MRSA and E.coli revealed what is probably a combination of debris 
from aggregates of dead bacteria and chemical residue from the perfusion of TSB.  
This is despite the catheter according to culture techniques resisting colonisation by 
MRSA and E.coli over the 12 week duration.  A possible explanation for this could 
be that with the catheter being subject to repeated high inoculums of bacteria, 
aggregates of bacteria from the culture may have attached to the surface before being 
killed by the antimicrobial agents.  This could have left behind remnants of the dead 
cells which were seen as distorted cells on the SEM images but which were not 
detectable by culture as they were non - viable by this stage.  This was confirmed by 
all culture plates being incubated for up to 72 hours to ensure that the antimicrobial 
agents had killed the bacteria.  The discovery of possible remnants of dead cells 
could have acted as anchor points which may have encouraged bacteria to colonise 
the catheter surface as was seen by K.pneumoniae, P.mirabilis and E.faecalis.        
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According to the resistance theory described in Section 2.1.4 by incorporating two or 
more drugs into a polymer may act to close the MSW as for resistance to occur two 
mutations are required for growth [122].  This is the case only if the drugs are 
released at a similar rate and ratio above the MIC required for the test organisms.  
The colonisation of the antimicrobial catheters by K.pneumoniae lead to an increase 
in the MIC of sparfloxacin by a factor of between 11 to 63 - fold up, to 2 µg/mL and 
that of triclosan by 5 to 10 - fold, up to 2 µg/mL.  Concentrations of drugs at 2 
µg/mL required to be active on the organism can be considered as showing signs of 
low level resistance.  This could suggest that either both drugs (sparfloxacin and 
triclosan) were being released at levels below the MIC that is active on the organism, 
in which case this would allow for bacterial populations to multiply, colonise the 
catheter and bring about the generation of new mutants that will become enriched by 
subsequent antimicrobial exposure.  Or, if sparfloxacin and triclosan were released at 
different ratios then one drug may have fallen below its MIC whilst the other 
remained above the MIC and in the MSW upon where resistance to that drug could 
be enriched.  If K.pneumoniae became resistant to one of the drugs, the catheter 
would be acting as a monoloaded catheter and resistance to the other drug would be 
likely to follow upon prolonged exposure.  Even though the SPTT infers that 
sparfloxacin and triclosan display activity towards K.pneumoniae for over 100 days 
with no emergence of resistance, the in - vitro model is a dynamic system through 
which drug release and drug clearance is more likely to simulate that in the human 
catheterised urinary tract.  It is therefore a more clinically predictive approach to 
assessing the potential for bacterial colonisation and resistance development.   
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The colonisation of the antimicrobial catheters by P.mirabilis led to a slight increase 
in the MIC of triclosan of between 2 to 4 - fold, up to 0.38 µg/mL.  Triclosan is the 
main agent effective against P.mirabilis but the increase in MIC was lower than the 
increase in MIC towards K.pneumoniae colonised catheters and would not be 
considered to be to resistant concentrations.  The MIC of sparfloxacin to P.mirabilis 
which colonised the test catheters remained similar to the original P.mirabilis strain, 
probably because released concentrations were only active on P.mirabilis only over a 
short period according to SPTT results.  If the in - vitro experiment was not stopped 
as soon as the antimicrobial catheters became colonised with bacteria, it is likely that 
more bacteria would mutate upon the prolonged exposure to triclosan resulting in 
higher MICs.  It is possible that triclosan concentrations were too low to prevent the 
progression of P.mirabilis colonisation, however an 8 week duration of protective 
activity without signs of resistance was achieved and drug release studies are 
required to assess concentrations of drugs being released. 
  
Antimicrobial catheters became colonised with E.faecalis upon the 2nd challenge 
(day 8).  This corresponds well with the short duration of activity shown by the 
SPTT and indicates that the drugs do not possess sufficient activity to prevent 
colonisation by E.faecalis over prolonged periods.  Appendix 2 also shows that 
E.faecalis grew better in TSB than artificial urine which could act in favour of the 
growth of E.faecalis making the in - vitro model challenge more difficult.  The 
antimicrobial catheters lack of ability to prevent E.faecalis colonisation over a 
prolonged duration could be of concern but the clinical implication of it in terms of 
symptomatic CAUTI requires further investigation.          
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The in - vitro model has shown that the antimicrobial catheter is most effective in 
preventing colonisation caused by the MRSA and E.coli strains studied.  It also 
showed protective activity against colonisation by K.pneumoniae and P.mirabilis for 
a minimum of 50 days but was not active against E.faecalis over the long - term.  
The antimicrobial catheter has shown it is able to prevent bacterial colonisation 
caused by certain organisms associated with CAUTI over a prolonged course, 
however, drug release information is required to ascertain whether concentrations are 
sufficient to affect those bacteria which colonised the catheter.  
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4.0.  DRUG CONTENT AND RELEASE 
 
4.1.  INTRODUCTION 
Administration of systemic antibiotics can result in concentrations at the site of 
infection that are below desired therapeutic levels and many therapies tested in 
animal models which have been effective, are at doses greater than could safely be 
applied in humans [175].  The concept of local drug controlled - delivery devices is 
one of great interest.  There are a variety of definitions used to describe controlled 
delivery systems, but all refer to systems that consist of a drug and a drug carrier.  
The purpose of drug delivery systems is to deliver drugs locally to the site of 
infection/injury within an effective therapeutic range which avoids systemic toxicity 
[176].  A variety of biomaterials, for example, polymeric materials have been used as 
drug carriers.  As for urinary catheters, silicone is an example of a material in which 
liquids, gases and drug particles can easily penetrate.  Work has led to the 
conclusions that low molecular weight and lipophilic drugs easily diffuse into 
silicone [176].  The ease with which substances can penetrate silicone is due to its 
structure.  The large atomic volume of the silicon atom as well as the size and 
position of the constituent groups leads to rotation around the Si-O-Si bonds [176].  
Silicone polymers form helices and the silicon-oxygen bond angles create large 
amounts of free volume in silicone elastomers and this is responsible for their 
permeability to certain liquids, gases and drugs [176].   
 
Drug release encompasses several processes that contribute to the transfer of drug 
from the carrier to the bathing solution.  Drug release can occur by diffusion, 
degradation/erosion, dissolution or swelling [176].  Depending on the system, the 
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release may occur through any or all of these mechanisms.  Drug release data can be 
analyzed to determine the drug release mechanism by fitting the data into 
mathematical models as shown in equations 4.1 to 4.5.  The graphical presentation of 
those can be used to evaluate the mechanism of drug release, with the model that best 
fits the release data being selected on the basis of the highest correlation coefficient 
(r value).   
 
Equation 4.1:  Zero Order  Qt = Q0 + K0t 
Equation 4.2:  First Order  Log Qt = Log Q0 + Kt/2.303 
Equation 4.3:  Higuchi  Qt = KHt1/2 
Equation 4.4:  Hixson-Crowell cube root Q0 ± cube root Qt = KHCt 
Equation 4.5:  Korsmeyer-Peppas F = (Mt/M) = Kmtn 
 
Where: Qt = cumulative amount of drug released at time t, Q0 = initial amount of 
drug, t = time, K0 K, KH, KHC, Km = kinetic release constants, F = fraction of drug 
released at time t, Mt = amount of drug released at time t, M = total amount of drug 
in dosage form, n = diffusion or release exponent  
 
To determine the highest correlation coefficient, the following plots can be made:  
Cumulative % drug release vs time (zero order), log cumulative of % drug remaining 
vs time (first order), cumulative % drug release vs square root time (Higuchi), cube 
root initial drug concentration minus cube root cumulative % remaining in matrix vs 
time (Hixson-Crowell) and log cumulative % drug release vs log time (Korsmeyer-
Peppas) [177].  
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A brief description of each drug release mechanism is given below:    
x Zero order: describes systems where the drug release rate is independent of 
its concentration of the dissolved substances.  There is no time lag or burst 
effect over prolonged periods of time. 
x First order: the drug release rate depends on its concentration 
x Higuchi: this model suggests that the drugs are released by diffusion.  It 
describes the release of drug/s from an insoluble matrix as a square root of 
time - dependent process based on the Fickian diffusion equation. 
x Hixson-Crowell: is a cube root law - based model which describes drug 
release by dissolution and from systems where there is a change in surface 
area and diameter of particles. 
x Korsmeyer-Peppas: describes drug release from a polymeric system.  To 
establish the mechanism of drug release, the first 60% of release data is fitted 
into the Korsmeyer-Peppas equation.  The n value (slope of the line) is used 
to characterise the release mechanism for cylindrical shaped matrices.   
 
n = 0.45 Fickian diffusion 
n = 0.45 < n < 0.89 Anomalous (non-Fickian) diffusion 
n = 0.89 Case-II transport 
n = > 0.89 Super case-II transport 
 
Anomalous diffusion or non Fickian diffusion refers to a combination of both 
diffusion - and erosion - controlled rate release.  Case-2 relaxation or super case 
transport-II refers to the erosion of the polymeric chain. 
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Usually if the carrier system is silicone rubber, the release of a drug occurs by the 
diffusion mechanism [176].  Drug release through a matrix type controlled release 
device can be described by the classical Fickian diffusion theory.  According to 
)LFN¶V ODZ, the release of drug from a system is non-linear due to the increase in 
diffusional length resistance and/or the decrease in the inwardly releasing surface 
area with time [178].  There are a number of ways that drug release can be measured, 
for example, by ultra violet spectroscopy (UV-Spec) or high performance liquid 
chromatography (HPLC). 
 
4.1.1.  High Performance Liquid Chromatography 
High Performance Liquid Chromatography (HPLC) is a chromatographic technique 
used to separate, identify and quantify compounds in a mixture.  It is an analytical 
technique widely used on samples with components ranging from small organic and 
inorganic molecules and ions to polymers and proteins with high molecular weights.  
A schematic diagram of a basic HPLC system is shown in Figure 4.1.   
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Figure 4.1: Schematic diagram of a basic HPLC system [179]. 
 
 
The solvent delivery system (pump) delivers the mobile phase which typically 
consists of a water, methanol or an acetonitrile mix through the system at a specified 
flow rate.  The injector places the sample into the flowing mobile phase for 
introduction onto the column.  Most analytical columns are 10, 15 or 25 cm in length 
with internal diameters of 4.6 or 5 mm [180].  They are generally filled with 3, 5 or 
10 µm packing material such as silica.  Many HPLC separations are performed in the 
reverse-phase mode (RP-HPLC).  RP-HPLC uses a non polar stationary phase and a 
polar mobile phase.  Analytes are separated based on their relative solubility between 
two liquid phases and are eluted from the column in order of increasing 
hydrophobicity (decreasing polarity) [180].  The more polar or hydrophilic a 
compound is the faster it will elute from the column as it will travel with the mobile 
phase and the more nonpolar or hydrophobic an analyte is the longer it will be 
retained on the column through interaction with the non polar stationary phase.  To 
achieve separation of sample components isocratic or gradient elution can be used.  
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In isocratic elution, solvent composition and flow rate are held constant.  By varying 
the mobile phase composition or flow rate, this gradient type elution serves to elute 
components in a mixture that have varying polarities quicker than in isocratic elution.   
A detector translates concentration changes in the column effluent into electrical 
signals.  The most widely used detectors are based on ultraviolet-visible (UV-Vis) 
and fluorescence spectrophotometry, refractive index determination and 
electrochemical analysis.  A commonly used type of UV-Vis absorption detector is 
the diode array spectrophotometric detector of variable wavelength.  The detector 
response, in the form of an electrical signal can be recorded (the chromatogram) and 
used for qualitative and quantitative analysis via analyte retention times and peak 
areas [180]. 
 
4.1.2.  Objectives 
The aim of this chapter is to use RP-HPLC to (A) determine the total content of each 
antimicrobial agent within the antimicrobial urinary catheter and (B) to determine the 
concentrations of antimicrobial agents released over a 28 day period.  By 
investigating this, the concentration and ratios of drugs being release can be used to 
establish if sufficient concentrations are present to deliver a long lasting effect and if 
the concentrations are sufficient to reduce the opportunity for bacterial colonisation.       
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4.2.  METHODS 
 
4.2.1.  High Performance Liquid Chromatography Protocol 
1 cm segments were cut from silicone Foley catheters and impregnated with 
rifampicin, sparfloxacin and triclosan as described in section 2.2.4.  RP-HPLC 
analysis was performed on an Agilent 1090 HPLC machine with a diode-array 
variable wavelength UV detector (HPLC - UV) (Agilent Technologies, Berkshire, 
UK) connected to a Chemstation operating software system.  Chromatographic 
separations were performed on an Eclipse XDB-C8 (5 µm, i.d. 4.6 mm x 150 mm) 
column (Agilent Technologies).  Mobile phase was a mixture of aqueous sodium 
dihydrogen phosphate (15 mM, pH 2.5) (Sigma-Aldrich) with 10% acetonitrile 
(ACN) (Fisher Scientific, Loughborough, UK): methanol (MeOH) (Fisher Scientific) 
used after filtration through a 0.45 µm nylon membrane filter (Whatman, Dassel, 
Germany) and degassed.   Drugs were eluted using a gradient elution profile of 
methanol ranging from 58% to 90%.  A flow rate of 1 mL/min and temperature of 
40°C was employed and UV detection at 254 nm for rifampicin, 290 nm for 
sparfloxacin and 279 nm for triclosan.  Retention times were approximately 1.5, 4.0 
and 8.7 minutes for sparfloxacin, rifampicin and triclosan respectively.  
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4.2.2.  Total Antimicrobial Content 
 
4.2.2.1.  Calibration Curve for the Determination of the Total Drug  
Content in Catheter Segments 
To cover the expected drug range a series of at least five different concentrations of 
each antimicrobial agent was made.  0.01 g of rifampicin, 0.04 g of sparfloxacin and 
0.035 g of triclosan were accurately weighed and dissolved in ACN: HPLC grade 
water (Fisher Scientific): MeOH in a 1:3:6 ratio to a total of 100 mL.  Serial dilutions 
were made in 1:3:6 ratio of ACN: water: MeOH having a concentration of 5, 10, 15, 
20 and 25 µg/mL for rifampicin, 10, 50, 100, 200, 300 and 400 µg/mL for 
sparfloxacin and 10, 50 100, 200, 300 and 350 µg/mL for triclosan.  Concentrations 
were filtered through a 25 mm x 0.2 µm syringe filter (Sartorius Stedim Biotech, 
Goettingen, Germany) into 2 mL amber HPLC vials (Kinesis, Cambridgeshire, UK) 
and 5 µL injected into the column.  All injections were carried out in triplicate.  
 
4.2.2.2.  Total Drug Content in Catheter Segments   
1 cm catheter segments containing rifampicin, sparfloxacin and triclosan were placed 
into glass vials containing 2 mL chloroform.  The chloroform acts to expand the 
silicone matrix allowing the antimicrobial agents to be extracted.  Segments were left 
in chloroform at room temperature for 24 hours.  Catheter segments were then placed 
into new glass vials containing a further 2 mL of chloroform whilst the chloroform 
from the previous vial was left to evaporate at room temperature.  The process was 
repeated a total of three times to ensure that as much of the antimicrobial agents were 
extracted as possible.  All chloroform was pooled and evaporated to leave the drug 
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residue.  The drug residue was dissolved in ACN: HPLC grade water: MeOH in a 
1:3:6 ratio to a total of 1 mL, filtered through a 4.0 mm x 0.2 µm syringe filter 
(Sartorius Stedim Biotech) into amber HPLC vials and 5 µL injected into the 
column.  All experiments were carried out in triplicate. 
 
4.2.3.  Drug Release Studies 
 
4.2.3.1.  Calibration Curve for the Determination of Drugs 
Released from Catheter Segments 
0.01 g of sparfloxacin and triclosan were accurately weighed and dissolved in ACN: 
HPLC grade water: MeOH in a 1:3:6 ratio to a total of 100 mL.  Serial dilutions were 
made in 1:3:6 ratio of ACN: water: MeOH having a concentration ranging from 5, 
10, 20, 40 and 60 µg/mL for sparfloxacin and 5, 10, 20, 30 and 40 µg/mL for 
triclosan.  Concentrations were filtered through a 25 mm x 0.2 µm syringe filter into 
amber HPLC vials and 100 µL injected into the column.  All injections were carried 
out in triplicate.  
 
4.2.3.2.  Drug Release from Catheter Segments  
1cm catheter segments containing all three antimicrobial agents and catheter 
segments without antimicrobial agents as controls were placed into glass vials 
containing 2 mL HPLC grade water (pH7) in a 37°C incubator with constant 
agitation.  Segments were transferred daily or every 2 - 4 days into fresh 2 mL water 
to create nearly perfect sink conditions.  Elutions were collected and stored in a  
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-80°C freezer until required for HPLC analysis.  Drug release studies were carried 
out over 28 days and all tests were performed in triplicate.   
 
Elutions were concentrated by liquid - liquid extraction using chloroform.  2 mL of 
chloroform was added to the water in which the drugs had been released and shaken 
for 20 - 30 seconds.  Both phases were allowed to separate.  The organic phase was 
collected and further chloroform added to extract any further drug from the water.  
The two volumes of chloroform were pooled and evaporated at room temperature to 
leave the drug residue.  Drug residues were dissolved in ACN: HPLC grade water:  
MeOH in a 1:3:6 ratio to a total of 200 µL and filtered through a 4 mm x 0.2 µm 
syringe filter into amber HPLC vials.  100 µL was injected into the column.   
 
4.2.3.3.  Percentage Recovery Experiment 
10 and 20 µg/mL of sparfloxacin and triclosan were made up in chloroform and 
concentrated by liquid - liquid extraction.  Drug residues were dissolved in ACN: 
HPLC grade water: MeOH in a 1:3:6 ratio to a total of 200 µL and filtered through a 
4 mm x 0.2 µm syringe filter into amber HPLC vials.  100 µL was injected into the 
column and all experiments were performed in triplicate.  Peak areas were compared 
to a series of known sparfloxacin and triclosan concentrations and the % of drug 
recovered following liquid - liquid extraction determined.   
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4.3. RESULTS 
 
 
4.3.1.  Total Antimicrobial Content 
 
Figure 4.2 shows a typical chromatogram of rifampicin, triclosan and sparfloxacin 
and Figure 4.3 shows the calibration curves used to determine the total antimicrobial 
content extracted from the silicone segments. 
 
(A) 
 
(B) 
 
 
(C) 
Figure 4.2: HPLC chromatograms of (A) rifampicin at 254 nm, (B) sparfloxacin at 290 nm and (C) 
triclosan at 279 nm.  Peaks with a * represent the antimicrobial agents. 
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(A) 
 
 
(B) 
 
 
 (C) 
 
Figure 4.3: Graph dipicting the standard calibration curve of various concentrations of (A) rifampicin 
(B) sparfloxacin (C) triclosan plotted against the peak area as determined by HPLC - UV.  Each value 
represents the average of three tests with standard deviations.  The standard curves were used to 
determine the total antimicrobial content in catheter segments. 
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Table 4.1: Peak area of the total amount of rifampicin, triclosan and sparfloxacin extracted from 
catheter segments as determined by HPLC - UV.  Average of three segments with standard deviation 
and coefficient of variation are reported.   
 
                        Peak Area 
Segment Rifampicin  
 
Triclosan Sparfloxacin 
1 89.76 903.35 4259.31 
2 72.55 844.99 3373.52 
3 73.35 934.87 3704.34 
Average 78.55 894.40 3779.06 
StDev 9.71 45.6 447.6 
CV 0.12 0.05 0.12 
 
 
 
 
To establish the total concentration of each drug extracted from the catheter 
segments the equation from the calibration curves shown in Figure 4.3 were 
implemented.  Where: 
 
Equation 4.6:  y = mx + c therefore x = y-c/m 
 
y = peak area (from Table 4.1), m = gradient of the straight line, x = concentration of 
drug (µg/mL), c = y intercept 
 
 
To establish the total drug content per catheter as shown in Table 4.2, the total 
weight of a catheter (8.47 g) was divided by the average weight of 1 cm catheter 
segments (0.1346 g) and the sum (62.93) multiplied by the drug content per catheter 
segment.    
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Table 4.2: Total drug content per catheter and % w/w per catheter.  
 Rifampicin Triclosan Sparfloxacin 
Drug content in catheter segment 
(µg/cm) or (µg/mL) 
7.74 222.42 210.58 
Drug content per catheter (mg) 0.49 14.00 13.25 
% drug per catheter (w/w) 0.006 0.17 0.16 
 
 
By exposing silicone to chloroform containing 1% triclosan and 1% sparfloxacin, 14 
mg of triclosan and 13.25 mg of sparfloxacin were incorporated into the catheter, 
assuming all was extracted.  Of the 0.2% rifampicin, 0.49 mg representing 0.006% of 
the total weight of a catheter was incorporated.    
 
4.3.2.  Drug Release  
 
The quantity of rifampicin, sparfloxacin and triclosan released from the catheter 
segments was studied over 28 days and is shown in Table 4.3.  Drug extracts 
required concentration for detection and the percentage of each drug recovered from 
the liquid - liquid extraction process determined.  98.1% of sparfloxacin and 98.8% 
triclosan were recovered.  Concentrations of rifampicin being released were too low 
to detect using the HPLC protocol outlined.  
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Table 4.3: Concentrations of sparfloxacin and triclosan (µg/catheter) released from the antimicrobial 
urinary catheter over an elution period of 28 days.  Each value represents the average of three 
replicates with standard deviations. 
 
Day Sparfloxacin release 
µg/catheter 
Triclosan release 
µg/catheter 
1 506.01    ± 80.18 320.42    ± 120.23 
2 207.45    ± 127.00 329.60    ± 80.71 
3 198.42    ± 50.72 383.05    ± 43.71 
4 126.88    ± 55.58 318.72    ± 107.48 
5 121.08    ± 22.43 381.55    ± 22.84 
6 100.47    ± 6.42 295.06    ± 22.58 
8 188.62    ± 28.12 349.31    ± 8.54 
12 209.59    ± 75.43 299.06    ± 36.48 
14 161.84    ± 36.46 269.60    ± 83.39 
19 136.62    ± 15.04 286.07    ± 19.77 
21 194.01    ± 84.14 295.49    ± 80.75 
24 143.53    ± 15.83 195.01    ± 53.98 
26 150.28    ± 33.23 250.06    ± 46.17 
28 120.47    ± 13.25 218.07    ± 23.04 
 
 
 
A total of 2.6 mg sparfloxacin and 4.2 mg triclosan was released over 28 days 
representing 19.8% and 29.9% of the total content.  This gives a sparfloxacin release 
of approximately 0.07 mg/catheter/day following the initial burst effect (or 1.25 
µg/mL/day) and 0.15 mg/catheter/day (or 2.4 µg/mL/day) of triclosan over the 28 
day course.  (Refer to Appendix 3 for sparfloxacin and triclosan release as µg/mL).    
 
Extractive methods can give results with more variation which may be due to a loss 
of pharmaceutical substance during handling [181], which may be the reason why 
error margins are large and variable.  Figure 4.4 shows the drug release data as 
cumulative percentage release over the 28 days. 
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Figure 4.4: Cumulative percentage drug release over 28 days from the total drug content.  Values 
plotted are the average of three replicates.  
 
 
 
Drug release data were analyzed to determine the drug release mechanism by fitting 
the release data into the mathematical models shown in equations 4.1 to 4.5.  The 
model with the highest correlation coefficient shown from the graphical presentation 
of the data was used to select the type of model that best fitted the release data.  R2 
values are given in Table 4.4.  
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Table 4.4: R2 linear regression values for results from drug release data fitted into mathematical 
models to determine the mechanism of drug release from silicone catheter segments. 
 
                                        R2 
Model Sparfloxacin Triclosan 
Zero Order 0.9568 0.9287 
First Order 0.9653 0.9487 
Higuchi 0.9923 0.9834 
Hixson-Crowell 0.9626 0.9425 
Korsmeyer-Peppas 0.9916 0.9523 
 
The R2 values show that the drug release data fit well to the Higuchi model 
expression, suggesting that triclosan and sparfloxacin are released from the silicone 
by a diffusion controlled process.  A plot of the Higuchi model is given in Figure 4.5.   
 
 
 
Figure 4.5: Drug release data fitted into the Higuichi equation of cumulative % drug release versus 
the square root of time. 
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4.4.  DISCUSSION   
 
HPLC studies revealed from the chloroform solution containing 0.2% rifampicin, 1% 
sparfloxacin and 1% triclosan used in the impregnation process, 0.49 mg of 
rifampicin, 13.25 mg of sparfloxacin and 14 mg of triclosan became incorporated 
into the urinary catheter.  On a w/w basis a catheter contains 0.006% rifampicin, 
0.17% triclosan and 0.16% sparfloxacin.  The total drug content in a catheter 
compared to the content remaining in the immersion solution and the efficiency of 
drug uptake was not established as the total amount of each antimicrobial agent in 
the chloroform solution was not determined but is a point for future studies.  
 
As reported in Sections 2.1.5.1 and 2.1.5.2 a typical oral dose of rifampicin consists 
of 150 - 300 mg, reaching peak serum concentrations ranging from 4 - 32 µg/mL 
(average 7 µg/mL) [182] which is well tolerated and 400 mg reducing to 200 mg per 
day of sparfloxacin, reaching peak serum concentrations of 1 - 1.5 µg/mL [183].  The 
total amount of these drugs released from the catheter over a 24 hour period  is below 
a single therapeutic dose and due to the slow release into the localised surroundings 
it is envisaged that issues of drug intolerance and organ toxicity will not been seen.  
It is also possible that, due to the vast use of triclosan in everyday consumer 
products, individuals could well be exposed to higher usage than the concentrations 
released from the catheter.  Calafat et al (2008) [184], analysed the urine of 2,517 
people aged >6 years from the US general population and found it contained 
concentrations of triclosan ranging from 2.4 - 3790 µg/L.  Consumer soaps can 
typically contain 0.1 - 0.25% [185] triclosan and deodorant sprays/anti-perspirants 
between 0.15% and 0.25% w/v [186].  The urinary catheter releases a total of <400 
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µg of triclosan a day (or 2.4 µg/mL/day) into the surrounding vicinity and the urine, 
making toxicity unlikely.  Based on what is known there is not sufficient evidence to 
suggest that triclosan is a threat to human health, though a better understanding of 
potential health effects in respect to its wide use in consumer products is required.  
Due to the high lipid solubility of triclosan questions have been raised regarding its 
distribution properties and accumulation in the body [187].  There have however 
been reports [157] of triclosan incorporated into peritoneal dialysis catheters that 
were exposed to the sensitive perineum in mice and no gross lesions upon 
necroscopy at 7 or 30 days were seen.  Only minimal inflammation which was 
associated with the surgical process was reported [157].  Triclosan has also been 
bonded to vascular prostheses and in animal studies found not to cause a more 
pronounced inflammatory response than commonly used untreated vascular 
prostheses [188], making it suitable for use in patients at risk of infection.  Studies 
such as these have shown in animal studies that triclosan released from medical 
devices do not lead to local or systemic irritation and toxicity.  The in - vitro model 
has given an indication of the likely effect against bacterial colonisation and the drug 
studies revealed the quantities that are being released but in addition, to satisfy 
concerns over the use of triclosan long - term, further long - term in - vivo studies 
may be required. 
 
Efficacy of a device strongly depends on the rate and manner in which drugs are 
released.  This is dependent on the host matrix the drug is loaded into, the type of 
drug and drug clearance rate.  If drugs are released too quickly all could be released 
before infection is arrested and if release is delayed the infection may further set in.  
The release pattern observed by sparfloxacin (Table 4.3 and Appendix 3) was 
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bisphasic, characterised by an initial burst effect followed by a slower sustained 
release.  This could be important at the high risk time during catheter insertion to 
prevent bacterial colonisation.  Triclosan showed a more even release that gradually 
declined over the 28 day period (Table 4.3 and Appendix 3).  This correlates well 
with the duration of activity trend displayed by the SPTT (Figure 2.6 and 2.7) for 
both sparfloxacin and triclosan.  Rifampicin release was not detected as 
concentrations were too low but the SPTT (Figure 2.5) suggests that the pattern of 
release would follow a biphasic trend.  The total content of rifampicin in the catheter 
(0.006% w/w) was substantially less than sparfloxacin and triclosan which may have 
been why upon the release of rifampicin from the silicone the low concentrations 
were not detected.  To detect the presence of analytes at very low levels, more 
sensitive detection techniques such as fluorescence could be employed.  The main 
attraction of fluorescence detection is that for strongly fluorescent molecules, it can 
offer limits of detection two or three orders of magnitude lower than UV absorbance 
levels [189].  A higher concentration of rifampicin in the chloroform equivalent to 
sparfloxacin and triclosan may have enabled the drug to be detected on its release.  A 
greater total content and release of rifampicin may have also acted to have a more 
powerful killing effect on the Gram positive bacteria.  Liang et al (2007) [190] 
reported on silicone shunts containing 8.3% w/w rifampicin that showed a high 
initial release rate followed by a relatively constant release rate for a further 90 days.  
They reported a drug release mechanism that showed linearity against t0.5 (square 
root of time).  Mechanical properties of the silicone shunt were however not tested 
and it may be that at drug levels this high mechanical performance could be 
adversely affected.     
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Drug release data were fitted into the mathematical models as shown in equations 4.1 
to 4.5 to confirm the type of drug release mechanism.  Based on the interpretation of 
the correlation coefficient, the best fit (0.9834 for triclosan and 0.9923 for 
sparfloxacin) was observed from the Higuchi equation, which suggests that the drugs 
are released by a diffusion process.  This agrees with previous reports [176, 191] that 
agents released from matrix - loaded devices is via diffusion.  The mathematical 
modelling of release from diffusion - controlled systems relies on the fundamental 
)LFN¶V ODZ which describes the transport of molecules by a concentration gradient.  
Fickian drug release is characterised by a linear dependence of the released drug with 
the square root of time that is concentration - dependent.  It suggests that diffusion of 
molecules through a system decreases with time due to the extended distance that the 
drugs must diffuse through the matrix to the exterior [192].  Diffusion occurs as drug 
molecules inside the matrix move from one site to another as a result of random 
molecular motion.  For this to happen a system should be sufficiently dilute so that 
diffusion is not impeded by approach to saturation of the compound of interest 
(forming ideal sink conditions).  If the new site is occupied, the move is rejected, and 
the particle is removed from the lattice as soon as it migrates to a free site [193].  At 
the surface of a catheter, the drugs diffusing out become highly concentrated within 
the so-called stagnant diffusion layer (Nernst layer).  Underlying this shows a 
sustained release of sparfloxacin and triclosan.      
 
Kohnen et al (2003) [118], found that an equal release ratio was achieved from 
ventricular catheters impregnated with 1.4 wt% of rifampicin and 0.6 wt% of 
sparfloxacin.  It showed a high release rate in the initial phase dropping to lower 
amounts with time although the ratio between the antibiotics remained constant for at 
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least 40 days.  It is important to release the same ratio of drugs as excess elution of 
one drug compared to the other can lead to a catheter acting as a mono - loaded 
device in which bacterial resistance can emerge.  The release ratio of sparfloxacin 
and triclosan (19.8% and 29.9% respectively) over the 28 day period was found to 
differ and the low concentrations of rifampicin released did not allow assessment of 
levels corresponding to the MIC of susceptible organisms.  As the MIC of triclosan 
and sparfloxacin were found to increase following repeated challenges with 
K.pneumoniae and P.mirabilis during the in - vitro model challenge, it suggests that 
the concentrations of antimicrobial agents being released despite the MIC towards 
the organisms were not sufficient to prevent bacterial colonisation.  A study by 
Schierholz et al (1997)  [194], incorporated a much higher content of antimicrobial 
agents (5 wt%  rifampicin, 1.7 wt% fusidic acid and 1.4 wt% mupirocin) into a 
silicone catheter using a diffusion process and they report that they could not 
demonstrate bacterial resistance to the combination of drugs using gradient plates or 
killing experiments.  The antimicrobial urinary catheter may therefore have a greater 
effect on reducing bacterial colonisation and potential for resistance development if 
drug concentrations were increased and adjusted to release at equal ratios and more 
data could be gathered if drug release studies were taken to the end point of 12 weeks 
rather than 28 days.  Further investigation and optimisation of drug content and 
release is required to enable this to happen. 
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5.0.  SURFACE ANALYSIS 
 
5.1.  INTRODUCTION 
Biomaterials used in the production of medical devices will at some stage interface 
with the environment of the body, with which they must be biocompatible.  
%LRFRPSDWLELOLW\KDVEHHQGHILQHGDVWKHµXWRSLDQVWDWHZKHUHDELRPDWHULDOSUHVHQWV
an interface with a physiologic environment without the material adversely affecting 
WKDW HQYLURQPHQW RU WKH HQYLURQPHQW DGYHUVHO\ DIIHFWLQJ WKH PDWHULDO¶ [195].  
Understanding how a biomaterial interacts with the physical environment and how 
changes to materials, like the incorporation of drugs, or the development of new 
materials would help to determine whether new materials are more biocompatible 
than existing ones and better able to prevent some of the complications when 
implanted into the human body.  There are currently no standardised methods for 
comprehensively evaluating new biomaterials, but there is a string of scientific 
evidence towards using surface analysis techniques for studying and characterising 
biomaterials [196].  It is believed that most complications associated with medical 
devices take place at the surface of the device as this is the region that interfaces 
between the biomaterial and the biological environment and that differences in 
biomaterial surface characteristics such as roughness and hydrophobicity may be 
possible reasons for why one biomaterial is less prone to bacterial adherence than 
another [77].  The surface of a biomaterial is only a few atomic layers deep and it is 
the surface composition and structure of a biomaterial that triggers the sequence of 
biological events that occurs when a biomaterial is placed in the body [197].  As the 
surface composition and structure of a biomaterial can be different from its bulk 
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composition and structure, surface - sensitive techniques are required [197].  Over 
the past 20 years there has been a rise in the number of techniques capable of probing 
biointerfaces [198].  There is a large array of surface analytical techniques each 
designed with unique applications in mind.  These may entail determining the 
composition, structure and distribution of chemical species present on a biomaterials 
surface as well as topographical features of a surface and the likely interaction of 
solid surfaces with external environmental fluids (hydrophobic and hydrophilic 
effects).   
 
As there are currently no biomaterials used for urinary catheters that are completely 
biocompatible with the environment they are placed, it is important to gather an 
understanding of the relationship between surface properties and biological 
performance and to characterise the biomaterial surface in detail.  Section 5.1.1 to 
5.1.4 details the surface analytical techniques used in this study and the purpose of 
their use. 
 
5.1.1.  X-Ray Photoelectron Spectroscopy 
X-ray Photoelectron Spectroscopy (XPS) is a technique commonly used by surface 
analysts to identify and characterise the chemistry of surfaces, to characterise and 
optimise surface modifications and to characterise biological interactions especially 
the adsorption of proteins and other biomolecules at interfaces [198].  The 
components necessary to perform XPS are, an X-ray source, an electron energy 
analyser, a detection system and a sample stage, all maintained under ultra - high 
vacuum.  XPS involves the irradiation of a sample¶s surface by an X-ray beam.  This 
leads to the adsorption of X-rays by the atoms on the surface and the ejection of core 
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and valence electrons (photoelectrons).  Photoelectron emission occurs in all atoms 
in which core shell electrons have a binding energy (energy difference between the 
ground state and Fermi state of the electron) that is lower than the X-ray energy 
[199].  The kinetic energy of the emitted electrons is analyzed and the binding energy 
determined as described in the relationship shown by Equation 5.1.  
 
Equation 5.1:  EB = hʆ - EK - Ø 
 
Where:  EB = the energy binding the electron to the atom, hʆ = energy of the x-ray, 
EK = kinetic energy of the emitted electrons, Ø = work function. 
 
A spectrum of binding energy peaks are produced each having energies that are 
unique to a specific atomic element and sensitive to the chemical state of the 
element.  The intensities of the photoelectrons are proportional to the concentration 
of the element they are ejected from.  As the free path of photoelectrons is relatively 
short, only electrons emitted from the first 10 nm of a material reach the detector, 
making it a highly specific surface analysis technique [199].   
 
5.1.1.1.  X-Ray Photoelectron Spectroscopy Objective 
The impact that conditioning films on medical device surfaces have upon bacterial 
colonisation is important and was taken into account during the adherence studies 
(tk100) in Chapter 2.  To determine whether an hour exposure to urine was sufficient 
time for catheter surfaces to become coated with a urinary conditioning film was 
assessed using XPS.  The adsorption of protein elements from the urine and other 
urinary components to the surface was used to determine this.     
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5.1.2.  Atomic Force Microscopy 
Atomic Force Microscopy (AFM) was invented in 1986 and is a technique that 
produces high resolution images of the surface topography of a sample [200].  It 
operates by scanning the surface of a material using a very sharp tip (probe) which is 
commonly made from very fine silicon or silicon nitride in the shape of a pyramid 
and is placed on the end of a silicon or silicon nitride cantilever [201].  The 
cantilever is mounted on a piezoelectric ceramic scanner, usually in the form of a 
hollow cylinder which scans over the surface of a sample [202].  As the tip is brought 
close to a surface or is retracted from it, different forces e.g. van der Waals forces 
either attract or repel the tip and vertical displacement of the cantilever occurs.  A 
laser spot reflected from the top surface of the cantilever into an array of photodiodes 
is typically used to measure the deflection.  The forces depend on the nature of the 
sample, the distance between the probe and sample, the probe geometry and 
contamination of the sample surface.  These deflections are recorded and processed 
using imaging software to create a three dimensional topographical image of the 
surface.  Figure 5.1 illustrates the main components of an AFM.    
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Figure 5.1: A simple diagram of the main components of AFM [202]. 
 
 
Atomic force microscopy can operate under two principal modes namely contact and 
tapping modes.  In contact mode AFM the cantilever is in constant contact with the 
surface and the tip is dragged over the surface and contours measured.  However, 
samples and the tip can be easily damaged using this mode and images can be 
distorted.  In tapping mode AFM, cantilevers are oscillated with probes tapping the 
surface at speeds of 50,000 to 500,000 cycles/sec [203].  As the tip passes over a 
bump in the surface the cantilever has less room to oscillate and the amplitude is 
decreased.  As it passes over a depression the cantilever has more room to oscillate 
and the amplitude increases.  More recently, a new mode of AFM known as 
PeakForce Quantitative NanoMechanical Mapping (QNM) was introduced.  This is 
also based on tapping technology but keeps indentations small to deliver non - 
destructive, high resolution images which has allowed for samples from soft gels to 
rigid polymers to be analysed.  PeakForce AFM can map nanomechanical properties, 
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including modulus and adhesion whilst imaging sample topography i.e. surface 
roughness (commonly described as the root mean square).   
 
5.1.2.1.  Atomic Force Microscopy Objective 
Several studies have reported that an increase in surface roughness can promote 
bacterial adherence and subsequent colonisation [204, 205].  In this study, AFM was 
used to compare the surface topography (roughness) of the antimicrobial urinary 
catheters with the conventional (control) urinary catheter.  The effect on surface 
roughness as the antimicrobial catheters were immersed in an aqueous environment 
for 12 weeks to simulate drug release was also investigated to establish if there was 
any increase or decrease in the surface roughness due to elution of the drugs and if 
this may have any impact on bacterial colonisation.  
 
5.1.3.  Time of Flight - Secondary Ion Mass Spectroscopy 
 
Time of Flight - Secondary Ion Mass Spectroscopy (ToF-SIMS) is widely used by 
surface analysts in the characterisation of biomaterial surfaces.  A schematic diagram 
illustrating components of a ToF-SIMS analyser is depicted in Figure 5.2.   
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Figure 5.2: Schematic drawing of a SIMS instrument with a ToF analyzer [197]. 
 
 
Primary ion sources commonly used in ToF-SIMS include caesium, gallium and 
bismuth [206].  The surface of a sample is bombarded with primary ions as the ion 
beam is pulsed over it for short periods.  Collisions between primary ions and atoms 
of a surface are highly energetic resulting in extensive fragmentation and bond 
breakage at the collision site, emitting atomic particles.  As the collision cascade 
moves away from the collision site, collisions become less energetic and less 
fragmentation and bond breakage occurs resulting in the emission of molecular 
fragments [197].  Ionized species are accelerated by a fixed voltage through the flight 
tube to the mass analyser where in SIMS, positive and negative secondary ions (and 
neutral fragments) are separated and focused onto the detector.  As all ions have the 
same kinetic energy at the beginning of the flight path, the differing mass of the ions 
results in differing velocities and them arriving at the mass analyser at different times 
allowing for their separation.  Low mass ions arrive at the analyser faster than 
heavier ions.  Equation 5.2 describes this effect and from the time it takes the ions to 
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travel the length of the flight tube, the mass of the ions can be calculated as shown in 
equation 5.3. 
 
 Equation 5.2:  EK = 1/2mV2   
 
Where:  EK = kinetic energy, m = mass of ion, V = velocity of ion 
 
Equation 5.3:  t ± t0 = L (m/2EK)1/2 
 
Where:  t = arrival time at detector, t0 = start time from detector, L = length of flight 
path, m = mass of ion, EK = kinetic energy   
 
A reflectron helps compensate for energy and an angular dispersion that can occur 
during the emission process resulting in improved mass separation [197].  When 
analyzing polymers it is also necessary to provide surface charge stabilisation by 
means of a flood gun which floods the surface with electrons [206].  ToF-SIMS 
allows the chemical makeup of a sample to be mapped by focusing the primary ion 
beam to a narrow diameter and rastering it across the sample [199].  An immense 
number of peaks representing the full mass spectra of all ions can be obtained in a 
relatively short period of time.  By evaluating the masses of the signals, peaks can 
often be identified from the molecular ion of the analyte, fragments of the molecular 
ion or ions of any other components that may be in the sample [197].  Specific ions 
or combinations can be selected and their distribution mapped using imaging 
software to establish how uniform their distribution is.  
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5.1.3.1.  Time of Flight - Secondary Ion Mass Spectroscopy 
Objective 
 
In this study, ToF-SIMS was used to identify and map the distribution of the 
antimicrobial agents on the catheter surface and catheter cross sections through 
imaging and to track their profiles as the technique was used to penetrate the depths 
of the catheter.  This was performed in order to assess how uniformly the drugs were 
distributed within the catheter which could affect drug release and bacterial 
colonisation.  Catheters were examined both before and after 12 weeks in solution to 
elute the drugs from the antimicrobial catheter.  
 
5.1.4.  Water Contact Angle 
Water Contact Angle (WCA) measurements have been a major approach used to 
investigate problems associated with solid - liquid interfaces [207].  The WCA is the 
angle at which the liquid interface meets a solid surface and is dependent on the 
surface chemistry and roughness.  If water is placed on a solid surface the surface 
tension at the interfaces will cause the liquid to form a drop shape which has a 
defined contact angle (Figure 5.3).  WCA measurements are extremely sensitive 
techniques that depend on the top layer of a surface and are therefore highly 
susceptible to surface contaminants and surface deformations.  There are several 
ways to perform WCA measurements including static or sessile drop measurements 
where advancing and receding contact angles can be measured.  If a contact angle is 
close to 0° the droplet will completely spread out on the surface, meaning the 
material is completely hydrophilic.  A contact angle of less than 90° shows the liquid 
readily wets the material and the material is of a hydrophilic nature but less so than 
the above.  A contact angle of >90° indicates that the liquid resists wetting and the 
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material is more hydrophobic.  The degree to which a surface may be wet is a 
property that can influence bacterial attachment to surfaces.   
 
 
Figure 5.3: The contact angle of a liquid at the interface of a solid.  A FRQWDFW DQJOH Į RI !° 
indicates low wettablity and a hydrophobic surface.  A contact angle of <90° indicates high wettability 
and a hydrophilic surface [208]. 
 
 
5.1.4.1.  Water Contact Angle Objective 
In this study, WCA measurements were performed on urinary catheters LQ WKH ³DV 
received´ VWDWH from the manufacturer and on the antimicrobial incorporated 
catheters before and after 12 week soaking/drug elution to study if incorporation of 
the antimicrobial agents had any impact on the materials degree of hydrophobicity or 
hydrophilicity and therefore possible interaction within the urinary tract environment 
and bacterial colonisation. 
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5.2.  METHODS 
 
5.2.1.  X-Ray Photoelectron Spectroscopy 
6 mm silicone discs were impregnated with all three antimicrobial agents as 
described in section 2.2.4.  Discs were also used without the incorporation of 
antimicrobial agents and served as controls.  Half of both sets were exposed to sterile 
human urine (pH 6.8) for 1 hour in a 37°C incubator whilst the other half were left 
unprocessed.  Care was taken to avoid possible contamination of surfaces.  All four 
sets of discs were taken for XPS analysis to determine if a conditioning film had 
been deposited on the surface as indicated by the adsorption of proteins and other 
elements from the urine.        
 
 XPS spectra were recorded using a Kratos Axis Ultra spectrometer employing a 
monochromated Al KD X-ray source (hQ = 1486.6 eV), hybrid 
(magnetic/electrostatic) optics, hemispherical analyzer and a multi-channel plate and 
delay line detector with a collection angle of 30º and a take off angle of 90º.  X-ray 
gun power was set to 100 W.  All spectra were recorded using an aperture slot of 300 
x 700 microns with a pass energy of 80 eV for survey scans and 20 eV for high-
resolution core level scans.  All XPS spectra were recorded using the Kratos VISION 
II software.  Data files were translated to VAMAS format and processed using the 
CASA XPSTM software package (Version 2.3.2 and later). 
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5.2.2.  Atomic Force Microscopy 
1 cm catheter segments were impregnated with all three antimicrobial agents as 
described in section 2.2.4.  Segments without antimicrobial agents served as controls.  
Half of each of the two sets of segments were placed in PBS for 12 weeks to simulate 
drug elution over the period of catheter use in the body.  The buffer was replaced 
with fresh solution every week to prevent the build - up of antimicrobial agents.  
Small flat sections (approx 2 x 2 mm) of catheter segments were cut out and rinsed 
with ultra pure water and left to dry at room temperature.  Sections were mounted 
onto metal stubs using superglue for analysis by AFM. 
 
A MultiMode 8 AFM (Vecco Instruments) with a Nanoscope V controller operated 
in a PeakForce Quantitative NanoMechanical Property Mapping (QNM) mode in air 
was employed.  A silicon nitride cantilever with a 0.1 N/m nominal spring constant 
and a silicon probe was adopted.  The AFM was calibrated and two 5 x 5 µm surface 
area scans were performed on each catheter segment.  The roughness of the surface 
was measured by the root mean square (Rq value) which is calculated by taking the 
centre line of a surface profile and calculating the root mean square deviation of a 
number of points on the profile from the centre line [199].  Rq values were obtained 
by taking the average of ten 1.3 x 1.3 µm areas from the two scans of each catheter 
segment.  Values from control and antimicrobial catheter sections before and after 
soaking/ drug elution were compared.   
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5.2.3.  Time of Flight - Secondary Ion Mass Spectroscopy 
 
1 cm catheter segments were impregnated with all three antimicrobial agents as 
described in section 2.2.4.  Segments without antimicrobial agents served as controls.  
Half of each of the two sets of segments were placed in PBS for 12 weeks to simulate 
drug elution.  The buffer was replaced with fresh solution every week to prevent the 
build - up of antimicrobial agents.  All 1 cm segments were cut in half, rinsed with 
ultra pure water and left to dry at room temperature.  Crude preparations of cross 
sections of the catheter segments were also cut to assess the distribution of the drugs 
through the thickness of the catheter tubing.  Segments were also impregnated with 
rifampicin only, sparfloxacin only and triclosan only, without the 12 week drug 
elution for individual drug characterisation purposes.   
 
ToF-SIMS analysis was performed using an ION-TOF IV (GmbH, Münster, 
Germany) instrument equipped with a Bi liquid metal ion gun (LMIG).  Samples 
were mounted onto a sample holder using clamps and loaded into the ToF-SIMS 
vacuum chamber where pressure was maintained at 10-8 to 10-9 mbar.  Images of the 
catheters outer surface were formed by rastering a pulsed Bi3+ primary ion beam at a 
current of 1 pA.  The pulsed Bi3+ ion beam had a spot size of <2 µm diameter and 
was rastered in a 256 x 256 pixel array.  Charge compensation using an electron 
flood gun was employed due to the materials conductivity.  Mass spectrum obtained 
from positive and negative ion profiling were calibrated using IonSpec Version 4.0 
software supplied by the manufacturer.  Ion intensities were normalized to the total 
ion count and spectrums generated from the surface of antimicrobial loaded catheters 
were compared to those without antimicrobial agents.  A peak list was generated and 
those acting as markers for the material and drugs were identified.  Ion image 
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Version 4.0 software was used to create images of the selected ions and drug 
distribution analysed.  Drug distribution across the thickness (cross - sections) of the 
catheter tubing was assessed as above. 
   
For depth profiling, the ToF-SIMS instrument was equipped with a 10 keV C60 ion 
source for sputtering as well as a 25 keV cluster Bi ion source for analysis, both set 
at incident angles of 45°.  An µLQWHUODFHG¶ PRGH was employed, utilizing a beam 
target current of 200 pA for the C60+ sputter beam and a pulsed Bi3+ analysis beam 
set to 0.25 pA.  Sputtering and analysis beams were aligned and a sputter crater of 
300 x 300 µm2 etched with the central 100 x 100 µm2 compartment analysed.  Both 
positive and negative spectra were calibrated as above and selected ions representing 
markers of the drugs were reconstructed and exported into an excel spreadsheet to 
allow the profiles of the agents to be studied.    
  
5.2.4.  Water Contact Angle 
1 cm catheter segments were impregnated with all three antimicrobial agents as 
described in Section 2.2.4.  Segments without antimicrobial agents served as 
controls.  Half of each of the two sets of segments were placed in PBS for 12 weeks 
to simulate drug elution.  The buffer was replaced with fresh solution every week to 
prevent the build - up of antimicrobial agents.  Segments were rinsed with ultra - 
pure water and dried at room temperature for WCA measurements. 
 
A KRÜSS Drop Size Analyzer (DSA) 100 with DSA software version 1.6 was used 
to carry out WCA measurements.  Each catheter segment was placed on the drop size 
analyzer platform and 100 pL of ultra pure water was dispensed from a piezo dosing 
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unit onto the surface of the material.  Four scans per sample were performed 
covering a range of 2 mm along the catheter length.  A high speed camera was used 
to record the first second the spot of water touched the surface and a video image 
was taken.  The droplet angle was determined by the DSA software package.  A 
baseline was fitted to the water droplet circle and a tangent placed at the intersection 
of the liquid and solid.  WCA were recorded and the average taken.   
 
5.2.5.  Statistics 
Two tailed paired t-tests at the 95% confidence level were used to compare 
differences between control and antimicrobial catheter material.  
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5.3. RESULTS 
 
5.3.1.  X-Ray Photoelectron Spectroscopy  
X-ray Photoelectron Spectroscopy was employed to determine if material exposed to 
urine for 1 hour resulted in the adsorption of urinary elements i.e. proteins and salts 
to the catheter surface.  Wide survey scans were acquired to view all elements on 
catheter surfaces and high resolution scans performed on elements most commonly 
observed.  The binding energy scale was referenced to the main C (1s) peak, 
attributable to hydrocarbon (CH).  Relative atomic % were carried out using the peak 
area corrected with Kratos sensitivity factors supplied from the manufacturer and the 
average of three repeats reported as shown in Table 5.1.            
 
Table 5.1: XPS elemental atomic relative % of control material (silicone without antimicrobial 
agents) and test material (silicone with antimicrobial agents) before and after exposure to urine for 1 
hour to form a conditioning film layer.  All tests were performed in triplicate and figures represent 
averages with standard deviations.   
  
Atomic Relative % 
Element Control material  
minus 
conditioning film 
(± StDev)  
Control material 
plus 
conditioning film 
(± StDev) 
Antimicrobial 
material minus 
conditioning 
film (± StDev) 
Antimicrobial 
material plus  
conditioning film 
(± StDev) 
Na 1s 0.0       ± 0 0.2       ± 0  0.1      ± 0 0.6      ± 0.2 
O 1s 33.8     ± 1.2  29.6     ± 0.8 34.6    ± 0.7 25.8    ± 1.4 
N 1s 0.2       ± 0.1 1.3       ± 0.2 1.2      ± 0.4 5.1      ± 1.2 
Ca 2p 0.9       ± 0.1 0.5       ± 0.1 1.1      ± 0.1 0.1      ± 0.2 
C 1s 42.9     ± 1.8 47.6     ± 0.9 40.8    ± 0.9 54.8    ± 2.7 
Cl 2p 0.4       ± 0.2 0.1       ± 0 0.3      ± 0 0.9      ± 0.3 
Si 2p 19.2     ± 0.4 18.6     ± 0.4 18.2    ± 0.5 11.8    ± 2.4 
Mg 2p 2.8       ± 0.3 2.0       ± 0.2 3.7      ± 0.2 0.8      ± 0.5 
 
 
  Deconvolution  of C1s Peak  
C 1s 
aliphatic 
90.3    ± 1.2 85.7     ± 1.0 80.2    ± 3.3 68.3    ± 4.3 
C 1s  
C-OH 
8.8      ± 0.8 11.7     ± 0.4 18.8    ± 2.8 23.8    ± 1.7 
C 1s 
COOH 
0.9      ± 0.5 2.6       ± 0.7 1.0      ± 0.5 8.0      ± 2.7 
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Spectra from control and antimicrobial non - conditioned samples were compared to 
those with a conditioning film.  Wide survey scans, shown in Appendix 4, did not 
reveal a big difference between conditioned and un - conditioned samples.  High 
resolution scans however, highlight greater differences.  Conditioned samples 
revealed changes in the elemental composition and relative % of elements.  Elements 
of proteins e.g. nitrogen and carbon were found at increased levels on conditioned 
samples.  The atomic % of oxygen however decreased following exposure to urine.  
Sodium was also found to increase upon conditioning whilst the atomic % of silicone 
decreased.  Calcium and magnesium were found to be slightly higher on the un - 
conditioned samples.  Figure 5.4 depicts the high resolution scans of the nitrogen and 
sodium peaks for both control and antimicrobial material before and after exposure 
to urine.   
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Figure 5.4: XPS high resolution scan of the Nitrogen (N) peak of control material (A) without a 
conditioning film (B) with a conditioning film. Nitrogen (N) peak of antimicrobial material (C) 
without a conditioning film (D) with a conditioning film. Sodium (Na) peak of control material (E) 
without a conditioning film (F) with a conditioning film. Sodium (Na) peak of antimicrobial material 
(G) without a conditioning film (H) with a conditioning film.    
 
 
The increase in carbon on conditioned samples also revealed the addition of a new 
functional group as depicted in Figure 5.5.  The C (1s) peak on the non - conditioned 
samples was deconvoluted into two peaks.  Conditioned samples showed evidence of 
a different chemical type of carbon atom.  The peak with the lowest binding energy 
(282.0 eV) representing the reference peak of hydrocarbon (C-H) and the peak at 
283.5 eV representing the addition of a single bond of either oxygen or nitrogen to 
the carbon (C-(O,N) are present on both conditioned and un - conditioned samples.  
For both conditioned control and antimicrobial material XPS revealed the addition of 
an extra peak at 285.5 eV, which is indicative of carbon making a double bond with 
R[\JHQ&ő2 
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Figure 5.5: High resolution scan of the deconvolution of the C 1s peak performed by XPS.  Analysis 
is of control material (A) without a conditioning film (B) with a conditioning film and antimicrobial 
material (C) without a conditioning film (D) with a conditioning film.  Forming a conditioning film on 
the control and antimicrobial material revealed the addition of an extra peak at 285.5 eV. 
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5.3.2.  Atomic Force Microscopy  
Atomic force microscopy was performed to study if elution of the antimicrobial 
agents from the catheter over a 12 week period had any impact on the surface 
roughness compared to material without antimicrobial agents.  Two scans at different 
points on the catheters¶ outer surface were taken and the roughness values (Rq 
values) detemined by taking the average Rq of ten areas of size 1.3 x 1.3 µm on the 
scanned images.  Table 5.2 shows the average Rq values of the catheter surfaces and 
Figure 5.6 shows the topograpical images of control and test catheter segments 
before and after soaking/drug elution.    
 
Table 5.2: Roughness (Rq) values as determined by AFM for control and antimicrobial catheter 
segments before (p = 0.26) and after (p = <0.05) 12 week soaking/drug elution in buffered solution.  
Values reported represent the average of 2 scans upon which 10 areas were selected for average Rq 
determination with standard deviations.   
 
Catheter Treatment Rq Value (nm) 
(± St Dev) 
Control catheter material prior to drug elution 12.53      ± 1.79 
Antimicrobial catheter material prior to drug elution 13.14      ± 1.40 
Control catheter material post drug elution 9.57        ± 1.35 
Antimicrobial catheter material post drug elution 22.72      ± 4.33 
 
 
 
 
The impregnation of rifampicin, sparfloxacin and triclosan into the catheter material 
revealed no significant difference (p = 0.26) in surface roughness compared to the  
material without antimicrobial agents.  Elution of the antimicrobial agents revealed a 
significant difference (p = <0.05) in the roughness value between the antimicrobial 
and control material.  Catheter material containing the antimicrobial agents following 
elution of the drugs were found to have a significantly higher Rq value.   
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(A)                                                               (B) 
 
       
(C)              (D) 
Figure 5.6: AFM roughness analysis images of catheter segments. (A) control catheter material 
before soaking compared to (B) antimicrobial catheter material before drug elution (soaking) (p = 
0.26) and, (C) control catheter material after 12 week soaking compared to (D) antimicrobial catheter 
material after 12 week drug elution (soaking) (p = <0.05).  Antimicrobial catheter segments following 
drug elution (Image D) show a greater degree of surface roughness. 
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5.3.3.  Time of Flight - Secondary Ion Mass Spectroscopy 
 
Time of flight - secondary ion mass spectroscopy was used to identify the 
antimicrobial agents within the polymer and analyse their distribution on the surface 
through imaging.  A large number of peaks were generated when scanning the 
surface of the control and antimicrobial catheter material.  To identify markers of the 
three drugs, positive and negative ion control material spectra were compared with 
antimicrobial material spectra.  The chemical formulae of the antimicrobial agents 
are given below: 
 
Rifampicin C43H58N4012 
Sparfloxacin C19H22F2N403 
Triclosan C12H7Cl3O2 
 
Mass spectra may display the whole molecular ion peak, but this does not always 
appear and can be weak.  Peaks corresponding to fragments of the molecular ion may 
also represent markers of the drugs or isotope peaks.  Alternatively the molecular 
formula of each drug may reveal elements that enable the agents to be traced.  Mass 
spectra obtained from positive and negative secondary ions were viewed and the 
negative spectra revealed peaks that could be identified to the drugs.  Figure 5.7 
shows a typical mass spectrum of control and antimicrobial material. 
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Figure 5.7: Negative ion spectrum for (Top Image) control catheter material  (Lower Image) 
antimicrobial catheter material (before soaking/drug elution).  CN = carbon-nitrogen, 13CN = carbon-
nitrogen isotope, Cl = chlorine, 37Cl = chlorine isotope, F = fluorine, Si = silicone, SiH = silicone-
hydrogen.  The antimicrobial material shows the presence of F-, CN- and Cl- ions. 
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The negative ion spectra revealed that flourine ions (F-), chlorine ions (Cl-), its 
isotope (Cl37) and carbon-nitrogen (CN-) could be acting as markers for the drugs.  It 
is likely that as the molecular formula of sparfloxacin contains F-, this element could 
be acting as its marker and as triclosan contains Cl- in its structure, this and its 
isotope are likely to be representative of the drug.  CN- can be found in both 
rifampicin and sparfloxacin but not triclosan as it does not contain nitrogen.  To 
determine which drug CN- acted as a marker for, catheter material was impregnated 
with individual drugs.  Spectra obtained from rifampicin containing catheter 
segments showed no evidence of any distinguishing elements.  Neither CN-, the 
molecular ion or any fragment of rifampicin were at detectable levels.  This drug was 
therefore unable to be characterised.  CN- was therefore also a maker for sparfloxacin 
as revealed from spectra obtained when material was impregnated with sparfloxacin 
only.  The control material was also processed in the same manner as the 
antimicrobial catheter via exposure to chloroform (CHCl3) and the spectra shown in 
Figure 5.7 revealed that there was little Cl- contribution from the CHCl3 to 
significantly impact on the Cl- peak from triclosan.  Comparison of the spectra (data 
not shown) for control material exposed to chloroform against control material in its 
³DV UHFHLYHG´ VWDWH ZDV also used to infer that there was no residual CHCl3 in the 
silicone.  Gas chromatography of the samples would be further required to confirm 
this.  It was therefore only possible to confirm markers for two out of the three drugs.  
It can be surmised that F- and CN- are good indicators for sparfloxacin and Cl- (and 
isotope) for triclosan. 
   
Figure 5.8 shows images of selected elements F-, Cl-, CN-, Si (silicone), SiO2 
(silicone dioxide) and the total ions obtained from surface scans of the control and 
antimicrobial catheters.      
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(B)  
 
 
(C) 
 
 
(D) 
Figure 5.8: Negative ion ToF-SIMS images of the surface of (A) control catheter material and (B) 
antimicrobial catheter material before soaking/drug elution and (C) control catheter material and (D) 
antimicrobial catheter material after 12 week soaking/drug elution.  Chlorine (Cl-) represents triclosan, 
fluorine (F-) and CN- represent sparfloxacin whilst rifampicin could not be traced.  The presence of 
the agents on the antimicrobial catheter surface is dipicted by the more intense shade appearing 
relatively evenly distrubuted although a localization of drug can be seen (Image B) which diffuse 
away following drug elution (Image D).  Cl- on Image C is likely to be due the buffer used to soak the 
catheter in.  The silicone (Si) and silicone dioxide (SiO2) elements form part of the material and are 
shown to be uniformly distubed on all images.  Total ion images are also given.   
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The images in Figure 5.8 allowed for the distribution of drugs on the outer catheter 
surface to be assessed for uniformity.  Due to the swelling nature of the polymer 
upon immersion into the chloroform, it was expected that the drugs would be 
distributed the same on the outer surface as on the luminal surface.  Image A of the 
control material, shows Si and SiO2 to be representative of the polymer.  Control 
material exposed to 12 weeks in buffer solution in the same way antimicrobial - 
containing catheter segments were, revealed traces of Cl- (Image C).  This can 
however be attributed to the components within the buffer adsorbing to the surface.  
Images of Si and SiO2 remain similar following soaking.  The antimicrobial catheter 
prior to drug elution (Image B) showed a fairly even distribution of sparfloxacin on 
the catheter surface indicated by the intensity of F- and CN- across the image.  Cl- as 
a marker for triclosan was also fairly evenly distributed across the catheter surface.  
Image B also revealed the presence of aggregates of drugs formed on the catheter 
surface.  Following drug elution the Cl- intensity remained as triclosan continued to 
diffuse to the surface with some contribution from the buffer whereas the 
sparfloxacin markers, F- and CN-, appeared less intense.   
 
Depth profiling was used to trace the distribution of the chemical species 
representing sparfloxacin and triclosan as a function of depth from the surface. 
Figures 5.9 and 5.10 follow the profiles of the antimicrobial agents as they were 
tracked through the polymer. 
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(A)     
    
  
 
(B) 
Figure 5.9: Depth profiling performed by ToF-SIMS of (A) contol catheter material and (B) 
antimicrobial catheter material before soaking/drug elution.  Fluorine (F-) and carbon-nitrogen (CN-) 
represent sparfloxacin, chlorine (Cl-) triclosan and silicone (Si-) the catheter material.    
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Figure 5.10: Depth profiling performed by ToF-SIMS of (A) control catheter material and (B) 
antimicrobial cateter material after soaking/drug elution.  Fluorine (F-) and carbon-nitrogen (CN-) 
represent sparfloxacin, chlorine (Cl-) triclosan and silicone (Si-) the catheter material. 
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F-, Cl- and CN- intensities are negligible in the control material both before and after 
12 weeks soaking.  Si intensities were high at the surface and decreased as the 
material was penetrated.  It was expected that Si and SiO2 may have increased or 
remained the same throughout the depth profiling, but this may have been due to the 
degradation effects from the C60 beam.  The control material when soaked showed a 
lower intensity of silicone.  Image B displaying the profile for the antimicrobial 
material shows Cl-, F- and CN- intensities to peak at the surface and then decline 
through the bulk.  Cl- therefore triclosan intensities are greater than for the 
sparfloxacin markers F- and CN-.  Cl- intensities remain constant deep into the 
polymer whereas F- and CN- display a slight decline the deeper the scan continues.  It 
is evident that upon immersing the antimicrobial material into an aqueous 
environment for 12 weeks (Image D), the intensities of the elements representative of 
sparfloxacin and triclosan are reduced.  There is a peak of Cl- at the surface which is 
followed by a rapid decline to steady state conditions whilst the intensity of F- and 
CN- (sparfloxacin) are less than the Cl- (triclosan) and similar to the Si intensity. 
 
Images from cross sections of catheters are given in Figure 5.11.  Images were 
created by scanning the inner to the centre of the tubing and the centre to the outer of 
the tubing and viewing both to assess the uniformity of drug distribution through the 
thickness of the catheter.  Figure 5.11 depicts the scans taken from the inner catheter 
wall to the centre of the section.  Diagrams show the location of the scans on the 
cross sectional areas.  Combined viewing of the inner scans and outer scans (data not 
shown) revealed that sparfloxacin and triclosan penetrated the total thickness of the 
catheter wall. 
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Figure 5.11: Images taken from the inner catheter wall to the centre of the cross sectional area along 
with diagrams depicting the scan location of the (A) control catheter material and (B) antimicrobial 
catheter material before soaking/drug elution (C) control catheter material and (D) antimicrobial 
catheter material after soaking/drug elution (E) rifampicin only (F) triclosan only (G) sparfloxacin 
only catheter material before drug elution.  Images reveal the antimicrobial agents penetrate the 
thickness of the catheter wall. 
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5.3.4.  Water Contact Angle 
 
Water contact angle measurements were taken to discover if impregnating the 
catheter material with antimicrobial agents affected the degree of 
hydrophobicity/hydrophilicity displayed by the material.  Table 5.3 shows the 
average WCA measurements of control and antimicrobial catheter material prior to 
and post soaking/drug elution. 
 
Table 5.3: WCA measurements of control and antimicrobial catheter material before (p = 0.015) and 
after soaking/drug elution (p = >0.05).  All tests are the average of 4 replicates with standard deviation 
and coefficient of variation.   
 WCA (°) of 
control catheter 
material before 
soaking 
WCA (°) of 
antimicrobial 
catheter 
material before 
drug elution 
WCA (°) of 
control 
catheter 
material after 
soaking 
WCA (°) of 
antimicrobial 
catheter 
material after 
drug elution 
Average  90.68 79.95 84.73 78.33 
St Dev 0.85 3.88 3.73 1.55 
CV 0.01 0.05 0.04 0.02 
 
 
Results showed that there was a statistically significant difference (p = 0.015) in the 
WCA measurement when antimicrobial agents were added to the silicone catheter.  
The WCA decreased making the antimicrobial catheter slightly more hydrophilic.  
No significant difference (p = >0.05) was seen between the control and antimicrobial 
catheter segments following exposure to an aqueous environment or between 
catheters of the same type (p = >0.05) that were compared before and after 
soaking/drug elution. 
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5.4. DISCUSSION     
 
5.4.1.  X-Ray Photoelectron Spectroscopy   
 
The implantation of any medical device into the body is followed by the formation of 
a conditioning film onto its surface.  Conditioning films formed on urinary catheters 
are largely composed of proteins, electrolyte components and other unidentified 
molecules [10] and have the ability to change the physico - chemical properties of a 
materials surface which can affect interactions between bacteria and the surface, 
although this is dependent on the substrate material, the composition of urine which 
is influenced by a patient¶V LQGLYLGXDO FRndition and on the bacterial strain.  
Confirmation that exposing the material to urine for 1 hour was sufficient time for a 
conditioning film to form was necessary to ensure that adherence assays (tk100) 
were carried out in a way that is representative of the process within the body.  A 
variety of analytical techniques have been used in particular to study protein 
adsorption to biomaterial surfaces.  Examples include ultra violet spectroscopy, 
fluorescent labelling, quartz crystal microbalances (QCM), AFM, surface plasmon 
resonance (SPR), XPS as well as molecular techniques [197].  Santin et al (1999) 
[166] characterised the protein composition of the conditioning film deposited onto 
the surface of ureteral stents during in - vivo implantation by SDS-PAGE and 
Western blot.  Results showed the presence of albumin, Tamm-Horsfall Protein and 
ɲl-microglobulin adsorption.  
 
In this study, XPS was used to confirm that elements of proteins and other 
components from the urine adsorbed to the catheter material as an indication of the 
formation of a conditioning film.  The technique was not used to quantify the levels 
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of protein or for the differentiation between proteins.  Proteins are mostly composed 
of carbon, oxygen and nitrogen and lower levels of other elements such as 
phosphorus.  Tieszer et al (1998) [10] observed through XPS studies the conditioning 
film elements associated with ureteral stent removal from patients.  Most notable was 
the detection of calcium and phosphorus albeit in small amounts, four different 
chemical types of carbon atom, an increase in oxygen and nitrogen and a decrease in 
silicone.  Similar observations were revealed in this study as shown in Table 5.1.  An 
increase in carbon and nitrogen was seen on the conditioned samples indicating that 
some degree of protein adsorption had taken place.  Sodium deposits also rose on 
conditioned samples possibly due to the presence of salts within the urine.  A 
decrease in the silicone concentration resulting from the deposition of a surface 
conditioning film was found which masked the silicone - rich surface.  Calcium and 
magnesium levels were less on the conditioned samples.  Wollin et al (1998) [196] 
report on calcium, magnesium and phosphorus, elements of encrustation observed 
upon removal of ureteral stents following >11 days implantation, so it is not 
surprising to expect calcium and magnesium to adsorb at such a rate after a much 
shorter exposure time to urine.  XPS also revealed on conditioned control and 
antimicrobial material the addition of an extra peak at 285.5 eV, which is indicative 
RIFDUERQPDNLQJDGRXEOHERQGZLWKR[\JHQ&ő25HLGet al (1994) [170] also 
revealed the addition of carbonyl groups that adsorbed to the ureteral stents 
following 24 hours incubation in human urine.  The lowest binding energy of the C1s 
peak C-C or C-H are usually found as part of the polymer or as a surface 
contaminant from the air [170] &ő2DQG/or COOH additional groups added after 
conditioning show the conversion of C-O groups to more acidic or oxygenated 
groups due to the adsorption of a conditioning film [10, 170, 196].  The increase in 
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carbon, nitrogen and sodium, the decrease of silicone and addition of the carbon 
group suggest that a conditioning film had been formed on the surface of the catheter 
material.  The conditioning effect agrees with Lappin-Scott and Costerton [45] who 
say that adsorption of molecules onto surfaces occurs rapidly.  One hour exposure to 
urine is therefore sufficient time for a conditioning film layer to form and confirms 
that adherence assays were performed in a manner that reflected the conditioning 
film process as catheters are inserted into the body.  
 
5.4.2.  Atomic Force Microscopy 
An important component of catheter surfaces is their degree of 
roughness/smoothness as this can affect the ease of catheter insertion/removal and 
potential for bacterial colonisation.  Although appearing smooth, urinary catheters 
can show a variety of topographical features, ranging from smooth, to undulated to 
rough [170].  Surface roughness can be a result of the manufacturing process and can 
also be induced through long - term use in a patient.  In this study the effect of 
impregnating antimicrobial agents into the catheter had on the degree of surface 
roughness was observed using AFM and the impact drug elution over 12 weeks had 
on surface roughness values was also monitored.  Results showed that there was no 
significant difference in Rq values (p = 0.26) between material with and without 
antimicrobial agents prior to drug elution.  This suggests the drugs on the surface are 
the same size as the polymer making the surface topography equally smooth.  
Control material appeared smoother following exposure to an aqueous environment 
(Rq = 9.57 nm) where as the antimicrobial materials roughness value significantly 
increased (Rq = 22.72 nm) (p = <0.05).  This may imply that the drugs aggregate at 
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the surface and as they diffuse into the surrounding medium their release imparts a 
rougher surface. 
 
Studies have shown that irregularities of polymeric surfaces can promote bacterial 
adhesion and biofilm deposition [204, 205].  It is thought that this may happen since 
a rough surface has a greater surface area and the depressions in the surface provide 
more favourable sites for colonisation [52] with the greatest initial accumulation of 
bacteria being in the bottoms of the roughest parts of the surface where they are also 
protected from shear forces.  It is recognised that the size of the irregularities is 
important for bacterial colonisation, not just the degree of roughness, but without 
further studies it is difficult to establish if the 13.15 nm increase in the roughness 
value following elution of the antimicrobial agents would have had a direct impact 
on bacterial colonisation.   
 
Surface roughness is also important to consider in ensuring maximal ease of catheter 
insertion and removal.  Urinary catheters with rougher surfaces can cause more 
trauma, inflammation and discomfort to the patient upon insertion and removal than 
those of a smoother nature.  Jones et al (2001) [209] studied the relationship between 
the ease of catheter removal and surface roughness and found the relationship to be 
significant in which catheter lubricity increased as surface roughness decreased.  As 
no difference in surface roughness between control and antimicrobial catheters was 
seen, this suggests that insertion of the antimicrobial catheter would be no different 
from the conventional Foley catheter.  It is also not envisaged that the increase in 
roughness following drug elution would impinged on catheter removal as the 
increase was small. 
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5.4.3.  Time of Flight - Secondary Ion Mass Spectroscopy 
 
Exploration of the surface and bulk properties of antimicrobial polymers is important 
clinically as the distribution of the drug can influence the extent and rate of drug 
release.  ToF-SIMS was able to provide qualitative information on the uniformity of 
drug distribution.  Cl- ions and F- / CN- ions served as markers for triclosan and 
sparfloxacin respectively but rifampicin did not reveal any secondary ions that 
enabled for its characterisation so was therefore unable to be traced.  Images of the 
antimicrobial catheter surface prior to drug elution (Figure 5.8) revealed that 
sparfloxacin and triclosan were relatively evenly distributed but some aggregation of 
the drugs was seen  (Image B) which upon three - dimensional viewing suggests that 
these penetrate part - way into the polymer.  It is possible that the localization of the 
drugs on the surface may have added to the burst effect first seen when the catheter is 
exposed to an aqueous environment and that following 12 weeks of drug elution 
(Image D) the aggregates diffuse out.  This burst effect may aid in reducing bacterial 
colonisation at the time of catheter insertion.   
 
The depth profile graphs (Figures 5.9 and 5.10) show triclosan and sparfloxacin 
intensities to decrease through the bulk, suggesting that the drugs diffuse from the 
bulk of the polymer to the inner and outer surfaces where drug intensities are at their 
highest.  It is important to acknowledge that the C60 beam used in depth profiling 
can leave deposits of carbon on the surface which may mask the underlying material.  
Freezing the sample can act to reduce the carbonisation effect, but in this instance 
this was felt unnecessary as Cl-, F- and CN- ions were clearly detectable.  Elution of 
the drugs over the 12 week period showed lower intensities of sparfloxacin and 
triclosan but there was a greater intensity of triclosan compared to sparfloxacin.  This 
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finding correlates well to the results obtained from the SPTT in which zone sizes of 
susceptible organisms exposed to triclosan were greater and more persistent than for 
sparfloxacin. 
 
Viewing the cross - sectional areas of the catheters (Figure 5.11) revealed that the 
antimicrobial agents are distributed across the thickness of the catheter.  Inspected 
together with the graphical information (Figures 5.9 and 5.10) of the depth profile 
analysis suggests drugs diffuse constantly to give higher intensities at the inner and 
outer surfaces which lasts to in excess of 12 weeks.  To obtain improved images of 
the cross sections it may have been necessary to generate more accurate and thinner 
preparations of the sections using a microtome which could have been set in resin.  
This may have enabled the whole width of the cross sections to be analysed without 
creating edge effects as opposed to the inner to middle and middle to outer parts 
being examined in two halves.    
 
5.4.4.  Water Contact Angle 
The WCA measurement was used to determine the impact impregnating 
antimicrobial agents into the catheter material had on the polymer¶s degree of 
hydrophobicity/hydrophilicty.  A significant decrease (p = 0.015) in the CA was 
observed when plain silicone catheters were impregnated with antimicrobial agents, 
indicating the change to a slightly more hydrophilic biomaterial surface.  As catheter 
sections were exposed to 12 weeks in an aqueous environment, control and 
antimicrobial catheters showed no significant difference in CA measurements.  
Busscher et al (1984) [210], report on how surface roughening tended to increase the 
CA if the CA on the surface was >86o but it decreased the CA if the surface was 
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<60o, whilst in between 60 - 84o roughening had no influence on the CA measured.  
In contrast Chow et al (1998) [211] showed that the roughening of polymer surfaces 
reduced the CA and McGovern et al (1997) [212], found that the CA also decreased 
when polyurethane urinary catheters were incubated in urine and/or PBS for 24 
hours.  It is possible that the nature of the polymer is important for CA 
measurements.  In this study the increase in surface roughness as the drugs eluted 
showed a decrease in CA although this was not significantly different (p = 0.556) 
from the antimicrobial material before drug elution.   
 
It has been suggested that an increase in polymer hydrophobicity can act to promote 
bacterial adherence whereas more hydrophilic materials result in less bacterial 
adherence [77].  The more hydrophilic nature of the antimicrobial material would 
therefore appear to be positive and although CA measurements of surfaces appears to 
be a useful method of assessing changes arising in biomaterial surfaces in contact 
with fluids, further studies are required to determine direct influence CA over 
antimicrobial ability may have in respect of the urinary catheters response to 
bacterial colonisation.      
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5.4.5.  Summary 
In conclusion, as complications such as bacterial colonisation and encrustation 
associated with urinary catheters occur at the surface that interfaces with the urinary 
tract environment, analysis of the surface of newly developed materials is important 
to ensure that the characteristics of the new materials compare well to existing ones 
or are improved upon so to not adversely impact on bacterial colonisation.  XPS has 
confirmed an hour exposure to urine is sufficient for a urinary conditioning film to be 
formed on the surface which is important in the bacterial attachment process.  AFM 
used to compare the roughness of the antimicrobial catheter surface to the control 
catheter surface showed there was no significant difference but following 
soaking/drug release for 12 weeks the roughness value of the antimicrobial catheter 
surface increased, possibly due to elution of the drugs imparting a rougher polymer 
surface.  It is however thought that this would not be to a degree that would be likely 
to promote bacterial adherence (although further testing would be required) or have a 
negative impact on the ease in which the catheter is inserted or removed.  CA 
measurements revealed the antimicrobial material to be more hydrophilic, upon 
which reports suggest bacteria adhere least to more hydrophilic materials [77] and 
that upon drug elution no difference in CA was seen compared to control material.  
ToF-SIMS revealed that the impregnation process used to incorporate the 
antimicrobial agents into the catheter distributes them (triclosan and sparfloxacin) 
relatively evenly on the catheter surface with some drug aggregation which could aid 
in the prevention of infection during catheter insertion due to the possible added 
burst effect.  Drugs were shown to penetrate the whole cross section of the catheter 
with drugs diffusing from the bulk to the inner and outer surfaces where drug 
intensities are highest and where they become released into the surrounding 
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environment.  The homogeneous nature following the diffusion of the drug 
aggregates on the surface suggests that drugs release in a uniform manner which is 
important for the killing of bacteria over time. 
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6.0.  MECHANICAL PROPERTY TESTING  
 
6.1  INTRODUCTION 
 When making a urinary catheter antimicrobial, questions must be asked as to 
whether it has any effect on mechanical performance.  As with all catheters, the 
correct physical and mechanical properties are essential if a product is to be 
successful in clinical use.  Failure of mechanical performance could seriously 
endanger patients.  Specifications, to which catheter devices and materials must 
conform, exist in the form of British (BS) and American Standard Test Methods 
(ASTM).  Performance specifications establish performance requirements and 
describe associated tests that will ensure the safety and effectiveness of medical 
devices.   
 
There is currently no standard for testing the mechanical properties of long - term 
indwelling urinary catheters (>30 days).  This leaves long - term catheters open to 
separate standard development.  The ASTM F623 99 (Reapproved 2006) [213], 
standard performance specification for Foley catheters and BS EN 1616: 1997 
specifications [214] relate to single use, balloon retention urethral catheters but are 
for short - term use.  They relate to catheters made from various materials such as 
silicone and latex, of sizes 12 to 26 French either in a sterile state for single use or 
non sterile state for sterilisation.  Catheters for short - term use whose surfaces have 
been modified to reduce microbial colonisation may also be tested using these 
specifications.  The FDA: Guidance on Premarket Notification [510(K)] Submission 
for Short - Term and Long - Term Intravascular Catheters specification [215] issues 
guidance on mechanical testing of catheters intended for long - term use (30 days or 
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more).  However, the FDA has not currently classified devices such as urinary 
catheters intended for use for more than a 30 day placement.  These devices are 
µXQFODVVLILHG¶$QLQWHUSUHWDWLRQRIWKHDERYH specifications was however used as a 
guide upon which tests were established to perform on urinary catheters for long - 
term use. 
 
According to the BS EN 1616:1997 [214], the shaft, tip, balloon and eyeholes of 
urinary catheters should have a smooth finish.  By ensuring this, patient comfort, and 
mechanical trauma upon insertion and removal are kept to a minimum [12].  
Flexibility of the catheter shaft is also important for manoeuvring through the urethra 
and a pliable catheter tip is necessary to reduce the occurrence of urethral perforation 
during insertion.  The material must also be of a suitable strength and sufficiently 
resilient throughout its use to be capable of performing its primary function.  Whilst 
a catheter is in situ and upon its removal it can be subject to significant tensile forces. 
The catheter must be able to withstand the effects of the forces encountered which 
must not result in damage, detachment of the shaft from the balloon or the separation 
of the catheter into various parts [12].  The catheter balloon should be strong enough 
to resist rupture and leakage but allow for ease of inflation and deflation, making 
elastic recovery an important parameter [12].  Despite these stipulations there are 
very few data in the literature on the physical and mechanical properties of urinary 
catheters prior to or following clinical use. 
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Mechanical property parameters typically measured for vascular catheters are listed 
below  [215]: 
 
x Tensile strength of catheter body 
x Tensile strength of catheter body to hub attachment 
x Catheter stiffness 
x Catheter tip (distal) attachment strength 
x Catheter elongation 
x Leakage at hub 
x Catheter burst pressure (positive internal pressure) 
x Catheter collapse (negative internal pressure) 
x Catheter flexural fatigue tolerance  
 
Mechanical properties of materials and their components are commonly assessed 
using Instrons.  Typical tensile testing involves clamping a sample with a fixed cross 
- sectional area to the Instron which serves to stretch the material in a controlled 
manner with increasing force until the sample becomes deformed (elongated) or 
breaks.  For all testing applications, correct gripping of the device is essential to 
obtain accurate measurements.  Avoidance of slippage and premature breakage of 
materials due to the jaws used to clamp material must be avoided.  The use of video 
extensometers that are capable of performing stress/strain measurements have helped 
to gather more accurate measurements by capturing continuous images of markers on 
the specimen during testing. 
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6.1.1.  Objectives 
The incorporation of antimicrobial agents as a means of preventing bacterial 
colonisation on catheter surfaces warrants investigation into the possible effects that 
this may have on physical and mechanical parameters.  This is especially relevant if 
catheters are modified from proven types.  From a biocompatibility and patient safety 
prospective it is important that the inclusion of antimicrobial agents do not serve to 
adversely affect the mechanical properties of the catheters and balloons.  This 
chapter assesses the mechanical performance of the catheter shaft and balloon both 
before and after 12 week simulation in a physiological environment designed to 
reflect the period of placement within the body and compares it to standard Foley 
catheters without anti - infective properties.  It was expected that due to the small 
percentage of antimicrobial agents incorporated into the catheter that this would not 
adversely affect the mechanical performance of the catheter.  The tests described in 
Section 6.2 are those that are considered most relevant for long - term antimicrobial 
urinary catheters adapted from the ASTM F623 99 (Reapproved 2006) standard, BS 
EN 1616: 1997 specification and the FDA: Guidance on Premarket Notification 
[510(K)] Submission for Short - Term and Long - Term Intravascular Catheters 
specification.  Tests performed are those which were able to be undertaken within the 
ODERUDWRU\¶s capability.   
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6.2.  METHODS 
 
6.2.1.  Catheter Balloon Testing [213, 214] 
 
6.2.1.1.  Surface Finish 
After the incorporation of antimicrobial agents into the catheter material as described 
in Section 2.2.4, catheters were viewed by normal vision and at X2.5 magnification.  
The surfaces of the catheter shaft, tip, balloon and eyes were examined for 
extraneous material.  To pass the test, antimicrobial catheters were compared to 
urinary catheters without antimicrobial agents (controls) for freedom from 
extraneous material.  
 
6.2.1.2.  Strength 
Antimicrobial and control catheter balloon strength tests were carried out after 
immersion of the inflated balloons in artificial urine (Appendix 5) for 30 days at 
37°C.  Catheters were then suspended from a suspension device by passing a pin of 
50 - 75% of the diameter of the eyelet through the drainage eye.  A 1 kg weight was 
attached to the drainage funnel and held for 1 minute.  All unions of the catheter 
were examined for detachment or failure of bonds and any signs of the eyes splitting.  
  
6.2.1.3.  Connector security 
This test was designed to simulate a urinary collection bag attached to the drainage 
funnel upon which the drainage funnel should not become detached from the test 
  Chapter 6 - Mechanical Property Testing 
205 
 
connector.  A 1 kg weight was attached to the drainage funnel of the antimicrobial 
and control catheters and held for 1 minute.  If the test connector parted from the 
drainage funnel, this was deemed a failure.  
 
6.2.1.4.  Balloon Integrity 
To test balloon integrity, antimicrobial and control balloons were inflated with 10 
mL distilled water and submerged into artificial urine at 37°C for 30 days.  Catheter 
balloons that ruptured were deemed to have failed the test.     
 
6.2.1.5.  Balloon security 
Antimicrobial and control catheter balloons were immersed in artificial urine at 37°C 
for 30 days. The catheter tip and balloon were then placed through a funnel and the 
balloon re - inflated to 10 mL and allowed to rest in the funnel countersink.  A 1 kg 
weight was attached to the catheter drainage funnel and allowed to hang for 1 
minute.  A failure was incurred if upon examination the balloon leaked or eyeholes 
were occluded.  
 
6.2.1.6.  Inflated Balloon Response to Pullout 
This test assesses the catheter¶s response to forces occurring during use.  A funnel 
apparatus with a 28 French lumen was used to represent the bladder outlet and 
urethra and the proximal end of the antimicrobial or control catheter passed through 
the funnel inlet and the balloon inflated with 10 mL distilled water.  The balloon 
portion was pulled back until it rested into the V shape of the funnel and the distal 
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end of the catheter hung downwards from the funnel barrel.  For the static load test a 
1 kg weight was hung from the distal end of the catheter for 2 minutes and the 
balloon observed.  For the impact load test, the weight was lifted 60 cm from its 
hanging position and released.  The balloon was observed for its position in the 
funnel after the weight had been dropped.  For both tests, the passage of the balloon 
through the funnel or the deflation or rupture of the balloon resulted in a failure. 
 
6.2.1.7.  Balloon Volume Maintenance 
This test was performed to test the ability of the balloons to retain their injected 
balloon volume as a means of determining the functional integrity of the inflation 
system.  The antimicrobial and control catheter balloons were inflated with 10 mL 
methylene blue crystal solution (Sigma-Aldrich) (1 g in 2000 cm3 water).  The 
balloon was placed on a surface that allowed for any leakages to be easily detected 
whilst protected from light for 30 days.  A failure of the balloon to retain the solution 
was indicated when a discolouration or leakage of the methylene blue was observed 
on the surface beneath the balloon.  Evaporation was accounted for by re - inflating 
the balloon to the specified volume. 
 
6.2.1.8.  Deflation Reliability 
The test was designed to detect the failure of the balloon or the shaft lumen to deflate 
correctly in a simulated withdrawal.  Antimicrobial and control catheter balloons 
were filled with 10 mL distilled water and placed into artificial urine for 30 days at 
37°C.  Balloons were then deflated using a syringe and the resultant deflated balloon 
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shape/size measured.  To pass the test it should pass through a French gauge hole no 
more than four French sizes larger than the labelled French size.   
 
All tests were carried out in triplicate. 
 
6.2.2.  Catheter Tensile Testing 
 
Urinary catheters were used in the ³as received´ state from the manufacturers 
(controls) and following impregnation with the antimicrobial agents as described in 
Section 2.2.4.  Half of the control and antimicrobial catheters were placed in 
simulated urine (Appendix 5) which was replaced weekly for up to 12 weeks to 
mimic drug elution in the body, whilst the other half remained in an unchanged state.  
Catheter balloons and junctions were not subjected to testing. 
 
Mechanical performance of catheter shafts was assessed using an Instron 5985 
(Imetrum Limited, Bristol, UK) with a 5 kN loadcell connected to a video 
extensometer.  Data were recorded using Bluehill 2 software.  Various clamping 
methods were investigated and a specialised configuration was devised to connect 
the catheter tubing to the Instron as is shown in Figure 6.1.  This was required to 
avoid catheter slippage and breakage at the point of connection and to guarantee an 
even distribution of stress/strain along the length of the tested catheter.  Catheters 
were clamped to expose a 5 cm length along the mid - section of the catheter and 
coated metal targets were applied 3 cm apart to allow for tracking by the video 
extensometer.  A force was applied at a rate of 100 mm/min as the apparatus 
recorded the stress.  The force applied was continued until either the apparatus 
reached its maximum length limit or until catheter failure (breakage) occurred.  All 
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tests were conducted at room temperature and in all cases three replicates of each 
analysis were performed.  From the resultant relationship between the stress and 
strain, the load (N), ultimate tensile strength (MPa), elongation at break (mm) and 
modulus (MPa) determined at 280 - 320% elongation were calculated.   
   
  
                                      
(A)                                                                                 (B) 
Figure 6.1: Catheter set up on the Instron. (A) prior to tensile testing (clamping mechanisms consisted 
of clamping the catheter in an s-shaped configuration ensuring that the clamped portion was under no 
more excessive stress than the tested portion of the catheter) (B) during tensile testing.  
 
 
6.2.3.  Statistics 
Two tailed paired t-tests at the 95% confidence level were used to compare 
differences between control and antimicrobial catheter material.  
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6.3.  RESULTS 
 
6.3.1.  Catheter Balloon Testing 
 
Table 6.1: Control and antimicrobial catheter balloon testing results. 
Test Requirement Control Catheter Antimicrobial Catheter  
Surface finish Freedom from extraneous 
material 
Pass  
Freedom from extraneous 
material 
Pass  
Strength All unions intact 
Pass 
All unions intact 
Pass 
Connector security Drainage funnel and 
connections intact 
Pass 
Drainage funnel and 
connections intact 
Pass 
Balloon integrity No rupture or leakage 
Pass 
No rupture or leakage 
Pass 
Balloon security No balloon leakage or 
eyehole occlusion 
Pass 
No balloon leakage or 
eyehole occlusion 
Pass 
Inflated balloon response 
to pullout 
No deflation or rupture of 
balloon 
Pass 
No deflation or rupture of 
balloon 
Pass 
Balloon volume 
maintenance 
Retained solution/no 
leakage 
Pass 
Retained solution/no 
leakage 
Pass 
Deflation reliability Reliable deflation, passed  
through < 4 labelled 
French size hole 
Pass 
Reliable deflation, passed  
through < 4 labelled 
French size hole 
Pass 
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Table 6.1 shows that the antimicrobial balloon results were identical to the control 
catheter balloons.  The drainage funnel and all unions remained intact and no 
occlusions of eyeholes were seen when challenged with 1 kg weights.  The 
antimicrobial balloon remained secure and maintained its integrity throughout with 
no rupture or leakage occurring at any point.  Deflation of the antimicrobial balloon 
occurred in a reliable fashion and was within 4 French units from the original size 
(Figure 6.2).  Overall no significant differences were displayed between the control 
and antimicrobial balloons.   
 
 
 
                      
(A)                                                                                (B)                                 
Figure 6.2: Control and antimicrobial catheter balloons (A) inflated (B) deflated after 30 days. 
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6.3.2.  Catheter Tensile Testing 
 
Figure 6.3 shows a typical stress-strain curve for control silicone urinary catheters 
and Table 6.2 the parameters measured.  The graph displays the force applied to the 
catheter continuously increasing up until the apparatus reached its maximum length 
limit.  At the stage where the catheter was continually stretched it appeared to 
become deformed and as this coincided with the limits of the Instron this point was 
taken as the tensile strength of the material.  The stress-strain curve where strain is 
any kind of deformation, including elongation, can be used to determine the modulus 
which relates to a material¶s ability to resist deformation.  The slope of the plot 
(taken at 280 - 320% strain) relates to the modulus value.  High modulus values can 
be interpreted as a material which resists deformation and a modulus of a low value 
suggests a material which is easily deformed. 
 
Figure 6.3: Typical stress-strain curve (depicting three control catheters following 12 weeks soaking 
in an aqueous environment).  
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Table 6.2: Load, tensile stress and modulus values of control and antimicrobial catheter shafts before 
soaking/drug elution and after 12 weeks simulated in situ use as determined by tensile tests using an 
Instron. All tests were performed in triplicate and each value represents the mean with standard 
deviation.  
 
Material Load (N) 
(±StDev) 
Tensile Stress 
(MPa) (±StDev) 
Modulus (MPa) 
(±StDev) 
Control catheter 
before soaking 
60.82  (± 6.68) 5.39  (± 1.29) 0.43  (± 0.045) 
Antimicrobial 
catheter before drug 
elution  
68.21 (± 3.66) 6.97  (± 0.39) 0.69  (± 0.16) 
Control catheter after 
12 weeks soaking 
64.35 (± 3.42) 6.57  (± 0.35) 0.89  (± 0.15) 
Antimicrobial 
catheter after 12 
weeks drug elution 
66.23 (± 4.01) 6.76  (± 0.41) 1.21  (± 0.48) 
 
 
Despite a load of between 60 to 70 N being applied to the catheters they all failed to 
break, both before and after soaking in artificial urine.  The tensile stress taken at the 
maximum point on the graph would be in excess of this if the Instron had larger 
parameters.  Statistical analysis comparing control and antimicrobial material prior to 
12 week aging in a simulated urine environment showed there to be no significant 
difference (p = >0.05) in load, tensile stress, elongation or modulus values.  The 
parameters also remained the same (p = >0.05) between the two groups following 12 
weeks soaking/drug elution.  No significant difference (p = >0.05) was seen for all 
parameters when comparing antimicrobial catheters before and after drug elution or 
when comparing the load and tensile stress values between the control catheters 
before and after soaking.  The only significant difference (p = 0.016) was in the 
modulus value obtained from control catheters before soaking compared to control 
catheters after soaking.      
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All catheters at the start of the tensile test were 273 mm in length.  Following tensile 
tests, all elongated to the maximum limit on the instron of 1029.5 mm without 
breaking as dipicted in Figure 6.4.  This represents a 3.7 fold increase in length 
(377%).  On release of the load, permanent deformation of both the control and 
antimicrobial catheters had occurred.   
 
 
 
Figure 6.4: Typical extension (mm) of control and antimicrobial urinary catheters upon tensile 
testing, before and after 12 weeks soaking/drug elution in simulated urine. 
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6.4.  DISCUSSION 
The mechanical performance of urinary catheters is most important for patient safety. 
Boppart et al (2003) [216] reported on a Foley catheter which broke during clinical 
use.  They report on a patient with a 100% silicone rubber Foley catheter in place 
who forcibly removed the catheter without deflating the balloon, fracturing it mid - 
way along its length and leaving the distal portion of the catheter remaining in the 
urethra.  Although it is not common for urinary catheters to be placed under such 
extreme force, it is recognised that upon insertion, during use and removal, catheters 
and their balloons can be subject to significant alternating tensile forces.  The 
importance of correct mechanical properties and the ability of modified catheters to 
withstand the daily forces it encounters to the level of existing catheters are 
paramount if patient safety is to be upheld.   
 
Mechanical testing and modelling of a material for biomedical applications have to 
be based on conditions representative of the application of interest [217].  The 
behaviour of the inflated catheter balloon and catheter shaft when aged in simulated 
urine at 37°C can predict the functional performance during actual use in patients.  In 
this study, using the ASTM, BS and FDA specifications as guidelines, the tensile 
testing of catheter shafts and properties of balloons in their prior - to - use state and 
representing in situ use through incubation in artificial urine was assessed.  It is 
acknowledged, however, that this investigation would require further work and 
additional tests e.g. cyclic fatigue testing, to industrial standards in order truly 
evaluate the mechanical performance of the antimicrobial catheter.  Testing of 
catheter balloons is important to ensure symmetrical inflation, no leakage and 
reliable deflation.  Under inflation and asymmetrical inflation of balloons may cause 
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the catheter to slip out or result in leakage of urine around the catheter shaft.  Upon 
removal of the catheter after the intended period of use, the balloon has to be fully 
deflated.  On deflation, the balloon should ideally shrink back to its pre - inflated 
shape.  This allows for easier removal of the catheter from the patient and minimal 
tissue damage [218].  Silicone catheter balloons are however prone to forming 
cuffs/ridges after their contents have been manually aspirated.  Both control and 
antimicrobial balloons showed ridges upon deflation, though the catheter shaft 
diameter was less than 4 French units in size from the original so should not exhibit 
adverse effects to a patient upon its removal.  All unions remained intact when 
challenged with 1 kg weight with no occlusion of the eyeholes or any rupture and 
leakage throughout the tests.  Overall results obtained from tests performed on the 
antimicrobial balloons were the same as those from the control silicone balloons, 
which imply that they would be mechanically stable in clinical practice. 
 
Tensile testing of the catheter shafts revealed no significant difference (p = >0.05) in 
load, tensile stress or modulus values when control catheters were compared to 
antimicrobial catheters before and after soaking/drug elution.  The only significant 
difference (p = 0.016) observed was between the modulus value obtained when 
control catheters were compared to each other before and after soaking.  An increase 
in the modulus can render the material less flexible and slightly more resistant to 
deformation [219].  Ramesh et al (2001) [220] evaluated the mechanical properties 
of three commercially available siliconized latex Foley catheters aged in artificial 
urine for 14 days.  They report that tensile strength before aging was similar but 
following aging there was a considerable reduction in strength which they report may 
adversely affect the mechanical integrity of the catheter and breakage may happen 
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during the retrieval of the catheter from the patient.  In this study, testing of the 
catheter following aging appeared to have no adverse effects on performance 
characteristics.  
 
Schierholz et al (1997) [219], report that the incorporation of solvated rifampicin into 
swelling activated polydimethylsiloxane shunts at a concentration of 0.5% (w/w) 
resulted in a decreased tensile strength to 80% of the original and a decrease in 
elongation down to 62%.  However they reported that this reduction had no 
restriction on their use in modern medicine as shunt systems.  Similarly, van Noort et 
al (1979) [221] through manually incorporating gentamicin sulphate powder in the 
raw stock of room temperature - vulcanized silicone rubber found the tensile strength 
and extensibility to significantly decrease with increasing concentrations of 
gentamicin sulphate whilst the stiffness was comparatively little affected.  Changes 
in the mechanical properties were not however considered to be great enough to 
affect the application of drug impregnated silicone rubbers to cerebrospinal fluid 
shunting systems.  It is probable that a crystalline state of the drugs within the 
polymer and their angular shape may produce fracture points along the catheter and 
their release leave vacuoles and a honeycomb type matrix which could have caused 
the decrease in tensile properties of the material [221].      
 
In this investigation, the impregnation of antimicrobial agents into the silicone 
catheter had no significant (p = >0.05) impact on the load, tensile strength and 
modulus values compared to the catheter without antimicrobial agents.  Based on the 
parameters tested, this suggests that the mechanical performance of the antimicrobial 
catheter is equal to that of the catheter used as a control which is in clinical use.  This 
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may be because the drugs are uniformly distributed within the polymer on a 
molecular scale and their release following 12 week incubation in solution, albeit 
leaving a slightly rougher surface, does not impact on the mechanical performance of 
the antimicrobial catheter. 
 
Silicone is reported to have a low tensile strength, typically in the range of 1 - 8 MPa, 
D <RXQJ¶V PRGXOXV W\SLFDOO\  - 5 MPa and can elongate 200 - 1000% before 
breakage occurs [216, 220].  The low tensile strength and modulus of all sets of 
catheters mean that the material deforms easily.  Both control and antimicrobial 
catheters reached the maximum length limit of the Instron without breaking and 
elongated to in excess of 377% of their original size.  As the load was released a 
change in both the control and antimicrobial catheter shape and size causing them to 
become permanently deformed was observed.  However, it is considered that urinary 
catheters being exposed to such forces whilst in situ is rare and as indwelling Foley 
catheters are not re - used the clinical relevance of the effect of the release following 
exposure to high loads is unclear.  The ability to deform is what keeps the material 
flexible for manoeuvring through the urethra and from breaking and the 
antimicrobial catheter proved to be as effective as the conventional all silicone Foley 
catheter.  The point at which permanent deformation occurred which may be of more 
relevance was not measured and is a point for future work. 
 
The American, British and FDA standards specify the methodologies for testing the 
mechanical performance of catheters but literature on the varying types of Foley 
catheters used for LTC are limited and give differing experimental results.  To 
determine an acceptable value for short - term and long - term urinary catheters 
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would be a helpful guide.  Within the facilities available and the basic tensile and 
balloon tests performed, by correlating the performance of the all silicone Foley 
catheter used as a control with the antimicrobial catheter, experiments revealed no 
significant differences.  This implies that the incorporation of antimicrobial agents 
into the catheter appears to equal the mechanical ability of the Foley catheter in 
clinical use and should therefore be suitable if applied to clinical practice. 
  Chapter 7 - Discussion and Conclusions 
219 
 
 
 
 
 
 
 
CHAPTER 7 
DISCUSSION AND 
CONCLUSIONS 
 
  Chapter 7 - Discussion and Conclusions 
220 
 
7.0.  DISCUSSION AND CONCLUSIONS 
As modern day medicine becomes more reliant on the use of medical devices for 
diagnostic and therapeutic procedures, infection associated with them has become of 
major concern.  Bacterial colonisation on biomaterial surfaces and the development 
of biofilms can make eradication of infection extremely difficult.  Often to resolve 
the infection, removal of the device is necessary, as is the case with patients that are 
on long - term indwelling urinary catheterisation.  It is almost inevitable that patients 
on LTC will at some point go on to develop a CAUTI and with the high prevalence 
rate, degree of morbidity and associated costs, new ways of reducing bacterial 
colonisation on catheter surfaces is warranted but producing urinary catheters that are 
refractory to microbial colonisation continues to be an uphill task.  Little has changed 
in the design of the Foley catheter since it was first introduced and even with 
meticulous care, the system does not prevent bacteriuria and catheter colonisation in 
patients catheterised long - term.  The best prevention is to minimise urethral catheter 
use and to seek device alternatives, such as intermittent catheterisation, suprapubic 
catheterisation, urinary diversion HWF«whenever possible but this may not always be 
feasible.  The need for an indwelling urinary catheter should be reassessed while 
managing patient care but for some patients discontinuing catheterisation is not an 
option and urinary catheterisation can continue for years or even for the duration of 
the patient¶s life [222]. 
 
The molecular mechanisms of microbial adherence to surfaces and the development 
of new materials intrinsically resistant to colonisation along with host - pathogen 
interactions is an area that continues to be investigated [223] but until such time, 
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education into urinary catheter care, hand washing, correct aseptic techniques upon 
catheter insertion and the maintenance of a clean, closed drainage system continue to 
be important defences in protecting patients from bacterial invasion.  In line with 
other research such as aganocide instillation into the bladder, retention balloons 
instilled with antimicrobial solutions, catheter valves able to be turned on and off to 
allow for a more natural flushing mechanism effect rather than a constant trickle, the 
development of novel antimicrobial biomaterials is an area which has gained interest 
in recent years.   
 
There are now several options for antimicrobial catheter materials designed to reduce 
microbial colonisation.  Evaluations of the antimicrobial urinary catheters in clinical 
practice have been mixed and duration of protective activity is short.  At this time 
there are no antimicrobial urinary catheters available for long - term use, where the 
problem of infection is much greater.  The intention of this study was, through the 
impregnation of antimicrobial agents into silicone urinary (Foley) catheters, to 
evaluate a suitable combination and concentration that would provide protective 
activity against colonisation by principal microorganisms involved in CAUTIs over a 
prolonged period (12 weeks) and which would help protect against the emergence of 
bacterial resistance.   
 
After screening several antimicrobial agents, a combination of rifampicin, 
sparfloxacin and triclosan were impregnated into the catheter.  Each having different 
modes of activity on bacterial cells was a way to extend the spectrum of activity and 
to investigate the ability of the drugs to provide protection against bacterial 
resistance.  The SPTT used to monitor the potential duration of antimicrobial activity 
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against MRSA, CoNS, E.faecalis, E.coli, K.pneumoniae and P.mirabilis showed that 
activity continued for >100 days with the exception of E.faecalis.  It was envisaged 
that if the organisms were susceptible to the individual antimicrobial agents, when 
the agents were combined they would act in synergy to provide a dual drug therapy 
which would help reduce the chances of resistance.  The SPTT revealed that E.coli, 
K.pneumoniae, CoNS and MRSA had at least two drugs active on them over a 
prolonged course.  Whether the size of the ZI relates to the antimicrobial material¶s 
ability to provide protective activity against bacterial colonisation was not 
determined by the SPTT.  Time - kill assays (tK100) were therefore developed to 
assess this.  Exposing the material to urine to form a conditioning film is an 
important part of colonisation as bacteria may attach differently to conditioning films 
than bare material and XPS studies confirmed that urinary components (C, N, Na 
increased whilst the Si surface was masked) had adsorbed to the catheter surface.  
tK100 assays demonstrated that the antimicrobial catheter was able to kill 100% of 
all attached bacteria with the exception of ~25 - 50 cfu/mL P.mirabilis remaining 
within a 72 hour time frame.  As the tK100 test is a static test that challenges the 
material with high numbers of organisms only once, an in - vitro model designed to 
test the catheters¶ ability to prevent bacterial colonisation following repeated 
challenges under flow conditions was developed.       
 
The in - vitro model proved the antimicrobial catheter to be capable of preventing 
colonisation by MRSA and E.coli for the targeted period of 12 challenges/weeks (84 
days), K.pneumoniae and P.mirabilis for 8 challenges (50 days) and E.faecalis for 1 
challenge (8 days).  E.faecalis isolated from the effluent of the colonised catheters 
had rifampicin, triclosan and sparfloxacin MIC values which remained unchanged 
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from the original inoculum, suggesting that the susceptibility of E.faecalis to the 
agents as they released was not sufficient to prevent colonisation of the catheter.  
This was also implied by the short duration of activity indicated by the SPTT.  The 
lack of activity against E.faecalis may have been due to the higher rifampicin, 
triclosan and sparfloxacin MICs in the first instance and it was also noted that 
E.faecalis grew more favourably in TSB than in artificial urine (Appendix 2) which 
may have favoured the growth of E.faecalis in the in - vitro model tests.  The 
E.faecalis strain used in this study had an antimicrobial susceptibility profile that was 
typical of the clinical isolates collected and with a high proportion of E.faecalis 
being isolated from the urine of patients on LTC, the catheters lack of activity against 
it could be of concern, although its clinical implication with regards symptomatic 
CAUTI is a point for further investigation.         
  
The SPTT showed a >100 day duration of activity towards P.mirabilis with activity 
mostly being supplied by triclosan, but as the antimicrobial material did not clear 
100% of attached P.mirabilis in tK100 tests it was unclear how protective the 
catheter would prove upon repeated challenges with this organism in an in - vitro 
model.  Catheters became colonised with P.mirabilis on the 8th (day 50), 11th (day 
71) and 12th (day 83) challenge respectively with the MIC of triclosan increasing 
marginally from 0.094 µg/mL to a maximum of 0.38 µg/mL.  This is however still in 
the sensitive range.  The SPTT showed triclosan and sparfloxacin to be active against 
K.pneumoniae.  Catheters became colonised with K.pneumoniae following the 8th 
(day 50) and 9th (day 57) challenge with the MIC of sparfloxacin and triclosan 
increasing up to 2 µg/mL, which is approaching more resistant concentrations.  The 
average concentration of sparfloxacin released from the catheter was approximately 
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0.07 mg/catheter/day (or 1.25 µg/mL/day) following the initial burst effect and 
approximately 0.15 mg/catheter/day (or 2.4 µg/mL/day) of triclosan during the 28 
day drug release study and these concentrations are above the concentration required 
to inhibit K.pneumoniae and P.mirabilis.  In addition, ToF-SIMS also revealed that 
the distribution of sparfloxacin and triclosan on the catheter surface was mostly 
evenly distributed, which is important for uniform drug release but some drug 
localization was observed.  CAUTIs can be caused by bacteria gaining access to the 
catheter and bladder at the time of catheter insertion.  It might be assumed that the 
drug localization could add to the initial higher delivery (burst effect) of  
antimicrobial agents which could help reduce bacterial adherence and the early onset 
of infection [194].  If the drug release trend was to remain stable as the SPTT 
suggests, with 80.2% sparfloxacin and 70.1% triclosan remaining there should have 
been sufficient drugs to protect from colonisation over the 12 weeks.  It was expected 
that at the concentrations being released this would place the drugs above the MIC 
but below the MPC and hence within the MSW, but if two drugs released at 
concentrations above the MIC and superimposed each other resistance would not be 
seen as bacteria would require two mutations for them to grow in the presence of the 
antimicrobial agents.  To fully establish if the dual drug principle worked, the in - 
vitro model would need to be performed with catheters impregnated with drugs 
individually and bacterial colonisation and resistance compared to catheters 
impregnated with all three agents to observe if resistance to individual drugs is 
generated more readily than combinations of drugs. 
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Why the catheters became colonised with K.pneumoniae and P.mirabilis but not 
MRSA and E.coli is unclear but several reasons are proposed.  The device is not 
capable of inhibition of microbial adherence per se, but the killing of already 
adherent microorganisms.  SEM images of the P.mirabilis and K.pneumoniae 
colonised antimicrobial catheters revealed extensive biofilm formation and it is 
possible that by chance a few bacteria remained attached to the catheter during the 
latter in - vitro challenges in spite of the concentrations of drugs being released from 
the catheter surface.  These may have then rapidly multiplied and started to become 
phenotypically insusceptible to the drugs.  If bacteria were sonicated from the 
catheter lumens and cultured, it is expected that the MICs would have been higher 
than from the planktonic samples taken from the effluent.  SEM images of the 
antimicrobial catheters challenged with MRSA and E.coli showed the presence of 
what appeared to be remnants of dead bacteria and although these passed the 12 
week in - vitro challenge, it could indicate that dead cells may act as anchor points 
and promote subsequent bacterial colonisation as was exhibited by P.mirabilis and 
K.pneumoniae.  A further reason may be that as the flow rate was decreased when 
the in - vitro model was left for a period of time the decrease in flow rate and shear 
may have encouraged any bacteria if attached to the catheter surface to multiply.  
Their presence on the catheter surface and in the perfusion fluid despite the 
antimicrobial agents may have overwhelmed the catheter, causing bacteria to 
permanently attach to the surface and survive to change phenotype.  The drugs would 
therefore not be inhibitory to biofilms.  AFM also revealed that the roughness of the 
catheter surface appeared to be significantly greater as the drugs eluted which may 
have caused some bacteria to adhere to parts of the abraded surface which may have 
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initiated the initial stage of bacterial colonisation.  Further testing would however be 
required to prove or disprove this theory.     
 
Blanco et al (2009) [224] reported that the elution of triclosan from polyglycolide 
sutures was enhanced when a serum medium was used because the presence of 
proteins and lipids increased the solubility and elution of triclosan.  A further reason 
for bacterial colonisation may be that the elution of triclosan, sparfloxacin and 
rifampicin under flow conditions in TSB could have produced a greater degree of 
drug release than that shown through the diffusion into water upon which drug 
release measurements were taken.  Due to the flow rates that the catheters were under 
it is possible that this could cause a greater degree of drug diffusion into the 
surrounding medium, making concentrations released between weeks 8 - 12 below 
the MIC or minimal bactericidal concentration (MBC) of the organisms.  If drug 
release was greater in the in - vitro setting the concentrations may not have been 
sufficient to prevent colonisation.  Drug studies also revealed that triclosan and 
sparfloxacin release at different rates, and if in the latter stages during the in - vitro 
challenge, one drug fell below the MBC necessary to kill K.pneumoniae or 
P.mirabilis, resistance to one drug may have occurred followed by resistance to the 
second agent which could have resulted in colonisation of the catheter.  This may be 
logical for the case of K.pneumoniae where both sparfloxacin and triclosan MIC 
values increased.  That being said the antimicrobial catheter prevented the 
colonisation of E.coli which had very similar MIC values, SPTT and tK100 results to 
K.pneumoniae. 
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The situation where the antimicrobial catheter could have the most beneficial effect 
is in patients who are symptomatic, where relapses are common and more frequent 
catheter removal and replacement is normally required.  By removing the catheter the 
biofilm is removed and patients will usually be prescribed a course of antibiotics to 
kill residual bacteria in the bladder.  It is hoped that the antimicrobial catheter would 
protect against colonisation from principal invading organisms to an extent that a 
patient would not experience symptoms associated with infection.  In patients with 
repeat symptomatic CAUTIs opposed to newly catheterised patients it may be 
necessary to treat residual organisms in the bladder with an appropriate course of 
antibiotics prior to insertion of the antimicrobial catheter to reduce bacterial 
numbers.  This may be helped by the catheter having been proved to have an 
antimicrobial burst effect which should prevent the early onset of infection at the 
time of catheter insertion.  With 10% of catheterised patients showing symptoms 
associated with infection, if the antimicrobial catheter with further research proved to 
be as effective against other problematic bacterial species and strains then a 
considerable saving in hospital time and treatment and vastly improved quality of life 
for patients could be achieved. 
 
Whether the use of the catheter will replace susceptible bacteria with those that are 
resistant to the agents in the catheter and just as many infections occur but with 
resistant organisms is a question that needs to be asked.  This cannot be fully 
answered until clinical trials take place but the use of other antimicrobial catheters 
has provided an insight.  A study by Wong et al (2010) [225], compared the 
effectiveness of the antimicrobial Bactiseal EVD (impregnated with 0.15% w/w 
clindamycin and 0.056% w/w rifampicin) with plain conventional EVDs coupled 
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with systemic antibiotics in terms of nosocomial infection and cerebrospinal fluid 
(CSF) infection.  They found the proportion of patients with nosocomial infections 
and secondary outcomes such as CSF infection in the antimicrobial catheter group 
was not statistically different from the group of patients receiving the conventional 
catheter with antibiotics.  There was also no significant difference between the two 
groups in the incidence of resistant infections or in the named resistant infections.  
Interestingly even though the Bactiseal agents are not active upon Gram negative 
bacteria, there was no evidence of an increase in the absolute number of these 
infections.  The antibiotic impregnated EVD proved to be as effective in reducing 
infections as the conventional EVD with systemic antibiotics and this could also be 
the case for the antimicrobial urinary catheter.  In respect of the clinical impact of the 
long - term antimicrobial urinary catheter it should also reduce the need for the 
consistent use of oral antibiotics prescribed to some symptomatic patients.  Frequent 
use of systemic antibiotics can lead to an environment of more resistant microbial 
populations and their overuse is always a concern with regards to resistant 
opportunistic infections e.g. Clostridium difficile.  The study by Wong et al (2010) 
[225] supports that the dangers of systemic antibiotics could potentially be avoided 
by the use of an antimicrobial catheter.  The less frequent use of systemic antibiotics 
with the use of an antimicrobial urinary catheter should make the use of systemic 
antibiotics more effective when they are really needed. 
 
In addition to the microbiological testing of the antimicrobial urinary catheter, the 
low concentrations of antimicrobial agents in the catheter caused no adverse effects 
to the mechanical performance of either the catheter shaft or balloon.  In clinical 
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practice the catheter would therefore be expected to be as mechanically stable as the 
control catheter used in this study. 
 
This preliminary study suggests that, with further work, the catheter has the potential 
to have a positive impact on reducing bacterial colonisation.  With little prior 
information regarding the concentration of antimicrobial agents in the chloroform 
that become incorporated into the silicone, the impact that drug loading has upon 
drug release is an area that requires further investigation.  In particular the 
concentration of rifampicin could be increased so that it has a more prolonged and 
powerful effect against Gram positive bacteria (e.g. staphylococci) and increased to a 
level that is in line with the release of sparfloxacin and triclosan.  Kohnen et al 
(2003) [118], reported on drug optimisation that achieved a 1:1 ratio of rifampicin 
and sparfloxacin release which remained stable for at least 40 days.  Optimisation of 
drug release so that concentrations are higher and the release ratio of each is the same 
may deliver the agents in a more sustained manner which could reduce bacterial 
colonisation over the targeted 12 weeks and beyond and help reduce bacterial 
resistance.  To repeat the in - vitro model with more replicates and to test the 
catheters against a larger array of microorganisms is necessary to obtain a broader 
view of its ability to prevent colonisation.  To make the in - vitro model more 
clinically predictive, a method would need to be devised to test the ability of the 
catheters to prevent bacterial colonisation using real human urine.  Any alteration to 
drug content and release would require adjacent in - vitro model testing and to gather 
more precise drug release information it may be necessary to collect effluent from 
the antimicrobial catheters, as they are under flow conditions in the in - vitro model, 
and measure drug release concentrations over a period of 12 weeks.  The effect of 
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storage on the stability of the antimicrobial agents and shelf life of the device must 
be determined as the loss of activity could cause failure when used.  Sensitivity, 
allergic reaction and toxicity testing may also be required to assess local and 
systemic effects of exposure of the antimicrobial agents to the urinary tract 
environment prior to clinical trials.  Attention must also be paid to the ability of the 
antimicrobial catheter to prevent encrustation by urease - producing organisms like 
P.mirabilis.  A bladder model similar to the design by Stickler et al (1999)  [7], could 
be used to assess this and atomic absorption spectroscopy (AAS) employed to 
examine mineral deposition.   
 
The eventual aim is to progress the catheter to a stage in which it can be trialled in - 
vivo and in the form of a small - scale clinical trial.  With the optimisation of drug 
release to overcome the potential for bacterial resistance, the testing of more 
organisms in the in - vitro model including trials with human urine and encrustation 
studies, it is considered that the catheter will show promise in providing protection 
against bacterial colonisation over a long duration.  If the new catheter proves in 
clinical trials to reduce bacterial colonisation, encrustation or to extend catheter life, 
then a significant impact could be made on reducing CAUTIs in patients on LTC. 
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APPENDICIES 
 
Appendix 1:  Agar incorporation protocol for determining MIC of        
bacterial strains to sparfloxacin and triclosan 
  
 
1. 0.03 g of sparfloxacin and/or triclosan were weighed out and placed in 50 mL 
of ethanol to dissolve and 50 mL of sterile distilled water to make a 
concentration of 300 µg/mL  
2. A 1:10 dilution was performed to make a concentration of 30 µg/mL. 
3. Serial dilutions were made to cover a concentration ranging from 0.08 - 30 
µg/mL (as shown below).     
4. 2 mL of each concentration was added to 18 mL of molten ISA to give a 
further 1:10 dilution to yield a final concentration ranging from 0.008 - 3 
µg/mL and poured into petri - dishes. 
5. Plates were swirled well to evenly distribute the antimicrobial agents and left 
to set.   
      
 
 
Initial 
Concentration 
(µg/mL)  
Amount taken 
from previous 
concentration 
(mL) 
Amount of 
water added 
(mL) 
Final 
Concentration 
(µg/mL)  
30   3 
20 13.33 6.67 2 
10 10.0 10.0 1 
7.5 15.3 5.0 0.75 
5 13.33 6.67 0.5 
3.8 15.20 4.8 0.38 
2.5 13.15 6.85 0.25 
1.9 15.20 4.80 0.19 
1.25 13.15 6.85 0.125 
0.94 15.04 4.96 0.094 
0.64 13.60 6.40 0.064 
0.47 14.68 5.32 0.047 
0.32 13.60 6.40 0.032 
0.23 14.37 5.63 0.023 
0.16 13.90 6.4 0.016 
0.12 15.00 5.0 0.012 
0.08 13.33 6.67 0.008 
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Appendix 2:  Growth Curves 
 
 
 
Growth curve of MRSA in TSB and artificial urine 
 
 
 
 
 
Growth curve of E.faecalis in TSB and artificial urine 
 
  Appendicies 
250 
 
 
Growth curve of P.mirabilis in TSB and artificial urine 
 
 
 
 
 
 
Growth curve of K.pneumoniae in TSB and artificial urine 
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Appendix 3:  Drug Release 
 
 
 
 
Concentrations (µg/mL) of sparfloxacin and triclosan released from the antimicrobial urinary catheter 
over a 28 day elution period.  Each value represents the average of three replicates with standard 
deviations.  
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Appendix 4:  XPS scans from conditioned and non - conditioned 
control and antimicrobial catheter material 
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XPS wide scan from non - conditioned control      XPS wide scan from conditioned control 
material         material     
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XPS wide scan from non - conditioned     XPS wide scan from conditioned   
antimicrobial material        antimicrobial material     
  Appendicies 
253 
 
 
 
O 1s/16
O
 
1s
x 102
10
20
30
40
50
60
70
C
PS
536 534 532 530 528 526 524
Binding Energy (eV)
   
 
O 1s/86
O
 
1s
x 102
10
20
30
40
50
60
C
PS
536 534 532 530 528 526 524
Binding Energy (eV)
 
 
XPS high resolution scan of O 1s peak from non -  XPS high resolution scan of O 1s peak from 
conditioned control material    conditioned control material 
      
 
  
 
 
 
    
 
O 1s/63
O
 
1s
x 102
10
20
30
40
50
60
70
C
PS
536 534 532 530 528 526 524
Binding Energy (eV)
     
 
O 1s/109
O
 
1s
x 102
10
15
20
25
30
35
40
45
50
55
C
PS
536 534 532 530 528 526 524
Binding Energy (eV)
 
XPS high resolution scan of O 1s peak from non -  XPS high resolution scan of O 1s peak from 
conditioned antimicrobial material    conditioned antimicrobial material 
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XPS high resolution scan of Ca 2p peak from non -  XPS high resolution scan of Ca 2p peak from 
conditioned control material    conditioned control material 
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XPS high resolution scan of Ca 2p peak from non -  XPS high resolution scan of Ca 2p peak from 
conditioned antimicrobial material    conditioned antimicrobial material 
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XPS high resolution scan of Cl 2p peak from non -  XPS high resolution scan of Cl 2p peak from 
conditioned control material    conditioned control material 
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XPS high resolution scan of Cl 2p peak from non -   XPS high resolution scan of Cl 2p peak from 
conditioned antimicrobial material    conditioned antimicrobial material 
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XPS high resolution scan of Mg 2p peak from non -  XPS high resolution scan of Mg 2p peak from 
conditioned control material    conditioned control material 
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Appendix 5:  The composition of simulated urine used in the 
urinary catheter mechanical property testing 
 
 
 
 
Artificial Urine from BS EN 1616 - 1997 [173, 214] 
 
Chemical Mass (g) 
Urea 25 
Sodium chloride 9 
Disodium hydrogen orthophosphate, anhydrous 2.5 
Ammonium chloride 3 
Potassium dihydrogen orthophosphate 2.5 
Creatinine 2 
Sodium sulfite, hydrated 3 
Distilled water 1000 
 
 
 
Chemicals (Sigma-Aldrich) were accurately weighed out and dissolved in 1 L of 
distilled water.  The artificial urine was sterilised by filtration through a 0.2 µm pore 
and pH was recorded at approximately 6.6. 
